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ABSTRACT 
BACKGROUND 
Surgical, traumatic and obstetric bleeding are important causes of mortality and morbidity. The 
antifibrinolytic drug, tranexamic acid (TXA), inhibits clot breakdown and may have a role in the 
management of excessive bleeding.  
AIM 
Evaluate the evidence from randomised trials for the effects of TXA in patients with surgical 
bleeding, traumatic bleeding, and for preventing postpartum haemorrhage (PPH). 
METHODS 
Using systematic reviews and meta-analytic techniques, evaluate the evidence from randomised 
trials to: i) quantify the effects of TXA for surgical bleeding; ii) investigate the quality of trials of 
TXA for surgical bleeding; iii) to quantify the effects of TXA for traumatic bleeding; iv) estimate 
the number of avoidable trauma deaths by the routine use of TXA; v) quantify the effects of TXA 
for preventing PPH; and vi) propose a trial of TXA for preventing PPH. 
RESULTS 
A systematic review including 129 trials involving 10,488 patients suggests that TXA reduces 
bleeding in surgical patients by about one third, although its effect on death and 
thromboembolic events is uncertain. Evidence that TXA reduces surgical bleeding has been 
available for many years, although, poor methodological quality of trials may mean that it is 
unreliable.  
There is reliable evidence that TXA reduces death due to bleeding in trauma patients. This 
evidence originates from a large, high quality randomised trial in 20,211 patients. If TXA was 
given to all patients soon (<3 hours) after injury over 100,000 deaths could be prevented every 
year.  
A systematic review including 26 trials involving 4191 women suggests that there is no reliable 
evidence for the effects of TXA for preventing PPH. The trials are poor quality and contain serious 
flaws. The proposed WOMAN-2 trial of TXA for preventing PPH in 10,000 women with anaemia 
aims to resolve the uncertainties. 
CONCLUSIONS 
Most trials assessing the effect of TXA for surgical bleeding and for preventing PPH are small and 
poor quality. Although together they provide promising evidence that TXA reduces bleeding, 
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further evidence from large trials at low risk of bias is required to determine reliably the effects 
of TXA for these indications.  
There is reliable evidence that TXA reduces the risk of death in trauma patients and no further 
trials are required. Instead, dissemination of the evidence and implementation of TXA into 
trauma protocols worldwide, should be a priority.  
Although there is no evidence from randomised trials that it increases risk, the effect of TXA on 
thromboembolic events remains uncertain.  
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1.0 INTRODUCTION TO THESIS 
1.1 EPIDEMIOLOGY OF SURGICAL, TRAUMATIC AND OBSTETRIC BLEEDING 
Haemorrhagei is a major cause of mortality and morbidity worldwide. Acute severe 
haemorrhage resulting from vascular injury during surgery, trauma, and childbirth account for 
much of the morbidity and are responsible for many premature deaths. 
Surgical haemorrhage 
Surgery is an essential component of health systems in high, middle and low-income countries. 
In 2012, there were an estimated 310 million surgical procedures worldwide, a number expected 
to increase in subsequent years in line with ageing populations and shifting patterns of disease 
towards chronic illnesses.1  
Blood loss and exposure to blood transfusion are common complications of surgery and are 
associated with poorer patient outcomes. In addition to its adverse physiological impact, 
bleeding impairs the visibility of the surgical site compromising the success of the procedure. 
Bleeding can prolong the surgery and require further interventions such as blood transfusion 
and re-operation.  
A retrospective cohort study conducted in the USA included over 1.6 million procedures across 
eight surgical specialities and observed that on average 30% suffered a bleeding-related 
complication, with blood product transfusions being the most common.2 The authors also 
estimated the additional costs and resource use incurred. After adjusting for covariates, patients 
with bleeding complications stayed in hospital six days longer than those without. The cost of 
treating these patients was also higher, varying between 31-93% more depending on the surgery 
type.2 
Death during surgery is relatively rare, although in the presence of acute severe bleeding it 
increases from less than 1% to 20%.3 A cohort study of cardiac surgery patients found that 10% 
of patients suffered blood loss severe enough to receive five or more units of blood within 24 
hours of surgery, which was associated with an eight-fold increase in the odds of death.4 
The challenge of managing severe bleeding during surgery is likely to become more common as 
the number of complex procedures rises, alongside the advancing age of surgical patients and 
the growing use of anti-coagulants, which increase the risk of bleeding.  
 
                                                            
i I use the terms ‘haemorrhage’ and ‘bleeding’ interchangeably throughout this thesis. 
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Traumatic haemorrhage 
There are an estimated five million deaths due to trauma every year, which account for 9% of 
global mortality.5 Almost half of trauma deaths are young adults aged 15-44 years, and over 90% 
of deaths occur in low and middle income countries (LMICs).5, 6 Many millions more experience 
non-fatal injuries and suffer long-term disability.  
Haemorrhage is second only to traumatic brain injury as the leading cause of death in trauma 
victims. It is responsible for up to 40% of deaths, most of which occur in the first 24 hours after 
injury.7-11 Furthermore, bleeding contributes to other leading causes of death, including central 
nervous system injury and multi-organ failure.8 In trauma patients who survive, haemorrhage is 
associated with complications such as organ failure and sepsis, with greater blood loss 
associated with poorer outcomes.8, 12  
A cross-sectional study involving bleeding trauma patients presenting to 22 hospitals in England 
and Wales estimated the prevalence, patterns of blood use, and outcomes of patients with 
major haemorrhage.11 A quarter (26.5%) of patients with major haemorrhage (≥4 units red blood 
cells in first 24 hours) and one-third (38.5%) of those with massive haemorrhage (≥10 units red 
blood cells in first 24 hours) died in hospital. Most patients died within 24 hours and most of 
these deaths occurred within four hours of arriving at hospital. 
There is a substantial economic burden of treating bleeding trauma patients. Estimates based 
on resource use data from 22 NHS hospitals, suggest that it costs an average of £20,000 to treat 
a trauma patient with severe bleeding, of which the cost of blood components accounts for 12% 
(£2,300).13 When extrapolated to the national (England) level, this costs the NHS £148 million 
per year.13  
Obstetric haemorrhage 
Severe bleeding is a common complication of childbirth. Primary postpartum haemorrhage 
(PPH), commonly defined as blood loss ≥500 mL within 24 hours of birth, follows 6% to 10% of 
all births and accounts for 50,000 to 100,000 maternal deaths every year.14-17 Although PPH is 
common throughout the world, 99% of deaths occur in LMICs.18 Similar to traumatic bleeding, 
most deaths from PPH occur early. The majority of deaths occur within 24 hours of delivery, 
many within the first few hours.14 The leading cause of PPH is uterine atony, followed by 
bleeding due to trauma to the genital tract, retention of placental tissue, and failure of the 
coagulation system.16 
Many women who survive PPH experience severe morbidity that may require costly, urgent 
care, and a prolonged hospital stay. Many women need surgery to control the bleeding and 
some require a hysterectomy.19 PPH can lead to, or worsen existing, anaemia, which can result 
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in debilitating fatigue that interferes with the woman’s ability to care for herself and her baby.20 
There is also evidence that morbidity resulting from PPH adversely affects a mother’s ability to 
breast-feed and bond with her baby.21 PPH can be an extremely frightening experience that may 
have a long-term psychological impact.22 
Although death due to PPH is rare in high income countries, it is an important cause of maternal 
morbidity and there is some evidence to suggest that the incidence is increasing.23 The reasons 
for this increase are uncertain but may be due to increasing maternal age, obesity, higher rates 
of intervention and caesarean sections.23, 24 
Blood transfusion 
The administration of blood and blood products is a common intervention for the management 
of excessive surgical, traumatic and obstetric bleeding, which together place enormous pressure 
on donor blood supplies.  
One third of transfused blood in the UK is used for surgical patients who each receive an average 
of two units.25 Blood usage data from the UK suggest that 63% of patients with significant trauma 
receive a blood transfusion, over half of whom receive eight or more units.26 A survey of hospital 
data from 28 countries suggests that one third (32.5%) of women with PPH receive blood 
products.27  
However, blood for transfusion is a scarce and costly resource and most people in the world do 
not have access to donor blood. The blood donation rate in Africa is 5 per 1000 population 
compared to 47 per 1000 population in the USA, and it is estimated that 35 of the 40 sub-
Saharan countries collect less than half of the donor blood required to meet the needs of their 
populations.28 It is estimated that 26% of maternal haemorrhagic deaths in sub-Saharan Africa 
are due to lack of blood for transfusion.29  
Where it is available, safe blood for transfusion is expensive. In the UK, for example, a single unit 
of blood costs of £125, presenting an annual cost to the NHS of £266 million.30 
As well as issues with cost and availability, the practice of giving blood for transfusion is not 
without risk and it may not improve patient outcomes. A systematic review of randomised trials 
comparing ‘liberal’ and ‘restrictive’ transfusion protocols, found that patients in the restrictive 
group were less likely to receive a blood transfusion (RR=0.57, 95% CI 0.49 to 0.65), but found 
no difference in 30 day mortality (RR=0.97, 95% CI 0.81 to 1.16).31 
Moreover, blood transfusion is associated with several infectious and non-infectious risks. The 
extent and type of the risk posed by blood transfusion varies considerably by country and the 
adequacy of the donation and blood screening systems. In countries with comprehensive blood 
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screening processes such as the UK, the transmission of known infections is very rare (0.2 events 
per 100,000 components) and most (~70%) harm results from transfusion of mismatched 
blood.32  
However, not all countries are able to provide comprehensive screening of donor blood and 
transfusion-transmitted infections are the primary concern. In 2004, 88% of blood collected in 
sub-Saharan Africa was not tested for HIV in a quality-assured manner. 28 A mathematical model 
of the risk of transfusion-transmitted viral infections in sub-Saharan Africa estimated that the 
median overall risks of infection with HIV, HBV, and HCV from blood transfusion were 1, 4.3, and 
2.5 infections per 1000 units, respectively.33 Between 5-10% of global HIV infections were 
acquired through transfusion of contaminated blood.34 
Because of the scarcity, cost and associated risks of blood transfusion, the identification of cost-
effective alternatives is a public health priority and treatments that can safely reduce bleeding 
are needed. 
1.2 HAEMOSTASIS 
Maintenance of the circulating blood volume is a basic homeostatic mechanism essential for 
supporting life.35 Bleeding caused by vascular injury, leads to a reduction in the amount of 
haemoglobin in the circulation and loss of blood volume (hypovolaemia) which if extensive or 
uncontrolled, leads to haemorrhagic shock and ultimately organ failure and death.36  
In response to blood loss, the body initiates a series of compensatory mechanisms that allow 
low levels of blood loss to be tolerated without notable adverse health effects. However, the 
loss of relatively minor amounts of blood can be harmful in individuals who are less able to 
compensate for the loss, such as the elderly, those with anaemia or with existing cardio-
respiratory or hepatic disease.36 
Trauma, surgery and childbirth are leading causes of acute haemorrhage, the complications of 
which result in substantial global mortality and morbidity and are the focus of this thesis. 
Vascular injury, regardless of cause, initiates a common haemostatic response. 
Recommendations for the haematological management of major haemorrhage are common 
across clinical situations.37 As a result, those seeking to improve the management of bleeding in 
trauma and obstetric patients have looked to use evidence from surgical disciplines and vice 
versa. 
1.3 COAGULATION AND FIBRINOLYSIS 
Vascular injury, irrespective of the cause, triggers a series of physiological responses aimed at 
maintaining the integrity of the circulatory system.38 Two regulatory responses are involved: the 
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coagulation cascade leading to clot formation, and the fibrinolytic response leading to clot 
breakdown.39 The coagulation and fibrinolysis cascades are summarised in Figure 1.1. 
Figure 1.1 Summary of the coagulation and fibrinolysis cascadesii  
 
The immediate haemostatic response to vascular injury is localised vasoconstriction and 
movement of blood into the surrounding tissues that reduces the flow through the damage 
vessel. This is followed by the aggregation and deposition of platelets at the point of injury.39 
Activation of thrombin results in the production of fibrin which interacts with the platelet plug, 
and produces a clot resistant to dissolution that acts as a haemostatic seal at the point of 
damage.41 
The coagulation response is accompanied by a fibrinolytic response that results in the 
breakdown of the fibrin mesh. Tissue plasminogen activator (t-PA) secreted from the endothelial 
cells, converts plasminogen trapped within the clot into plasmin.41 Plasmin attaches to and 
digests the fibrin causing clot breakdown. 
A delicate balance of these regulatory responses prevents inevitable death that would be caused 
by either uncontrolled bleeding or uncontrolled clotting.38 However, in the context of major 
blood loss, this delicate balance can be compromised by the accompanying physiological 
stresses, including over-activation of t-PA that can lead to hyperfibrinolysis (a state of excessive 
                                                             
ii Reproduced from Bodary et al40 
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fibrinolysis and uncontrolled bleeding). Hyperfibrinolysis is associated with a range of bleeding 
conditions including trauma, surgical, and obstetric haemorrhage and causes excessive or 
recurrent bleeding,41 the outcomes of which includes death, organ dysfunction, multiple organ 
failure and sepsis.42 The latter of which can be exacerbated by immunologic stress associated 
with blood transfusion.42 
1.4 TRANEXAMIC ACID AND ITS EFFECT ON BLEEDING 
TXA is a synthetic lysine amino acid derivative that inhibits fibrinolysis by blocking the interaction 
between plasmin and fibrin (Figure 1.2).41  
Figure 1.2 Antifibrinolytic action of tranexamic acidiii 
 
TXA exerts its antifibrinolytic effect by forming a reversible bond with the lysine binding site on 
the plasminogen molecule. Plasmin is therefore prevented from interacting with fibrin and clot 
stability is achieved. It is marketed in tablet and injection form as a treatment for a variety of 
chronic and acute bleeding conditions.  
In the UK, TXA injection is licensed for administration as a slow intravenous injection for short-
term use for the prophylaxis and treatment of patients at high risk of perioperative bleeding 
associated with prostatectomy, conisation of the cervix, surgical procedures and dental 
extractions in people with haemophilia; haemorrhage complications in association with 
thrombolytic therapy; and haemorrhage associated with disseminated intravascular coagulation 
with predominant activation of the fibrinolytic system.44 TXA is a relatively inexpensive drug - 
                                                            
iii Reproduced from Dunn & Goa43  
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the total cost of administering a dose is about US$13 ($8 drug, $2 staff time and $3 supply 
cost).45 
In view of the antifibrinolytic effect of TXA, there is interest in its use in a range of conditions 
involving excessive bleeding.  
1.5 ROLE OF SYSTEMATIC REVIEWS AND META-ANALYSES FOR ASSESSING THE EFFECTS OF 
TRANEXAMIC ACID 
Since husband and wife team Shosuke and Utako Okamoto first described TXA as an inhibitor of 
fibrinolysis in 1962,46 there has been interest in its use for a range of bleeding conditions. 
Although research into TXA has been published in the medical literature for many decades, the 
last 10 years or so has seen rapid growth in the number of publications. The LSHTM CTU 
maintains a register of bibliographic records of publications about TXA. Figure 1.3 shows the 
number of records included in the register by publication year.  
Figure 1.3 Number of TXA research publications published per year from 1962 to 2017.iv  
 
The LSHTM CTU maintains a register of publication records identified through comprehensive 
searches of bibliographic databases. This register includes 2225 records of articles published up 
to the end of 2017, most of which were published in the last decade. Over the last 10 years, 
there has been a five-fold increase (from 46 in 2008 to 286 in 2017) in the number of 
publications. This abundance of research presents a considerable challenge for those who are 
looking to understand the evidence for the effects of TXA. To stay up-to-date with the articles 
                                                             
iv Numbers extracted from the register of bibliographic records maintained by the LSHTM CTU. 
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published in 2017 alone would require reading 5-6 articles every week. Systematic reviews 
therefore have an important role for translating the existing abundance of research into 
manageable, valid syntheses. 
A systematic review is an epidemiological study design that uses explicit and systematic methods 
to collate all evidence that meet pre-defined inclusion criteria to answer a well-defined 
question.47 Systematic reviews are key tools in the practice of evidence-based medicine that has 
guided medical practice and teaching since the 1990s. Systematic reviews often include meta-
analysis, the statistical pooling of aggregate data from individual studies, to increase statistical 
precision and generate a summary effect estimate.  
Systematic reviews of randomised controlled trials are often considered to be at the top of the 
hierarchy of evidence and increasingly support the development of health care guidelines at the 
national and international level.48, 49 They also have an important research role. Systematic 
reviews are useful for identifying treatment uncertainties, which initiate the conduct of further 
primary research. However, like all epidemiological study designs, systematic reviews are 
vulnerable to bias, which requires careful consideration when planning, conducting, and 
interpreting the results.  
Systematic review methodology has evolved rapidly as its role in healthcare decision-making has 
grown. As well as improvements in techniques for searching and assessing the methodological 
quality of trials, extensions to standard meta-analytic techniques have allowed for further 
investigation into the quality, reliability, and heterogeneity of the evidence.  
This thesis presents a series of Research Papers in which I have explored the evidence for the 
effects of TXA. Using systematic reviews alongside standard and more novel meta-analytic 
techniques, I have undertaken a detailed investigation into the effects of TXA for surgical 
bleeding, traumatic bleeding, and for preventing postpartum bleeding. 
1.6 AIMS AND OBJECTIVES 
I have undertaken a programme of work using systematic review methodology to evaluate the 
evidence from randomised trials for the effects of TXA in patients with surgical bleeding, 
traumatic bleeding, and for preventing postpartum haemorrhage. 
My specific aims and objectives are: 
1) To evaluate the evidence from randomised trials for the effects of TXA in patients undergoing 
surgery, specifically to: 
• quantify the effects of TXA on bleeding, blood transfusion, death and thromboembolic 
events in surgical patients; 
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• investigate the quality of randomised trials of TXA for surgical bleeding.  
2) To evaluate the evidence from randomised trials for the effects of TXA in patients with 
traumatic bleeding, specifically to: 
• quantify the effects of TXA on death, blood transfusion, and thromboembolic events in 
bleeding trauma patients; 
• estimate the number of avoidable trauma deaths by the routine use of TXA. 
3) To evaluate the evidence from randomised trials for the effects of TXA for preventing 
postpartum bleeding, specifically to: 
• quantify the effects of TXA on postpartum bleeding, blood transfusion, death and 
thromboembolic events in women giving birth; 
• outline a proposed trial of TXA for preventing postpartum bleeding in women with 
anaemia. 
1.7 STRUCTURE OF THESIS 
I have prepared a paper-style thesis. It comprises six Research Papers published in peer-
reviewed journals, as well as one submitted manuscript currently under journal review. 
The submitted and approved versions of the published papers are presented in the main text 
with abstracts and endnotes omitted for clarity. Copies of the full, published versions are 
included in the Appendices. The Research Papers are presented in Chapters 2-4.  
The three Research Papers included in Chapter 2 address the effects of TXA in patients with 
surgical bleeding. Research Papers 1 and 2 present the results of a systematic review of 129 trials 
assessing the effect of TXA in surgical patients. In Research Paper 3, I present the results of my 
further investigations into the quality of the evidence from the randomised trials.  
Research Papers 4 and 5 included in Chapter 3 address the effects of TXA in patients with 
traumatic bleeding. In Research Papers 4 and 5, I describe my research to quantify the effects of 
TXA in bleeding trauma patients and the potential public health impact in terms of deaths 
averted by the routine use of TXA.  
Research Papers 6 and 7 included in Chapter 4 address the effects of TXA for preventing 
postpartum haemorrhage. Research Paper 6 presents the evidence for the effects of TXA for 
preventing postpartum bleeding and Research Paper 7 presents the protocol for a trial of TXA 
for preventing postpartum bleeding in anaemic women.  
Chapter 5 is the concluding section in which I summarise how, together, the results of the 
individual papers further our understanding of the evidence from randomised trials for the 
10 
 
effects of TXA in patients with surgical bleeding, traumatic bleeding, and for preventing 
postpartum haemorrhage, including implications for clinical practice and future research.  
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2.0 WHAT ARE THE EFFECTS OF TRANEXAMIC ACID IN PATIENTS UNDERGOING 
SURGERY? 
2.1 INTRODUCTION TO RESEARCH PAPERS 1, 2 AND 3 
As described in Chapter 1, surgical haemorrhage is an important cause of morbidity and is a 
common indication for blood transfusion. TXA has been used in some surgical patient groups for 
many years. However, uncertainties about its effects have prevented its routine use.  
This chapter addresses Aim 1 of this thesis in which I use systematic review and meta-analytic 
techniques to evaluate the evidence from randomised trials for the effects of TXA in surgical 
patients. The chapter includes Research Papers 1-3.v 
 
                                                            
vCopies of the PDF versions of the published manuscripts are included in Appendix D, Appendix J and 
Appendix P 
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Introduction 
In October 2011, the BMJ published a randomised controlled trial of the effect of tranexamic 
acid (TXA) on blood transfusion in patients undergoing radical retro-pubic prostatectomy.1 The 
authors pointed out that this was the first trial to assess the effect of TXA on blood transfusion 
in this particular operation. Whilst this may be the case, it was not the first trial to examine the 
effect of TXA on blood transfusion in surgery more generally. A systematic review published in 
2001 presented data from 18 clinical trials and showed that TXA reduces the probability of blood 
transfusion in elective surgery by 34% (RR=0.66, 95% CI 0.54 to 0.81; p=0.004).2 In this paper, 
we assess the current evidence for the effect of TXA on blood transfusion, thromboembolic 
events and mortality in surgical patients and use cumulative meta-analyses to examine how the 
evidence has changed over time.  
Methods 
Methods of the analysis and inclusion criteria for this systematic review were specified in 
advance and documented, although the protocol was not registered. The PRISMA checklist is 
presented in Appendix E. We searched for all randomised controlled trials comparing TXA with 
no TXA or placebo in elective and emergency surgery. There was no age restriction. Potentially 
eligible trials were identified by searching the Cochrane Central Register of Controlled Trials 
(2011, issue 3), MEDLINE (1950 to September 2011) and EMBASE (1980 to September 2011), 
using a combination of subject headings and text words to identify randomised controlled trials 
of any antifibrinolytic drug (the MEDLINE search strategy is presented in Appendix F). Searches 
were not restricted by language or publication status. The WHO International Clinical Trials 
Registry Platform was searched to identify ongoing or unpublished trials. The reference lists of 
eligible trials and reviews were also examined. The search output was screened by two authors 
working independently to identify records of potentially eligible trials, the full texts of which 
were then retrieved and assessed for inclusion.  
Outcome data 
Outcome measures of interest were the number of patients receiving a blood transfusion, the 
number of patients suffering a myocardial infarction, stroke, deep vein thrombosis and 
17 
 
pulmonary embolism, and the number of deaths. We contacted trial authors to obtain any 
missing outcome data.  
Data extraction and risk of bias assessment 
We extracted data on the age and gender of trial participants, type of surgery, dose and timing 
of TXA, type of comparator and outcome data. We also collected information on whether a 
systematic review had been conducted to support the rationale of the trial and whether a 
systematic review was cited in the trial report. We assessed the risk of bias associated with the 
method of sequence generation, allocation concealment, blinding and the completeness of 
outcome data. As the risk of bias for blinding may vary according to outcome, it was assessed 
separately for each outcome. Risk of bias was rated as being low, unclear or high according to 
established criteria.3  
Statistical analysis 
Risk ratios (RR) and 95% confidence intervals (CI) were calculated for each outcome and pooled 
using a fixed effect model. Subgroup analyses were carried out to examine whether the effect 
of TXA on blood transfusion varies by type of surgery. Sensitivity analyses were conducted to 
quantify the effect of TXA on all outcomes when restricted to trials with adequate allocation 
concealment and blinded outcome assessment. We conducted a cumulative meta-analysis of 
the effect of TXA on blood transfusion based on the date of publication and cumulative meta-
analyses of the effect of TXA on blood transfusion, myocardial infarction and mortality when 
restricted to adequately concealed trials. Heterogeneity was examined by visual inspection of 
forest plots, the I-squared statistic and the chi-squared test. We inspected funnel plots for the 
presence of small study effects. Statistical analyses were conducted using STATA version 11 and 
RevMan version 5. 4, 5  
Results 
Figure 2.1 shows the trial selection process. We identified 127 articles1, 6-131 describing 129 
randomised controlled trials that included 10,488 patients 5,484 were allocated to TXA and 
5,004 were allocated to a control group. The median sample size was 60 patients (range 10 to 
660). There were 126 (98%) trials in elective surgery and three trials (2%) in emergency surgery. 
Eleven (8%) trials involved paediatric patients.  
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Figure 2.1 PRISMA flow diagram of the selection of trials 
 
 
We contacted the authors of 86 trials for missing data, 39 of whom provided additional 
information. Blood transfusion data were available for 95 (74%) trials, myocardial infarction data 
for 73 (56%) trials, stroke data for 71 (55%) trials, deep vein thrombosis data for 72 (56%) trials, 
and pulmonary embolism data for 66 (51%) trials and mortality data for 72 (56%) trials. Seven 
(5%) trials did not present any data on the outcome measures of interest to this review or 
reported data in a format that was unsuitable for inclusion in the analyses.  
We identified 14 ongoing trials 110-123 with a median planned sample size of 130 patients. The 14 
trials were in orthopaedic (n=5), cardiac (n=4), cranial (n=2), hepatic (n=1), ENT (n=1) and 
gynaecological (n=1) surgery. In 12 of the 14 trials blood transfusion was a main outcome 
measure.  
 
Records identified through database 
searching (n=6366) 
Additional records identified through 
other sources (n=10) 
Records excluded  
(n=5765) 
Records screened  
(n=5924) 
Records after duplicates removed  
(n=5924) 
Full-text articles assessed for eligibility 
(n=158) 
full texts not available n=1 
Full-text articles excluded (n=29) 
duplicate publication n=10  
ineligible or unclear study design n=12 
ineligible intervention or comparator n=7 
Trials included in qualitative synthesis 
(n=129) 
Trials included in meta-analyses (n=115) 
transfusion n=95 
myocardial infarction n=73 
stroke n=71 
deep vein thrombosis n=72 
pulmonary embolism n=66 
mortality n=72 
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Risk of bias 
The risk of bias judgements for each methodological quality item for the included trials are 
presented in Appendix G. We judged 44 (34%) trials to be at low risk of bias for sequence 
generation and five (4%) trials to be at high risk. The risk of bias in the remaining 80 (62%) trials 
was unclear due to lack of information. Allocation was adequately concealed in 36 trials (28%), 
inadequately concealed in six (5%) trials, with the other 87 (67%) trials presenting insufficient 
information to allow judgement. For blinding, of the 95 trials with data on blood transfusion, 69 
(73%) were judged low risk, four (4%) at high risk and 22 (23%) were unclear. The risk of bias for 
blinding was similar for thromboembolic outcomes (myocardial infarction, stroke, deep vein 
thrombosis and pulmonary embolism), with approximately 70% judged to be at low risk, 5% at 
high risk and 25% at unclear risk. All 72 trials with mortality were judged to be at low risk of bias 
for blinding. Of 115 trials reporting eligible outcome data, 72 (63%) were at low risk of bias for 
incomplete outcome data, 17 (15%) at high risk, and 26 (23%) trials did not describe adequate 
information to permit judgement. 
Quantitative data synthesis 
The results of the meta-analysis are presented in Table 2.1. 
Table 2.1 Meta-analysis of effect of TXA on blood transfusion, thromboembolic events and 
mortality 
 Events  
(TXA/control) 
Pooled Risk Ratio 
(95% CI) 
Test for 
effect 
(p value) 
Heterogeneity 
(I2; p value) 
Blood transfusion 
All trials 
Well concealed trials 
Adequate blinding 
 
1067/1520 
459/ 609 
847/ 1182 
 
0.62 (0.58 to 0.65) 
0.68 (0.62 to 0.74) 
0.63 (0.59 to 0.68) 
 
<0.001 
<0.001 
<0.001 
 
69%; <0.001 
55%; <0.001 
54%; <0.001 
Myocardial infarction 
All trials 
Well concealed trials 
Adequate blinding 
 
23/35 
16/25 
18/33 
 
0.68 (0.42 to 1.09)  
0.70 (0.39 to 1.25) 
0.59 (0.36 to 0.98) 
 
0.11 
0.22 
0.04 
 
0%; p=0.90 
0%; p=0.82 
0%; p=0.81 
Stroke 
All trials 
Well concealed trials 
Adequate blinding 
 
23/16 
5/4 
23/16 
 
1.14 (0.65 to 2.00) 
1.18 (0.36 to 3.83) 
1.14 (0.65 to 2.00) 
 
0.65 
0.78 
0.65 
 
0%; p=0.92 
0%; p=0.92 
0%; p=0.92 
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Deep vein thrombosis 
All trials 
Well concealed trials 
Adequate blinding 
 
25/29 
13/14 
18/22 
 
0.86 (0.53 to 1.39) 
0.92 (0.45 to 1.85) 
0.82 (0.46 to 1.44) 
 
0.54 
0.81 
0.49 
 
0%; p=0.96 
0%; p=0.81 
0%; p=0.98 
Pulmonary embolism 
All trials 
Well concealed trials 
Adequate blinding 
 
4/8 
1/3 
4/6 
 
0.61 (0.25 to 1.47) 
0.52 (0.10 to 2.75) 
0.70 (0.26 to 1.87) 
 
0.27 
0.44 
0.48 
 
0%; p=0.96 
0%; p=0.80 
0%; p=0.91 
Mortality 
All trials 
Well concealed trials 
Adequate blinding 
 
20/34 
9/15 
20/34 
 
0.61 (0.38 to 0.98) 
0.67 (0.33 to 1.34) 
0.61 (0.38 to 0.98) 
 
0.04 
0.25 
0.04 
 
0%; p=0.97 
0%; p=0.85 
0%; p=0.97 
 
Risk of blood transfusion 
Data on blood transfusion were available for 95 trials including a total of 7,838 patients. TXA 
reduced the probability of receiving a blood transfusion by 38% (pooled RR=0.62, 95% CI 0.58 to 
0.65; p<0.001). When the analysis was restricted to the 32 adequately concealed trials involving 
3,408 patients, TXA reduced the risk of receiving a blood transfusion by 32% (pooled RR=0.68, 
95% CI 0.62 to 0.74; p<0.001). When the analysis was restricted to the 69 trials involving 5,968 
patients with adequate blinding for this outcome, TXA reduced the risk of blood transfusion by 
37% (pooled RR=0.63, 95% CI 0.59 to 0.68; p<0.001). 
The trials with blood transfusion data involved cardiac (n=42), orthopaedic (n=36), cranial & 
orthognathic (n=7), gynaecological (n=5), hepatic (n=2), urological (n=2), and vascular (n=1) 
surgery. There was a statistically significant reduction in blood transfusion in cardiac, 
orthopaedic, cranial & orthognathic, hepatic, and urological surgery (Table 2.2). The pooled 
estimates for blood transfusion were consistent with a reduction in the TXA group amongst trials 
in vascular and gynaecological surgery although the results were imprecise. Heterogeneity in 
the effects of TXA by surgery type: I² = 59%, p=0.02. 
Table 2.2 Meta-analysis of effect of TXA on risk of blood transfusion, stratified by type of surgery 
Type of surgery 
Events  
(TXA/control) 
Pooled Risk Ratio 
 (95% CI) 
Test for effect 
(p value) 
Heterogeneity 
(I2; p value) 
Cardiac 622/835 0.65 (0.60 to 0.70) <0.001 60%; p<0.001 
Orthopaedic 298/462 0.55 (0.49 to 0.61) <0.001 83%; p<0.001 
Hepatic 29/54 0.52 (0.39 to 0.68) <0.001 93%; p<0.001 
Urological  40/60 0.66 (0.48 to 0.91) 0.01 2%; p=0.31 
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Type of surgery 
Events  
(TXA/control) 
Pooled Risk Ratio 
 (95% CI) 
Test for effect 
(p value) 
Heterogeneity 
(I2; p value) 
Vascular  11/19 0.58 (0.34 to 0.99) 0.05 - 
Gynaecological  17/50 0.86 (0.48 to 1.54) 0.61 65%; p=0.06 
Cranial & 
orthognathic 
52/76 0.63 (0.45 to 0.86) 0.004 
46%; p=0.12 
 
Thromboembolic events 
There was uncertainty regarding the effect of TXA on myocardial infarction (RR=0.68, 95 % CI 
0.43 to 1.09; p=0.11), stroke (RR=1.14, 95 % CI 0.65 to 2.00; p=0.65), deep vein thrombosis 
(RR=0.86, 95 % CI 0.53 to 1.39; p=0.54) and pulmonary embolism (RR=0.61, 95% CI 0.25 to 1.47; 
p=0.27). The results were similar when the analyses were restricted to trials with adequate 
allocation concealment and trials with blinded outcome assessment.  
Mortality 
There were fewer deaths in the TXA treated group (RR=0.61, 95% CI 0.38 to 0.98; p=0.04) 
although there was uncertainty regarding this effect particularly when the analysis was 
restricted to the 28 adequately concealed trials (RR=0.67, 95% CI 0.33 to 1.34; p=0.25).  
Cumulative meta-analyses 
The results of the cumulative meta-analysis of the 95 trials with data on blood transfusion are 
presented in Appendix H. A statistically significant effect of TXA on transfusion was first observed 
after publication of the third trial in 1993 (RR=0.59, 95% CI 0.43 to 0.80; p=0.001). Although 
subsequent trials have increased the precision of the point estimate, there has been no 
substantive change in the direction or magnitude of the treatment effect.  
Figure 2.2 shows the cumulative meta-analyses of the effect of TXA on blood transfusion, 
myocardial infarction and mortality amongst the trials with adequate allocation concealment. A 
statistically significant effect of TXA on blood transfusion was consistently observed after 
publication of the tenth trial in 2001.  
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Figure 2.2 Meta-analysis and cumulative meta-analysis of effect of TXA in surgery on risk of 
blood transfusion, myocardial infarction and mortality in adequately concealed trials 
 
Small study effects 
Inspection of the funnel plot (Figure 2.3) for the outcome blood transfusion suggested the 
presence of small study effects favouring TXA. There was no clear asymmetry in the funnel plots 
for the other outcomes. 
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Figure 2.3 Funnel plot with pseudo 95% confidence limits for meta-analysis of effect of TXA on 
risk of blood transfusion 
 
Citation of previous systematic reviews 
We identified 30 systematic reviews of the effects of TXA in surgery published between 1994 
and 2011.2, 89, 132-161 Assuming a 12 month publication time lag, 98 of the 116 (84%) included trial 
reports published as full journal articles were published when at least one systematic review 
was available. Examination of the references lists of these reports indicated that 45 (46%) did 
not cite any of the available systematic reviews. The authors of two of the 116 trial reports had 
conducted a systematic review and presented the findings within the final trial publication. 
Discussion 
Principal findings 
Reliable evidence that tranexamic acid (TXA) reduces blood transfusion in surgical patients has 
been available for over a decade. The treatment effect varies somewhat according to the type 
of surgery but the effect is consistently large and remains so when the analysis is restricted to 
trials with adequate allocation concealment. The effect of TXA on thromboembolic events and 
mortality has not been adequately assessed by clinical trials in surgery and remains uncertain. 
In view of the evidence, those planning further placebo controlled trials should explain why they 
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think that TXA might not reduce blood transfusion in the particular group of surgical patients 
under consideration, and focus their efforts on resolving the uncertainties about the effect of 
TXA on thromboembolic events and mortality.  
Strengths and weaknesses  
The inferences that can be made from the included trials depend on their quality and many had 
methodological limitations. However, the large and statistically significant effect on blood 
transfusion remained when the analysis was restricted to trials with adequate allocation 
concealment and with adequate blinding. 
We systematically searched a range of databases for published and unpublished trials. However, 
we cannot exclude the possibility that some were missed. Indeed, the observed asymmetry in 
the funnel plot could be explained by publication bias. If there are many unpublished trials 
showing little or no effect of TXA on blood transfusion, then this meta-analysis may have 
overestimated the treatment effect. Although some degree of overestimation is likely, it seems 
improbable that publication bias could account for all of the observed effect.  
Although there was no obvious asymmetry in the funnel plots for the mortality and 
thromboembolic outcomes, publication and other reporting biases remain a potential threat to 
the validity of the effect estimates. Mortality data were reported in only one third of the 
included trials and less than half reported data on myocardial infarction, stroke, deep vein 
thrombosis and pulmonary embolism. Inadequate reporting of adverse events is not unusual in 
reports of clinical trials and hinders the reliable estimation of treatment effects.162, 163 After 
contacting the trial authors we obtained some missing data and were able to include mortality 
data for three-quarters of the included trials and data on myocardial infarction, stroke, deep 
vein thrombosis and pulmonary embolism for about half of the trials. However, the effect of 
outcome reporting bias in this review remains open to question. Even if there was no significant 
bias, the precision of the estimates is low and the data are compatible with either a moderate 
increase or a moderate decrease in the risk of thromboembolic events.  
Implications 
The evidence in this review suggests that the uncertainty regarding the effect of TXA on blood 
transfusion in surgical patients was resolved over a decade ago however, uncertainties about its 
effect on thromboembolic events and mortality persist. Despite this, trials of TXA continue to 
assess the effect on blood transfusion. One reason may be a reluctance to generalise the 
evidence across surgery types, although there is no evidence that the relative effect of TXA on 
blood transfusion varies by type of surgery. A second reason may be that trialists are unaware 
of the existing evidence when initiating a new trial. Our observation that only half of the trials 
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cited one or more of the available systematic reviews and just two conducted their own 
systematic review, does suggest that many trialists are indeed failing to adequately consider the 
existing evidence.  
Blood is a scarce and costly resource and blood transfusion is not without risk. The cost of a unit 
of red cells to the NHS has increased from £78 in the year 2000 to £125 in 2011 and blood 
transfusion has a number of rare but serious adverse effects. Worldwide, most people do not 
have access to safe blood. Globally, the most important transfusion-related risks are HIV, 
hepatitis B virus and hepatitis C virus, due to their high prevalence. That TXA safely reduces the 
need for blood transfusion in surgery has important health and economic implications in high, 
middle and low income countries. The evidence that TXA reduces transfusion is strong but the 
safety of the routine administration of TXA to surgical patients remains uncertain. A modest 
increase in the risk of thromboembolic effects could outweigh the benefits of reduced blood 
use. Although some increased risk might be expected on theoretical grounds, recent evidence 
from the CRASH-2 trial of TXA in bleeding trauma patients showed a statistically significant 
reduction in mortality with no increase in thromboembolic effects. Indeed, there was a 
statistically significant reduction in the risk of myocardial infarction in trauma patients who 
received TXA.164 
Further small trials of TXA in surgical patients considered in isolation will not resolve the 
uncertainties about the effects on thromboembolic events and mortality. Because 
thromboembolic events are relatively rare, such trials lack statistical power to detect clinically 
important increases in risk, and a meta-analysis of small trials remains vulnerable to publication 
bias. The ongoing ATACAS trial165 with a planned sample size of 4,300 high-risk coronary artery 
surgery patients, should contribute importantly to resolving the uncertainty about the effect of 
TXA on mortality and thromboembolic events in this specific group. We urge investigators 
involved in all ongoing trials of TXA in surgery to collect data on thromboembolic events and 
mortality, for inclusion in a prospective meta-analysis until the uncertainties are resolved. 
However, there remains a need for a large pragmatic clinical trial of the effect of the routine 
administration of TXA in a heterogeneous group of surgical patients. The possibility that TXA 
might reduce mortality without any increase in the risk of thromboembolic events would justify 
the effort and expenditure involved. 
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2.3 SYSTEMATIC REVIEW, META-ANALYSIS AND META-REGRESSION OF THE EFFECT OF TRANEXAMIC 
ACID ON SURGICAL BLOOD LOSS 
Katharine Ker, David Prieto-Merino, Ian Roberts 
British Journal of Surgery 2013 Sep;100(10):1271-9.  
Introduction 
Tranexamic acid (TXA) reduces the probability of receiving a blood transfusion in surgery. A 
systematic review of randomised controlled trials showed that TXA reduces the probability of 
blood transfusion by 38% (pooled risk ratio=0.62, 95% CI 0.58 to 0.65; p<0.001).1 However, the 
extent to which TXA reduces surgical bleeding and its relationship with the dose of TXA and type 
of surgery remains uncertain. Because the decision to transfuse depends on factors other than 
blood loss, the effect on blood transfusion may not be an accurate indicator of the effect of TXA 
on surgical bleeding.  
Clinical trials of TXA in surgery usually report the mean blood loss in each group. Previous 
systematic reviews have combined these data to obtain the average difference in mean blood 
loss between the TXA and control groups. However, the usefulness of such a measure is 
questionable. It would be surprising if TXA reduced blood loss by the same volume in surgical 
procedures that involve different amounts of bleeding. On the other hand, it may be reasonable 
to expect a similar percentage reduction in blood loss with TXA.  
The objective of this study is to examine whether the effect of TXA on blood loss varies with the 
extent of surgical bleeding. The magnitude of the percentage reduction in blood loss with TXA 
is estimated and how the effect varies by type of surgery, timing of TXA administration, trial 
quality, and dose is assessed.  
Methods 
A systematic review of randomised controlled trials of TXA in surgical patients was conducted. 
The methods used to identify trials for the review are described in detail elsewhere1. In brief, a 
comprehensive search was undertaken for all randomised controlled trials comparing 
intravenous TXA with placebo or no intervention in elective or emergency surgery. Two authors 
screened the search output and the full texts of all eligible trials were obtained. Information was 
extracted on patient characteristics, type of surgery, dose and timing of TXA administration and 
average blood loss (mean and standard deviation). The risk of bias associated with sequence 
generation, allocation concealment, blinding, and the completeness of outcome data was 
assessed for each trial.  
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Data analysis 
To explore the relationship between the reduction blood loss with TXA and the extent of 
bleeding, for each trial the mean blood loss in the TXA group was plotted against the mean blood 
loss in the control group. This relationship was examined using a linear regression estimated 
using a Bayesian model as proposed by Thompson et al2 to account for random sampling error 
in the estimates of the regression variables (i.e. in the sample means from each trial). Statistical 
details of the model are given in Appendix K.  
To quantify the effect of TXA on the percentage reduction in blood loss, a meta-analysis using 
both fixed and random effects models was conducted. For the purpose of the meta-analysis, 
blood loss data were log transformed and the analysis conducted using the transformed values. 
The formulae used for the transformations are given in Appendix K. A meta-analysis (using 
arithmetic means) of the differences in means using the transformed blood loss data 
corresponds to a meta-analysis (using geometric means) of the ratio of means in the original 
scale. The pooled estimates were back-transformed to give the blood loss ratios and 95% 
confidence intervals on the original scale. Statistical heterogeneity was examined by visual 
inspection of forest plots, the I2 statistic and the χ2 test. 
Subgroup analyses were undertaken to assess the effect of TXA by the type of surgery, timing of 
TXA administration (pre-incision, post-incision), allocation concealment (adequate, unclear, 
inadequate) and type of comparator (placebo or no intervention). Heterogeneity between 
subgroups was assessed using the χ2 test (fixed effect analysis only). Finally, a random effects 
meta-regression was carried out to investigate the association between the effect of TXA on 
blood loss and the total dose of TXA (mg/kg) as a continuous variable. If a fixed dose was used 
in the trials (e.g. 1000mg) it was converted to mg/kg by dividing by 70kg. A funnel plot was 
inspected for the presence of small study effects. We used STATA (version 12)3 statistical 
software for all analyses.  
Results  
Figure 2.4 PRISMA flow diagram for the selection of trials shows the trial selection process.  
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Figure 2.4 PRISMA flow diagram for the selection of trials 
 
One hundred and twenty-nine randomised controlled trials were identified. The characteristics 
of the included trials are summarised in (Appendix L). Nine reports described multi-arm trials 
involving a total of 23 eligible pair-wise comparisons; each of these was included in the analysis 
as separate trials. One hundred and four randomised comparisons described in 90 articles,4-93 
reported data on blood loss in a format suitable for this analysis. These trials involved a total of 
8030 patients, 4224 received TXA and 3806 received a placebo or no intervention.  
The trials involved cardiac (n=54), orthopaedic (n=33), obstetric & gynaecological (n=7), head & 
neck (n=7), breast cancer (n=1), hepatic (n=1) and urological (n=1) surgery. Eighty trials gave TXA 
prior to surgical incision and 24 trials gave TXA after incision. Thirty-three trials were assessed 
as being adequately concealed (low risk of bias), five trials as inadequately concealed (high risk 
of bias). The remaining 66 trials presented insufficient information on allocation concealment to 
allow judgement and were rated as unclear. Seventy-five trials were placebo-controlled, 
whereas a no intervention group was used as the control in the remaining 29 trials. 
44 
 
Effect of TXA on blood loss 
Figure 2.5 shows the relationship between mean blood loss in the TXA group and mean blood 
loss in the control group.  
Figure 2.5 Mean blood loss in the TXA group versus mean blood loss in the control group with 
regression lines 
 
The mean blood loss in the TXA group increased as the mean blood loss in the control group 
increased, but to a lesser extent. The intercept of the regression line (dotted line) estimated by 
the Bayesian model was 4 ml (95% credibility interval -8 ml to 18 ml), a negligible value in the 
context of the observed blood loss estimates. The Bayesian model corresponded closely with 
the regression line predicted assuming a constant percentage reduction in blood loss (dashed 
line) and an intercept of zero.  
Figure 2.6 shows the summary results of a fixed effect meta-analysis of the percentage reduction 
in blood loss with TXA.  
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Figure 2.6 Results of fixed effect meta-analysis of the effect of TXA on blood loss stratified by 
type of surgery, timing of TXA administration, adequacy of allocation concealment and type of 
comparator. 
 
A forest plot showing the estimates from each trial is shown in Appendix M. The back-
transformed pooled ratio of blood loss with TXA was 0.66 (95% CI 0.65 to 0.67; p<0.001) 
indicating that TXA reduced blood loss by 34%. There was substantial statistical heterogeneity 
between trials (I2=83%). There was heterogeneity in the magnitude of effect by type of surgery 
although the extent of the variation was small. All of the subgroup estimates were consistent 
with a reduction in blood loss, and all but one was statistically significant at the 5% level. TXA 
had a greater effect on blood loss when given after incision, although the difference between 
the pre and post-incision estimates was small. There was heterogeneity in the magnitude of 
effect by adequacy of allocation concealment. When the analysis was restricted to the 33 
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adequately concealed trials, TXA reduced blood loss by 30% (0.70, 95% CI 0.68 to 0.72; p<0.001). 
There was no evidence for heterogeneity in the estimated effects of TXA when compared to a 
placebo or a no intervention control group. The results from random effects meta-analyses were 
similar to the fixed effect analyses and are shown in (Appendix N). 
A fixed dose was converted to the equivalent mg/kg dose in 21 trials. The total dose of TXA used 
in the trials ranged from 5.5mg/kg to 300mg/kg. The median dose was 22mg/kg with the 
majority of trials (70%) using a total dose of 30mg/kg or less. Results from the meta-regression 
suggested that the effect of TXA on blood loss did not vary over the dose range assessed 
(coefficient=0.889, 95% CI 0.787 to 1.004; p=0.059).  
There was no clear asymmetry in the funnel plot (Figure 2.7).  
Figure 2.7 Funnel plot with pseudo 95% confidence limits for meta-analysis of effect of TXA on 
blood loss 
 
Discussion  
Tranexamic acid reduces surgical blood loss by about a third. Although the magnitude of the 
reduction differs by type of surgery and timing of TXA administration, the differences are small 
and are unlikely to be clinically important. A total dose of 1g is likely to be sufficient for most 
adults and there is no evidence to support the use of high doses.  
The validity of these results depends on the quality of the included trials and many were of low 
quality. Less than a third of trials were judged to be at low risk of bias on the basis of allocation 
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concealment. Nevertheless, even when the analysis was restricted to adequately concealed 
trials, the effect of TXA on blood loss remained large and highly statistically significant. 
Statistical heterogeneity between trials was substantial and was not explained by type of 
surgery, trial quality, the timing of TXA administration or dose. Differences in the methods used 
to estimate blood loss, the duration over which blood loss was measured, and other aspects of 
trial quality may explain some of the heterogeneity.  
The subgroup analyses showed that the effect of TXA on blood loss varied by type of surgery, 
trial quality and timing of TXA. However, the extent of the variation was small and the clinical 
importance of such small variations is questionable.  
There was no obvious asymmetry in the funnel plot, but reporting bias remains a concern 
particularly as about one fifth of trials were not included in the analysis due to unsuitable data 
or inadequate reporting. If many of these or other unpublished trials, showed little or no effect 
of TXA on blood loss, the analysis would have overestimated the treatment effect. Although, in 
consideration of the magnitude and precision of the effect, it is unlikely that any such bias would 
account for all of the observed effect.  
The reduction in bleeding with TXA is almost identical to the reduction in the risk of receiving a 
blood transfusion with TXA suggesting that in surgery, transfusion may be closely titrated to 
blood loss. This might not be the case in trauma patients. The CRASH-2 trial found that early 
administration of TXA reduced the risk of death due to bleeding by about one third but there 
was no clear reduction in the risk of receiving a blood transfusion.94, 95  
Although there is reliable evidence that TXA reduces bleeding and blood transfusion in surgery, 
its effect on other important outcomes including death and thromboembolic events remains 
uncertain.1 There is no evidence that it increases the risk of thromboembolic events but it is a 
theoretical concern that may deter some surgeons from using TXA. These uncertainties need to 
be resolved before TXA can be recommended for routine use in surgery.  
The apparent lack of a dose-response relationship across the range of doses examined (5.5 to 
300 mg/kg) has important implications for the use of TXA in surgery. TXA crosses the blood brain 
barrier and there is some evidence from observational studies of patients undergoing cardiac 
surgery that high-dose TXA (≥100 mg/kg) may cause seizures.96, 97 Our results imply that the 
clinical benefit of TXA on bleeding can be achieved at doses much lower than those associated 
with such adverse effects.  Indeed, a total dose of about 14 mg/kg (or about 1g in adults) appears 
to be sufficient for most patients.  
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2.4 EXPLORING REDUNDANT RESEARCH INTO THE EFFECT OF TRANEXAMIC ACID ON SURGICAL 
BLEEDING: FURTHER ANALYSIS OF A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS 
Introduction to paper 3 
The results of the systematic review described in Research Papers 1 and 2 suggest that TXA 
reduces surgical bleeding. The results of the cumulative meta-analysis in Research Paper 1 
suggest that this has been known for many years. Despite this, trials continued to be initiated. 
To explore this further, I undertook further analyses to explore possible explanations for the 
continued trial activity. The results of these analyses are presented in Research Paper 3. 
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Exploring redundant research into the effect of tranexamic acid on surgical bleeding: further 
analysis of a systematic review of randomised controlled trials 
Katharine Ker, Ian Roberts 
BMJ Open. 2015 Aug 24;5(8):e009460.  
Introduction 
Results from cumulative meta-analyses are often cited as proof that many researchers fail to 
systematically review the evidence from existing trials before initiating new trials. For example, 
a cumulative meta-analysis of aprotinin in cardiac surgery1 showed that trials were initiated long 
after the pooled estimates showed a statistically significant effect. Commenting on the paper, 
Chalmers observed that it "compellingly demonstrates why all new research – whether basic or 
applied – should be designed in the light of scientifically defensible syntheses of existing research 
evidence, and reported setting the new research in the light of the totality of the available 
evidence”.2 Similar conclusions have been made on the basis of other cumulative meta-
analyses.3-5  
When the apparently redundant aprotinin trials were conducted, systematic reviews were 
relatively uncommon and failure to review the previous trials was a plausible explanation for the 
redundancy. However, given the increase in published reviews and their easy availability, lack of 
awareness of what has gone before is nowadays a less credible explanation for redundancy. We 
found that seemingly redundant trials of the effect of tranexamic acid (TXA) on blood transfusion 
were conducted even though many of them cited a systematic review concluding that the 
uncertainty had been resolved.6 Habre et al7 found that 73% of trials of an anaesthetic 
intervention, cited a systematic review showing that the uncertainty about its effects had been 
resolved. They also observed that the number of new trials increased after publication of the 
review and suggested that the strong pressure to publish and the failure of ethics committees 
to ensure the clinical relevance of new trials could be the main reasons.  
We considered two alternative explanations for the apparent redundancy. First, that trialists 
may be sceptical about the results of even seemingly conclusive reviews. Such scepticism may 
arise from concerns about systematic or random errors distorting the results. Poor quality trials 
can introduce bias and multiple statistical testing as new trials accumulate may increase the risk 
of false positive results. Second, even in the absence of substantial bias or random error, there 
may be a reluctance to generalise trial results to different patient groups.  If this were the case, 
strong evidence of a treatment effect might be expected to lead to more trial activity rather 
than less, as researchers examine the impact of patient or intervention characteristics on the 
results.  
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We used data from a cumulative meta-analyses of trials examining the effect of TXA on blood 
transfusion in surgery, to explore whether deficiencies in the quality of the evidence justify the 
continuation of trial activity. We explored the impact of trial quality on effect estimates and 
used trial sequential analysis to quantify required information sizes and construct monitoring 
boundaries to assess the risk of random error affecting the cumulative estimate. We examined 
whether patient characteristics changed over time and the reasons given by the trial 
investigators for conducting their trial.   
Methods 
Systematic review 
We extracted data from trials included in our previous systematic review of tranexamic acid 
(TXA) for surgical bleeding. The methods used to the identify trials are described in detail 
elsewhere.6 Briefly, we searched for all randomised controlled trials comparing TXA with placebo 
or a no treatment control. We searched the Cochrane Central Register of Controlled Trials, 
Medline, Embase and the WHO International Clinical Trials Registry Platform, using a 
combination of subject headings and text words to identify randomised controlled trials of any 
antifibrinolytic drug (see Appendix Q for Medline search strategy). We updated our searches to 
May 2014 to incorporate trials published since the original version of the review. Data were 
extracted on patient characteristics, type of surgery and the number of patients who received a 
blood transfusion. We used the Cochrane Collaboration’s tool for assessing risk of bias in the 
included trials.8 We assessed the risk of bias associated with the method of sequence 
generation, allocation concealment, blinding and the completeness of outcome data. Trials were 
rated as being at high, low or unclear risk of bias for each domain. We considered trials with 
adequate allocation concealment and blinded outcome assessment to be at low risk of bias.  
Analysis 
Systematic review and meta-analyses 
We calculated risk ratios and 95% confidence intervals to assess the effect of TXA on blood 
transfusion. We pooled the data in a fixed effect cumulative meta-analysis based on date of 
publication. We conducted separate meta-analysis for all trials, trials at low risk of bias, and trials 
at low risk of bias that had pre-specified blood transfusion as an outcome on a registration 
record.  
Trial sequential analyses 
We used trial sequential analyses (TSA) to examine the reliability of the cumulative meta-
analysis. TSA involves calculating the number of participants (i.e. information size) required 
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before the result of a meta-analysis can be considered reliable and constructs statistical 
monitoring boundaries to account for type I and type II errors due to multiple testing.9 We 
conducted three analyses: (1) all trials, (2) trials at low risk of bias, and (3) prospectively 
registered, low risk of bias trials with blood transfusion as a pre-specified outcome. We 
calculated the required meta-analysis information size assuming a type I error of 5% and 90% 
power, a baseline event rate of 40% and a relative risk reduction of 15%. We chose a relative 
risk reduction of 15% as we judged this to represent a minimally clinical important effect. The 
estimate was adjusted for maximum anticipated heterogeneity of I2=75%.  
We used Microsoft Excel, STATA version 1310, RevMan 5.311 and the TSA Software version 0.9 
beta12 for the analyses. 
To explore the hypothesis that reliable demonstration of a treatment effect leads to an increase 
in trial activity, we plotted the precision of the pooled effect estimate (described by the standard 
error of the cumulative pooled risk ratio) against the number of new trials initiated (defined as 
start date of recruitment) per year. We did this both for all trials and for the subset of cardiac 
surgery trials.  
We also plotted the publication date of each trial stratified by surgery type. 
We examined trial reports to explore the reasons given for trial initiation and categorised the 
reasons into main themes. 
Finally, we explored how the size and quality of trials changed over time. We compared the 
mean sample size and the proportion of trials at low risk of bias that were published before and 
after the Cochrane systematic review by Henry et al.13 This systematic review was chosen as it 
was the first and most comprehensive review conducted on the effect of TXA in surgical 
bleeding. The review was published in October 1999. We allowed for a five year time lag for the 
results of the review to have an impact on published research and compared trials published 
before and after 1 November 2004.  
Results 
Systematic review and meta-analyses 
We found 126 trials with 12,429 patients of the effect of tranexamic on blood transfusion in 
surgery with data suitable for analysis. One hundred and twenty trials (95%) were conducted in 
a single-centre. The median sample size was 79 patients (range 10 to 660). The trials involved 
cardiac (n=51), orthopaedic (n=49), obstetric and gynaecological (n=10), cranial (n=9), urological 
(n=3), hepatic (n=2), vascular (n=1), and abdominal (n=1) procedures. Thirty-eight (30%) trials 
had adequate allocation concealment and blinded outcome assessment and were considered at 
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low risk of bias. We identified a clinical trial registration record for 24 (19%) trials. Six (5%) trials 
had been prospectively registered, four (3%) of which had pre-specified blood transfusion as an 
outcome and two of these (2%) were at low risk of bias. Allowing for a 12 month publication 
time lag, 110 of the 118 (93%) trial reports published as journal articles were published when at 
least one systematic review was available. Examination of the references lists showed that 68 
(62%) cited one of the available systematic reviews.  
Based on all 126 included trials, TXA administration appeared to reduce the risk of receiving a 
blood transfusion by 38% (pooled RR=0.62; 0.59 to 0.65; p<0.0001). The cumulative estimate 
was statistically significant (p<0.05) after the second trial (published in August 1993) and 
remained so thereafter. Based on data from the 38 trials at low risk of bias, TXA appeared to 
reduce the risk of receiving a blood transfusion by 32% (pooled RR=0.68; 0.63 to 0.73; p<0.001).  
The cumulative estimate was first statistically significant after the fourth high quality trial but 
remained statistically significant after the sixth trial. For all trials and for trials at low risk of bias, 
we observed funnel plot asymmetry consistent with a deficit of small trials showing no 
treatment effect. When the analysis was limited to the two low risk of bias, prospectively 
registered trials that pre-specified blood transfusion as an outcome measure, TXA appeared to 
reduce the risk of transfusion by 21% (pooled RR=0.79, 0.71 to 0.87; p<0.001). 
Trial sequential analyses 
Figure 2.8 shows the results of the trial sequential analyses. The required information size was 
estimated at 10,888 patients. For each analysis an information size (IS) was calculated on the 
basis assuming α=5%, β=10%, control group event rate of 40%, relative risk reduction of 15% 
and anticipated maximum heterogeneity of I2=75%. The solid black line illustrates the 
cumulative z curve, the solid grey line shows the trial sequential monitoring boundary. 
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Figure 2.8 Results of trial sequential analyses for a) all trials; b) trials at low risk of bias; and c) 
low risk of bias trials with transfusion pre-specified on prospective registration record.  
 
Based on data from all 126 trials, there appears to be strong evidence that TXA reduces the risk 
of blood transfusion in surgery. The z-curve crosses the monitoring boundary before the 
heterogeneity-adjusted information size is achieved when the 28th trial published in March 
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2001. Prior to this point there were 26 potentially spurious p-values. Since the monitoring 
boundary was crossed, a further 98 trials have been published.  
Based on the 38 low risk of bias trials, there appears to be strong evidence that TXA reduces 
blood transfusion. The z-curve crosses the monitoring boundary after the 22nd high quality trial 
published in November 2008. Prior to this point there were 18 potentially spurious p-values. 
Since the monitoring boundary was crossed, a further 15 high quality trials have been published.  
When the analysis is restricted to the two low risk of bias trials which had pre-specified blood 
transfusion as an outcome, the z-curve does not cross the monitoring boundary and the 
heterogeneity-adjusted information size is not achieved. There is one potentially spurious p-
value. 
Figure 2.9 shows the precision of the cumulative pooled estimate (standard error of the log 
cumulative RR) and the number of trials initiated per year from 1991 to 2014.  
Figure 2.9 Precision of the cumulative pooled estimates described by the standard error of the 
RRs (left hand axis) and the number of trials (five year moving averages, right hand axis) initiated 
per year. 
 
As the precision of the pooled estimate increases (i.e. decrease in the standard error), the 
number of new trials initiated each year also increases. A similar pattern is observed for trials in 
cardiac surgery (Figure 2.10). 
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Figure 2.10 Precision of the cumulative pooled estimates for the effect of TXA in cardiac surgery 
described by the standard error of the RRs (left hand axis) and the number of trials (five year 
moving averages, right hand axis) initiated per year. 
 
Figure 2.11 shows a timeline of the publication of the trials, stratified by surgery type. It appears 
that trials were first conducted in cardiac surgery and shortly afterwards in orthopaedic surgery. 
Trial activity then expands to other types of surgery namely cranial, urological and 
gynaecological surgery.   
Figure 2.11 Timeline of publication of trials of TXA stratified by type of surgery. 
 
Qualitative review of trial justifications 
Eight trials were reported in abstract or summary form only, leaving 118 trials reported in 
sufficient detail to extract information on the rationale. A summary of the extracted information 
is shown in Table 2.3. Concerns about the generalisability of the available evidence was used to 
justify 71 (60%) trials. These trials sought to replicate a previously observed beneficial effect of 
TXA on surgical bleeding but in a different group of patients, such as those undergoing a different 
type of surgical procedure. Thirty-one (26%) trials were initiated to answer a different research 
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question to the effect of TXA on bleeding. Most of these trials were conducted to examine the 
effect of different doses or timings of TXA despite the inclusion of a placebo or no-TXA control 
group. Five (4%) trials appeared to have been conducted because of a failure to synthesise prior 
evidence. The trial rationale was unclear in four (4%) trials.  
Table 2.3 Summary of reasons for initiating trials of TXA for surgical bleeding based on 
information extracted from the final reports  
 
Failure to 
synthesise 
evidence 
Confirmatory Generalisability 
Assessing a 
different 
research 
question 
Unclear 
Trials citing ≥1 
available systematic 
review (n=68) 
- 2 51 11 4 
Trials not citing an 
available systematic 
review (n=42) 
2 3 21 16 - 
Trials published 
before a systematic 
review was available 
(n=9) 
3 - - 6 - 
All trial reports 
(n=118) 
5 (4%) 5 (4%) 72 (61%) 33 (28%) 4 (3%) 
 
Comparison of trials conducted before and after publication of the Henry et al systematic 
review 
Of the 126 trials, 47 (37%) were published before 1 November 2004 compared to 79 (63%) 
published afterwards up to May 2014. The average sample size had increased between the two 
periods (mean ± standard deviation, 64±50 versus 119±103; p<0.0001). A larger proportion of 
trials published after November 2004 were judged to be at low risk of bias for both allocation 
concealment and blinding (12 [26%] versus 28 [35%]; P=0.23). 
Discussion 
Principal findings 
We examined two hypotheses for the redundancy in a cumulative meta-analysis. First, that 
despite the apparently conclusive results, legitimate concerns about bias and random error 
justified new trials. We found some support for this. Most trials were small, single centre, low 
quality and hardly any were prospectively registered. Nevertheless, when only high quality trials 
were considered, with steps taken to reduce the risk of false positive results, there remained 
strong evidence that TXA reduces transfusion.  
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Our second hypothesis was that new trials are conducted because of concerns about the 
generalisability of the results. We found strong support for this. Increasing evidence that TXA 
decreases the need for blood transfusion resulted in more trial activity and not less. The change 
in patient characteristics over time and the rationales given by trialists also indicate that 
generalisability concerns motivated the new trials. That over half of trials cited at least one of 
the existing systematic reviews, suggests that ignorance of the existing evidence does not fully 
explain ongoing trial activity.  
The average sample size of trials has increased and there is some suggestion that the quality of 
trials has improved over time. 
Strengths and weaknesses 
We examined trial reports to find the reasons authors gave for conducting new trials. This 
process was inevitably subjective and different assessors might have made different 
judgements. Furthermore, trial reports might not accurately reflect the rationale at trial 
inception. We did not contact authors, although whether this would have provided more reliable 
information is uncertain. There are other, non-scientific motivations, such as monetary and 
academic, for initiating a new trial which would not be publically reported. Nevertheless, the 
reasons given in trials reports are the openly given justifications that are accepted by the 
scientific community and are therefore a reasonable focus for review. 
Our study was based on clinical trials of TXA in surgery and the extent to which the results apply 
to other topics is questionable. However, we have also found that publication of a systematic 
review showing strong evidence that TXA reduces mortality in bleeding trauma patients also 
resulted in increased trial activity rather than less. A 2004 systematic review of TXA in acute 
traumatic injury14 found no eligible trials even though TXA was commonly used in other bleeding 
conditions. The review prompted the CRASH-2 trial which included 20,211 bleeding trauma 
patients and showed that TXA reduces death due to bleeding and all-cause mortality.15 The 
subsequently updated review included two trials and reported that the uncertainty had been 
resolved.16 Nevertheless, some authors, pointing out that many of the patients in the CRASH-2 
trial were recruited from hospitals in Africa, Asia and Latin America, questioned whether the 
results can be applied in “modern” trauma care systems17 and have initiated new clinical trials 
rather than implementing the results.18, 19 Although subgroup analyses show that the CRASH-2 
trial results do not vary by geographical region,20 two placebo controlled trials are underway. 14, 
15 Habre et al7 also found that publication of a conclusive review coincided with increased trial 
activity and that most new trials cited the conclusive review.  
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There are other potential explanations for the continuation of trial activity that we have not 
explored. Habre et al suggested that redundant trials of an anaesthetic intervention may have 
been motivated by the self-interest of researchers wishing to gain more research publications. 
In relation to our study, trials of the effect of TXA on blood transfusion are relatively easy to 
conduct and since a treatment effect is highly likely, it would be an attractive topic for research.  
Implications 
Our results raise questions about the process of scientific generalisation. If there is strong 
evidence that TXA reduces bleeding in cardiac and orthopaedic surgery, is it necessary to 
examine its effect in obstetric surgery? Rothman et al21 argues that the reluctance to generalise 
results to populations that were not represented in the original research confuses statistical and 
scientific inference. Statistical inference, the process of using sample information to reach 
conclusions about the population from which it was drawn, is helped by having a representative 
sample. However, generalising trial results involves scientific inference, a process of reaching 
general conclusions about how a treatment works. The main prerequisite for scientific inference 
is a biological insight into the mechanism of action of the treatment and an awareness of the 
circumstances that may be relevant to this mechanism. Rather than using statistical reasoning, 
it is more appropriate to use biological reasoning and ask whether there is any good reason why 
TXA would work differently in orthopaedic or urological surgery? 
A further concern is the number of inappropriately designed trials. This typically concerns trials 
which aimed to build on the existing knowledge by comparing different doses or timings of TXA, 
yet opted to include a no-treatment comparison group. The inclusion of a no-treatment 
comparison group in such trials is wasteful and unethical - failings that implicate both trialists 
and the ethical review committees approving the trials. In this article we focus on the potential 
explanations for trialists’ decision to initiate further trials of TXA, yet there is also a question 
regarding why patients continue to agree to participate in apparently ‘redundant’ trials in which 
there is a chance they will forego receiving an effective treatment. We did not attempt to obtain 
the patient information sheets used in the trials, and there remains an unanswered question 
regarding the extent to which trial participants are made aware of the existing evidence as part 
of the consent giving process. 
Our results suggest that low quality trials are a more important cause of ‘research waste’ than 
the failure to systematically review the existing evidence. When only high quality trials are 
considered, the number of statistically ‘redundant’ trials was reduced from 98 to 15. Most trial 
reports clearly indicated an awareness that TXA had been shown to reduce bleeding but sought 
to examine its effect in different types of surgery. For this reason, more systematic reviews and 
greater attention to existing reviews will only increase research waste unless determined efforts 
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are made to increase quality in the form of adequately powered trials that are properly 
randomised with adequate allocation concealment and blinding. 
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3.0 WHAT ARE THE EFFECTS OF TRANEXAMIC ACID IN PATIENTS WITH TRAUMATIC 
BLEEDING? 
3.1 INTRODUCTION TO RESEARCH PAPER 4 
As described in Chapter 1, bleeding is an important cause of death and morbidity in trauma 
patients. As an inhibitor of fibrinolysis, tranexamic acid (TXA) has the potential to reduce 
bleeding.  
Based on evidence from trials in surgery, it was surmised that TXA might also be effective in 
bleeding trauma patients, although no randomised trials had been conducted in this patient 
group.1 The CRASH-2 trial involving 20,211 bleeding trauma patients was conducted to resolve 
this uncertainty.2  
The CRASH-2 trial results were published in June 2010. As the results of all trials should be 
interpreted in the context of a systematic review,3 I updated the Cochrane systematic review of 
‘Antifibrinolytic drugs for acute traumatic injury’ to incorporate the results of the CRASH-2 trial 
and any other trials of antifibrinolytic drugs that had been conducted since the first publication 
of the review in 2004.1  
The updated review was published as a ‘substantive update’ in November 2010. I completed a 
further update in November 2012 to incorporate findings of subgroup analyses of the CRASH-2 
trial data and it is this version that I have included in this thesis. 
The inclusion criteria of the review include all antifibrinolytic drugs (aprotinin, tranexamic acid 
and epsilon-aminocaproic acid). Since I am focussing on the effects of TXA in this thesis, I have 
only included results relevant to the evidence from trials of TXA in the proceeding section; 
however, the full published version of the review is presented in Appendix T. 
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3.2 ANTIFIBRINOLYTIC DRUGS FOR ACUTE TRAUMATIC INJURY  
Ian Roberts, Haleema Shakur, Katharine Ker, Tim Coats, on behalf of the CRASH-2 Trial 
collaborators 
Cochrane Database Systematic Reviews 2012;12:CD004896 
Background 
Description of the condition 
For people aged five to 45 years, trauma is second only to HIV/AIDS as a cause of death. Each 
year, worldwide, about three million people die as a result of trauma,1 many after reaching 
hospital. Among trauma patients who do survive to reach hospital, exsanguination is a common 
cause of death, accounting for nearly half of in-hospital trauma deaths in some settings.2 Central 
nervous system injury and multi-organ failure account for most of the remainder, both of which 
can be exacerbated by severe bleeding.3 
Clotting helps to maintain the integrity of the circulatory system after vascular injury, whether 
traumatic or surgical in origin.4 Major surgery and trauma trigger similar haemostatic responses 
and the consequent massive blood loss presents an extreme challenge to the coagulation 
system. Part of the response to surgery and trauma in any patient, is stimulation of clot 
breakdown (fibrinolysis) which may become pathological (hyper-fibrinolysis) in some cases. 
Antifibrinolytic agents have been shown to reduce blood loss in patients with both normal and 
exaggerated fibrinolytic responses to surgery, without apparently increasing the risk of post-
operative complications. 
Description of the intervention 
Antifibrinolytic agents are widely used in major surgery to prevent fibrinolysis and reduce 
surgical blood loss. A Cochrane systematic review of randomised controlled trials of 
antifibrinolytics (mainly aprotinin or tranexamic acid [TXA]) in elective surgical patients showed 
that antifibrinolytics reduced the numbers needing transfusion by one third, reduced the 
volume needed per transfusion by one unit, and halved the need for further surgery to control 
bleeding.5 These differences were all statistically significant at the p<0.01 level. Specifically, 
aprotinin reduced the rate of blood transfusion by 34% (relative risk [RR]=0.66; 95% confidence 
interval [CI] 0.60 to 0.72) and TXA by 39% (RR=0.61; 95% CI 0.53 to 0.70). Aprotinin use saved 
1.02 units of red blood cells (RBCs) (95% CI 0.79 to 1.26) in those requiring transfusion, and TXA 
use saved 0.87 units (95% CI 0.53 to 1.20). There was a non-significant reduction in mortality 
with both aprotinin (RR=0.81; 95% CI 0.63 to 1.06) and TXA (RR=0.60; 95% CI 0.33 to 1.10). 
How the intervention might work 
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Because the coagulation abnormalities that occur after injury are similar to those after surgery, 
it is possible that antifibrinolytic agents might also reduce blood loss and mortality following 
trauma. A simple and widely practicable intervention that reduced blood loss following trauma 
might prevent tens of thousands of premature deaths. A reduction in the need for transfusion 
would also have important public health implications. Blood is a scarce and expensive resource 
and major concerns remain about the risk of transfusion-transmitted infection. Trauma is 
particularly common in parts of the world where the safety of blood transfusion cannot be 
assured. A recent study in Uganda estimated the population-attributable fraction of HIV 
acquisition as a result of blood transfusion to be around two percent although some estimates 
are much higher.6, 7 
Objectives 
To quantify the effect of antifibrinolytic drugs on mortality, vascular occlusive events, surgical 
intervention and receipt of blood transfusion after acute traumatic injury. 
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised controlled trials (RCT), as per the following definition. 
RCT: A study involving at least one intervention and one control treatment, concurrent 
enrolment and follow-up of the intervention and control groups, and in which the interventions 
to be tested are selected by a random process, such as the use of a random numbers table (coin 
flips are also acceptable). If the study author(s) state explicitly (usually by using some variant of 
the term 'random' to describe the allocation procedure used) that the groups compared in the 
trial were established by random allocation, then the trial is classified as an 'RCT'. 
Types of participants 
People of any age following acute traumatic injury. 
Types of interventions 
The interventions considered are the antifibrinolytic agents: aprotinin, tranexamic acid (TXA) 
and epsilon-aminocaproic acid (EACA).vi 
Types of outcome measures 
Primary outcome 
                                                            
vi Sections relating to the effects of aprotinin and EACA have been omitted from this thesis for clarity. 
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Mortality at the end of the follow up. 
Secondary outcomes 
• Number of patients experiencing an adverse event, specifically vascular occlusive events 
(myocardial infarction, stroke, deep vein thrombosis or pulmonary embolism). 
• Number of patients undergoing surgical intervention. 
• Number of patients receiving blood transfusion. 
• Volume of blood transfused (units). 
Search methods for identification of studies 
Searches were not restricted by date, language or publication status. 
Electronic searches 
We searched the following electronic databases: 
• Cochrane Injuries Group's Specialised Register (searched July 2010) 
• Cochrane Central Register of Controlled Trials Issue 3, 2010 (The Cochrane Library) 
• MEDLINE (1966 to July week 2, 2010) 
• PubMed (searched March 17, 2004) 
• EMBASE (1980 to week 28, July 2010) 
• Science Citation Index (searched March 17, 2004) 
• National Research Register (issue 1, 2004) 
• Zetoc (searched March 17, 2004) 
• SIGLE (searched March 17, 2004) 
• Global Health (searched March 17, 2004) 
• LILACS (searched March 17, 2004) 
• Current Controlled Trials (searched March 17, 2004) 
The search strategies used in the latest update are listed in full in Appendix U. 
Searching other resources 
All references in the identified trials and background papers were checked and study authors 
contacted to identify relevant published and unpublished data. Pharmaceutical companies were 
contacted in 2004 to obtain information on ongoing trials. 
Data collection and analysis 
Selection of studies 
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The titles and abstracts identified in the electronic searches were screened by two independent 
authors to identify studies that had the potential to meet the inclusion criteria. The full reports 
of all such studies were obtained. From the results of the screened electronic searches, 
bibliographic searches and contacts with experts, two authors independently selected trials 
meeting the inclusion criteria. There were no disagreements on study inclusion. 
Data extraction and management 
Two authors independently extracted information on the following: number of randomised 
participants, types of participants and types of interventions. The outcome data sought were: 
numbers of deaths in each group, numbers with vascular occlusive events, numbers requiring 
surgical intervention, and the amount of blood transfused. Information on loss to follow up, 
blinding, and whether an intention-to-treat analysis was performed was also extracted. The 
authors were not blinded to the authors or journal when doing this. Results were compared and 
differences would have been resolved by discussion had there been any. Where there was 
insufficient information in the published report, we attempted to contact the authors for 
clarification. 
Assessment of risk of bias in included studies 
Two authors assessed the risk of bias for allocation concealment. Each trial was assessed as 
being at high, low or unclear risk of bias according to the criteria presented in Higgins et al 2008.8 
Assessment of heterogeneity 
The presence of heterogeneity of the observed treatment effects were assessed using the I2 
statistic, which describes the percentage of total variation across studies due to heterogeneity 
rather than chance. A value of 0% indicates no observed heterogeneity, and larger values show 
increasing heterogeneity; substantial heterogeneity is considered to exist when I2>50%.9 The 
following were specified a-priori as factors that could explain any observed heterogeneity: 
adequacy of allocation concealment; injury severity based on the injury severity score (an ISS of 
greater than or equal to 16 defines the severely injured strata); and according to whether the 
study population included predominantly blunt or penetrating trauma. 
Assessment of reporting biases 
We planned to investigate the presence of reporting (publication) bias using funnel plots, 
however there were too few included studies to enable meaningful analysis. 
Data synthesis 
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Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated. The risk ratio was chosen 
because it is more readily applied to the clinical situation. For transfusion volumes, the mean 
difference (MD) in the units of blood transfused were calculated with 95% CI. 
Subgroup analysis and investigation of heterogeneity 
We planned to conduct subgroup analyses to explore whether effect sizes vary according to the 
type of antifibrinolytic agent and the dosing regimen. However, there were too few trials for 
such analyses. 
Results 
Tranexamic acid 
Two trials compared TXA with placebo in trauma patients. The CRASH-2 trial recruited 20,211 
trauma patients with, or at risk of, significant haemorrhage.10, 11 A trial in Thailand by 
Yutthakasemsunt et al recruited 240 trauma patients with moderate to severe traumatic brain 
injury.12 As of November 2012, the Thai trial Yutthakasemsunt et al was only available as an 
abstract with publication of the full trial report pending. The trial has been included based on 
the data reported in the abstract. The full trial data will be incorporated into this systematic 
review once the full trial report is available. 
See 'Characteristics of included studies' in Appendix V for further details. 
Risk of bias in included studies 
The CRASH-2 trial was judged to be at low risk of bias. It was a large randomised controlled trial 
involving 20,211 adult trauma patients who were randomly allocated to receive TXA or placebo. 
TXA and placebo were packaged in identical ampoules. Hospitals with reliable telephone access 
used a telephone randomisation service, hospitals without used a local pack system; allocation 
concealment was adequate. Participants and trial staff were blinded to treatment allocation. 
Over 99% of patients were followed up. 
There was insufficient information presented in the abstract to assess the risk of bias of the trial 
by Yutthakasemsunt et al. 
Effects of interventions - Tranexamic acid versus placebo 
Mortality 
Both the CRASH-2 trial and the trial by Yutthakasemsunt et al reported mortality data. 
All-cause mortality was significantly reduced with tranexamic acid (pooled risk ratio (RR) 0.90, 
95% CI 0.85 to 0.97; p=0.003: Figure 3.1). There was no evidence of statistical heterogeneity 
(Chi²=0.77, df=1 (p=0.38); I²=0%). 
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Figure 3.1 Comparison 1 Tranexamic acid versus placebo, Outcome 1 All-cause mortality. 
 
The CRASH-2 trial also presented mortality data by cause. The risk of death due to bleeding and 
myocardial infarction were significantly reduced with TXA. There were no statistically significant 
differences in the risk of death from other causes: 
• Bleeding: RR 0.85, 95% CI 0.76 to 0.96; p=0.0077 
• Myocardial infarction: RR 0.32, 95% CI 0.14 to 0.75; p=0.0053 
• Vascular occlusion: RR 0.69, 95% CI 0.44 to 1.07; p=0.096 
• Stroke: RR 1.60, 95% CI 0.52 to 4.89; p=0.40 
• Pulmonary embolism: RR 0.86, 95% CI 0.46 to 1.61; p=0.63 
• Multi-organ failure: RR 0.90, 95% CI 0.75 to 1.08; p=0.25 
• Head injury: RR 0.97, 95% CI 0.87 to 1.08; p=0.60 
• 'Other’ causes: RR 0.94, 95% CI 0.74 to 1.20; p=0.63 
Although not prespecified subgroup analyses of this review, the effects of TXA on death due to 
bleeding by time to treatment, severity of haemorrhage, Glasgow coma score, and type of injury 
were assessed in the CRASH-2 trial.11 The results are presented below. 
Analysis of the risk of death due to bleeding indicated that the effect of TXA varied by time to 
treatment. Treatment within one hour of injury was associated with a 32% relative reduction in 
risk of death due to bleeding (RR 0.68, 95% CI 0.57 to 0.82; p<0.0001) and treatment between 1 
and 3 hours after injury was associated with a 21% reduction (RR 0.79, 95% CI 0.64 to 0.97; 
p=0.03). Treatment with TXA after three hours of injury was associated with a 44% relative 
increase in risk of death due to bleeding (RR 1.44, 95% CI 1.12 to 1.84; p=0.004). Test for 
subgroup differences: Chi²=23.51, P<0.00001. 
There was no evidence that the effect of TXA on death due to bleeding varied by the severity of 
haemorrhage, Glasgow coma score, or type of injury: 
• Severity of haemorrhage (as assessed by systolic blood pressure): >89 mm Hg (RR 0.88, 
95% CI 0.71 to 1.10); 76-89 (RR 1.01, 95% CI 0.79 to 1.30); ≤75 (RR 0.81, 95% CI 0.69 to 
0.95). Test for subgroup differences: Chi²=2.24, p=0.33. 
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• Glasgow coma score: severe (RR 0.92, 95% CI 0.76 to 1.13); moderate (RR 0.77, 95% CI 
0.59 to 0.99); mild (RR 0.86, 95% CI 0.72 to 1.02). Test for subgroup differences: 
Chi²=1.28, p=0.53. 
• Type of injury: blunt (RR 0.89, 95% CI 0.77 to 1.04); penetrating (RR 0.79, 95% CI 0.66 to 
0.96). Test for subgroup differences: Chi²=0.92, p=0.34. 
Vascular occlusive events 
The CRASH-2 trial reported data on vascular occlusive events. There was no difference in the risk 
of experiencing one or more vascular occlusive events (fatal or non-fatal; myocardial infarction, 
stroke, pulmonary embolism, deep vein thrombosis) between the TXA and placebo groups (RR 
0.84, 95% CI 0.68 to 1.02; p=0.084). TXA reduced the risk of myocardial infarction (RR 0.64, 95% 
CI 0.42 to 0.97; p=0.035). There was no difference in the risk of stroke (RR 0.86, 95% CI 0.61 to 
1.23; p=0.42), pulmonary embolism (RR 1.01, 95% CI 0.73 to 1.41; p=0.93) or deep vein 
thrombosis (RR 0.98, 95% CI 0.63 to 1.51; p=0.91). 
Surgical intervention 
Data from the CRASH-2 trial suggest that there is no statistically significant difference in the risk 
of receiving one or more surgical interventions (neurosurgery, chest, abdominal or pelvic 
surgery) (RR 1.00, 95% CI 0.97 to 1.03; p=0.79) (Figure 3.2). 
Figure 3.2 Comparison 1 Tranexamic acid versus placebo, Outcome 2 Proportion undergoing 
surgical intervention. 
 
Receipt of blood transfusion 
Of the patients allocated to TXA in the CRASH-2 trial, 5067 (50.4%) received a blood product 
transfusion versus 5160 (51.3%) of the patients allocated to placebo (RR 0.98, 95% CI 0.96 to 
1.01; p=0.21) (Figure 3.3).  
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Figure 3.3 Comparison 1 Tranexamic acid versus placebo, Outcome 3 Proportion receiving blood 
transfusion. 
 
There was no difference in the average number of blood units transfused (MD -0.17; 95% CI -
0.39 to 0.05; p=0.13) (Figure 3.4). 
Figure 3.4 Comparison 1 Tranexamic acid versus placebo, Outcome 4 Volume of blood 
transfused. 
 
Discussion 
Summary of main results 
Tranexamic acid reduces all-cause mortality in bleeding trauma patients, with no apparent 
increase in the risk of vascular occlusive events. This conclusion is based on the results of the 
CRASH-2 trial which recruited 20,211 bleeding trauma patients from 274 hospitals in 40 
countries. 
Overall completeness and applicability of evidence 
The large numbers of patients in a wide range of different health care settings around the world 
studied in the CRASH-2 trial help the result to be widely generalised. The treatment is effective 
in patients with blunt and penetrating trauma. Because TXA is inexpensive and easy to 
administer, it could readily be added to the normal medical and surgical management of 
bleeding trauma patients in hospitals around the world. 
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Each year, worldwide, about four million people die as a result of traumatic injuries and violence. 
Approximately 1.6 million of these deaths occur in hospital and about one third of these deaths 
(480,000) are from haemorrhage. The CRASH-2 trial has shown that TXA reduces mortality from 
haemorrhage by about one sixth. If this widely practicable intervention was used worldwide in 
the treatment of bleeding trauma patients, it could prevent over 70,000 deaths each year (see 
Table 3.1). 
Table 3.1 Deaths that could be avoided by the administration of TXA to bleeding trauma patients 
(ten countries with the highest numbers of avoided deaths shown) 
Country Trauma deaths Haemorrhage deaths 
Deaths averted with 
TXA 
India 714,730 85,768 12,865 
China 667,277 80,073 12011 
Indonesia 279,499 33,534 5030 
Russia 246,836 29,620 4443 
Brazil 122,953 14,754 2206 
USA 122,529 14,703 2206 
Iraq 99,968 11,996 1799 
Nigeria 87,811 10,537 1581 
Bangladesh 76,938 9233 1385 
DRC 73,579 8829 1324 
World 4,100,645 492,077 73,812 
 
Many trauma patients suffer a brain injury. Traumatic brain injury (TBI) is commonly 
accompanied by intracranial bleeding which can develop or worsen after hospital admission. 
Traumatic intracranial haemorrhage is associated with an increased risk of death and disability, 
and regardless of location, haemorrhage size is strongly correlated with outcome. If TXA reduced 
intracranial bleeding after isolated TBI then this could improve patient outcomes. Although, 
many of the bleeding trauma patients included in the CRASH-2 trial also suffered a brain injury, 
it is possible that the effects of TXA may differ in patients with isolated TBI. The trial by 
Yutthakasemsunt et al provides some promising evidence for the beneficial effect of TXA on 
mortality in patients with isolated TBI; however, further evidence is required from larger trials 
which also assess the effect on disability. 
The quality of the evidence supporting the use of tranexamic acid for trauma is high. The findings 
of this review are based primarily on the results of the CRASH-2 trial. This was a large, high 
quality randomised trial with low risk of bias. Sequence generation was appropriately 
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randomised, allocation was concealed and participants, trial personnel and outcome assessors 
were all blinded. Furthermore, there were minimal missing data with over 99% of patients 
followed up. 
Potential biases in the review process 
This systematic review addresses a focused research question and uses pre-defined inclusion 
criteria and methodology to select and appraise eligible trials. 
As with all systematic reviews, the possibility of publication bias should be considered as a 
potential threat to validity. However, in light of our extensive and sensitive searching we believe 
that the risk of such a bias affecting the results is minimal. 
Agreements and disagreements with other studies or reviews 
A systematic review of randomised trials assessing the effects of TXA in patients undergoing 
elective surgery has been conducted.5 This review found that compared to control, TXA reduced 
the need for blood transfusion without any apparent increase in the risk of adverse events. 
Unlike the Henry et al review, we found no evidence of any substantial reduction in the receipt 
of a blood transfusion or the amount of blood transfused in trauma patients. One possible 
explanation is that in the CRASH-2 trial, following the loading dose, TXA was infused over a 
period of eight hours, whereas decisions about transfusion are made very soon after hospital 
admission. The absence of any large effect on blood transfusion may also reflect the difficulty of 
accurately estimating blood loss in trauma patients when assessing the need for transfusion. 
Finally, the absence of any substantial reduction in transfusion requirements in patients treated 
with TXA acid may reflect the fact that there were fewer deaths in patients allocated to TXA acid 
than to placebo and patients who survive as a result of TXA administration would have had a 
greater opportunity to receive a blood transfusion (competing risks). 
Authors' conclusions 
Implications for practice 
Tranexamic acid (TXA) safely reduces mortality in bleeding trauma patients. As there is evidence 
that the effect on death due to bleeding depends on the time interval between the injury and 
treatment, TXA should be given as early as possible and within three hours of the injury as 
treatment later than this is unlikely to be effective. 
Implications for research  
The knowledge that TXA safely reduces the risk of death from traumatic bleeding raises the 
possibility that it might also be effective in other situations where bleeding can be life 
threatening or disabling and further research is warranted to explore this potential. Randomised 
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trials involving patients with isolated traumatic brain injury that assess both mortality and 
disability outcomes are required before TXA can be recommended for use in these patients. The 
ongoing CRASH-3 trial with a planned sample size of 10,000 patients with traumatic brain injury, 
will contribute to resolving the uncertainty about the effects of TXA in this group. 
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3.3 INTRODUCTION TO RESEARCH PAPER 5 
The results of the Cochrane systematic review updated with the CRASH-2 trial results described 
in Research Paper 4, showed that TXA reduces the risk of death in bleeding trauma patients. It 
also showed that early treatment (<3 hours) with TXA is superior to late treatment (>3 hours).  
These results along with the fact that TXA is cheap and a widely practicable treatment, suggests 
that it has the potential to save the lives of many trauma victims including in LMICs where most 
trauma deaths occur.  
Estimates of the number of deaths averted worldwide, along with country-specific estimates 
can be valuable for targeting dissemination efforts. In the Discussion section of Research Paper 
4, we estimated the number of bleeding deaths that could be avoided through the routine use 
of TXA when given within 8 hours of injury. However, in light of the knowledge the late 
treatment with TXA is unlikely to be effective (and may even be harmful), treatment with TXA if 
more than three hours after injury is not recommended. Therefore, I undertook further analyses 
to estimate the number of deaths that could be averted by the routine, early use of TXA. These 
analyses are presented in Research Paper 5 and include a systematic review of the literature 
which informed the parameter estimates.vii  
 
  
                                                            
vii A copy of the PDF version of the published manuscript is included in Appendix Z. 
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3.4 AVOIDABLE MORTALITY FROM GIVING TRANEXAMIC ACID TO BLEEDING TRAUMA PATIENTS: AN 
ESTIMATION BASED ON WHO MORTALITY DATA, A SYSTEMATIC LITERATURE REVIEW AND DATA FROM THE 
CRASH-2 TRIAL  
Katharine Ker, Junko Kiriya, Pablo Perel, Phil Edwards, Haleema Shakur, Ian Roberts 
BMC Emergency Medicine. 2012 Mar 1;12:3.  
Background  
Trauma is a leading cause of death and disability. Each year, worldwide, an estimated 5.8 million 
people die as a result of trauma,1 many after reaching hospital. Among trauma patients who 
survive to reach hospital, bleeding is a common cause of death, accounting for around 40% of 
in-hospital trauma deaths.2  
The CRASH-2 trial was an international randomised controlled trial of the early administration 
of tranexamic acid (TXA) to bleeding trauma patients. The trial recruited 20,211 patients from 
274 hospitals in 40 countries. The results show that TXA reduces mortality in trauma patients 
with or at risk of bleeding, with no apparent increase in side effects.3 If given within three hours 
of injury, TXA reduces the risk of death due to bleeding by about a third.4 TXA administration 
has been shown to be highly cost-effective in high, middle or low income countries.5 On the 
basis of the results of the CRASH-2 trial, TXA has been included on the WHO Essential Medicines 
List.6  
Since publication of the trial results, TXA has been included into trauma care guidelines in many 
high income countries. In March 2010, the British Army incorporated TXA into combat care 
treatment protocols7 and in July 2011 the UK NHS ambulance service agreed that TXA would be 
given to all adults and teenagers who suffer major injury in the UK. In 2011, the US Army 
reviewed the evidence from the CRASH-2 trial and included TXA into its trauma treatment 
protocols. However, bearing in mind that 90% of trauma deaths are in low and middle income 
countries,8 the potential of TXA to reduce premature mortality is likely to be much greater in 
these settings. An estimation of the number of deaths that could be averted through the use of 
TXA for in traumatic haemorrhage would allow better targeting of dissemination and 
implementation activities. In this study we used data from the CRASH-2 trial, WHO mortality 
database and a systematic review of the recent literature, to estimate the potential number of 
deaths that could be averted through the early administration of TXA to bleeding trauma 
patients.  
Methods 
Estimation of effect of TXA on death due to bleeding by geographical region 
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We used individual patient data from the CRASH-2 trial to assess the extent to which the effect 
of TXA on death due to bleeding varied according to geographical region. Hospitals participating 
in the CRASH-2 trial were grouped into four geographical regions: (1) Africa, (2) Asia, (3) Europe, 
Australia, North America, and (4) Central & South America. Heterogeneity in treatment effect by 
geographical region was assessed by a χ2 test. We pre-specified that unless there was strong 
evidence against the null hypothesis of homogeneity of effects (i.e. p<0.001), the overall risk 
ratio (RR) would be considered to be the most reliable guide to the approximate RRs in all 
regions. 
Estimation of number of in-hospital trauma deaths due to bleeding per year  
The number of in-hospital trauma deaths that are due to bleeding and thus potentially avoidable 
through the early administration of TXA was estimated in three steps. First, we obtained 
estimates of the number of trauma deaths (N) by country. Second, we estimated the proportion 
of trauma deaths that occur in hospital (P). Third, we estimated the proportion of in-hospital 
trauma deaths that were due to bleeding (B). The number of in-hospital trauma deaths due to 
bleeding per year (HBD) was then estimated according to the following equation:  
 HBD = N × P × B  
Since the proportion of deaths due to bleeding (B) may vary according to type of injury (i.e. blunt 
or penetrating)9, we obtained data on the proportion of blunt trauma deaths (PB) that was due 
to bleeding (BDB) and the proportion of penetrating trauma deaths (PP) that was due to bleeding 
(PDB). These estimates were combined to derive the overall proportion (B) using the equation: 
B = (PB × BDB) + (PP × PDB) 
The number of premature deaths potentially averted by TXA was then estimated by applying the 
relative risk reduction from the CRASH-2 trial to the number of in-hospital deaths due to bleeding 
as follows: 
Premature deaths averted = HBD × (1 – RR) 
Data sources 
Data from the WHO, the CRASH-2 trial and a systematic review of literature published since 2004 
were used to parameterise the equations. The number of trauma deaths for each country, were 
obtained from the WHO for the year 2008, the most recent year for which data were available. 
Blunt trauma deaths were estimated by adding the number of deaths from road traffic crashes, 
falls and other unintentional injuries. Penetrating trauma deaths were estimated by adding the 
number of deaths from violence and war. Deaths from drowning, poisoning, self-inflicted injuries 
or burns were not included as these injuries are not usually associated with life-threatening 
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bleeding. Estimates of the proportion of trauma deaths that are in-hospital and the proportion 
caused by bleeding were based on data from the CRASH-2 trial and from studies identified 
through a systematic review. 
Systematic review methods 
We searched for studies containing original data describing the epidemiology of trauma deaths. 
We searched MEDLINE, EMBASE and Cab Abstracts on 2 March 2011 using a combination of 
subject headings and key words based on the following terms; injuries, trauma, mortality, death, 
fatality, burden, epidemiology. We searched the internet and checked the reference lists of 
eligible articles. The searches were not restricted by language or publication status. To improve 
the applicability of the extracted data to the current patterns in trauma death epidemiology, we 
limited our search to studies published since 2004.  
Record screening, full text review and data extraction were performed independently by two 
authors (KK and JK), with any disagreements resolved through discussion. Data were extracted 
on study design, setting, sample size, the proportions of deaths occurring in hospital and due to 
bleeding, using a pre-designed form. Studies that did not provide data on any of the parameters 
of interest were excluded. 
To obtain a summary estimate for each parameter, the study proportions were transformed 
according to the Freeman Tukey variant of the arcsine square root transformed proportions to 
correct for over-dispersion.10 Pooled proportions were calculated as the back-transformation of 
the weighted mean of the transformed proportions using the random effects model.11  
Data analysis 
For each country, the number of in-hospital trauma deaths due to bleeding was calculated by 
applying the corresponding estimated proportions to the mortality data, as described above. For 
the primary analysis, the relative risk reduction from the CRASH-2 trial was applied to estimate 
the number of premature deaths that could be averted (1) if all patients received TXA within one 
hour of injury, and (2) if all patients received TXA within three hours of injury. The numbers of 
deaths averted in each country were combined to give an overall global estimate. To identify the 
countries with the greatest potential for benefit from TXA, countries were ranked in order of the 
estimated number of premature deaths averted.  
To investigate the impact on the results of uncertainty in the parameter estimates used in the 
modelling, a number of sensitivity analyses were conducted. First, the analysis was repeated 
using the lower and upper bounds of the 95% confidence intervals for the parameter estimates 
to explore the effect of parameter uncertainty. Second, we repeated the analysis using the 
relative risk estimate for all-cause mortality rather than death due to bleeding. This analysis was 
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conducted to take account of the possibility that some patients who do not die from bleeding 
because of TXA administration would nevertheless die of other causes such multi-organ failure 
or brain injury. Third, we repeated the analyses using the relative risk estimate for all-cause 
mortality with TXA when given at any time within eight hours of injury. Although, previously 
published subgroup analyses show that early treatment is more effective it is possible that 
treatment within three hours is not possible in some settings.  
For each estimate, to reflect statistical uncertainty around the relative risks of TXA, an 
uncertainty range was estimated by calculating the numbers of deaths averted based on the 95% 
confidence intervals for the relative risks. The analyses were conducted using Microsoft Excel 
and STATA 1112 software. 
Results  
Estimation of the effect of TXA on death due to bleeding by geographical region 
Figure 3.5 shows the effect of TXA given within three hours of injury on death due to bleeding 
by geographical region.  
Figure 3.5 Risk ratio (95% CI) for death due to bleeding with TXA given within three hours of 
injury, overall and by geographical region.  
 
 
There was no evidence for heterogeneity in the effect of TXA by region (χ2=1.445; p=0.70). The 
overall RRs for the effect of TXA on death due to bleeding when given within one hour (RR=0.68; 
95% CI 0.57 to 0.82) and within three hours (RR=0.72; 95% CI 0.63 to 0.83) of injury were 
therefore taken as the most reliable guide as to the approximate RRs in all regions, and were 
used to estimate the number of deaths that could be averted with TXA. 
Estimation of the annual number of in-hospital trauma deaths due to bleeding  
n/N Risk ratio (95% CI)
Africa 208/3,927 0.68 (0.52-0.90)
Asia 196/3,688 0.81 (0.62-1.08)
95/1,960 0.63 (0.42-0.94) 
Central & South America  316/3,909 0.72 (0.58-0.90)
Overall 815/13,484 0.72 (0.63-0.83)
Χ2 = 1.445; p=0.70
0.40.2 1.41.20.80.6 1
Europe, Australia &            
North America
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We identified 18 studies, described in 17 reports,13-29 which presented data on the parameters 
of interest and were included in the systematic review. Studies were conducted in 13 countries; 
USA, Canada, UK, Australia, Brazil, Denmark, Norway, Mozambique, South Africa, Italy, France, 
Spain and India. In addition, we obtained data collected as part of the CRASH-2 trial, which 
recruited patients from hospitals in 40 countries throughout the world. The study selection 
process is summarised in Figure 3.6. Data extracted from the studies are summarised in 
Appendix AA. 
Figure 3.6 Flow diagram of the study selection process for systematic review 
 
Fourteen studies14-16, 18, 20-28 involving 24,831 trauma deaths provided data on the proportion of 
deaths occurring in-hospital; the pooled proportion was 44% (95% CI 33 to 56%). Five studies3, 
13, 17, 19, 29 involving 9684 deaths presented data on the proportion of blunt trauma deaths due to 
haemorrhage; the pooled proportion was 18% (95% CI 13 to 23%). Four studies3, 13, 17, 29 involving 
2256 deaths presented data on the proportion of penetrating trauma deaths due to 
haemorrhage; the pooled proportion was 55% (95% CI 49 to 62%). 
After applying these parameter estimates to the WHO data, we estimate that worldwide every 
year approximately 400,000 trauma patients die in-hospital from bleeding. If all of these patients 
receive TXA within one hour of injury the about 128,000 (uncertainty range [UR] ≈ 72,000 to 
172,000) deaths could be averted. If all of these patients receive TXA within three hours of injury 
about 112,000 (UR ≈ 68,000 to 148,000) deaths could be averted. The global distribution of 
Records identified through 
database searching (n = 1114)
Additional records identified 
through other sources  (n = 6)
Records excluded
(n = 1041)
Records after duplicates 
removed and screened
(n = 1120)
Full-text articles assessed for 
eligibility (n = 79)
(7 full texts unavailable)
Full-text articles excluded
(n = 45)
Studies providing eligible data 
and included in pooled 
analyses (n = 19)
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number of premature deaths averted by TXA when administered within three hours of injury is 
shown in Figure 3.7.  
Figure 3.7 Global distribution of number of deaths averted with TXA administration within three 
hours of injury  
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Results for the countries where more than 1000 deaths could be averted are shown in Table 3.2.  
Table 3.2 Estimated number of premature trauma deaths averted by TXA per year 
 
In-hospital trauma 
deaths from bleeding 
Deaths averted 
TXA≤1 hour 
Deaths averted  
TXA≤3 hours 
Worldwide 400,467 128,149 112,131 
    
Countries with >1000 deaths averted 
India 58,801 18,816 16,464 
China 54,241 17,357 15,187 
Brazil  19,187 6,140 5,372 
Russian Federation 16,731 5,354 4,685 
Myanmar 13,193 4,222 3,694 
Iraq 12,786 4,091 3,580 
USA 12,489 3,996 3,497 
Indonesia 11,033 3,531 3,089 
DR Congo 9,373 2,999 2,624 
Sri Lanka 8,979 2,873 2,514 
Pakistan 8,770 2,806 2,456 
Ethiopia 8,768 2,806 2,455 
Nigeria 8,258 2,643 2,312 
Colombia 7,348 2,352 2,058 
Sudan 7,292 2,334 2,042 
Bangladesh 7,210 2,307 2,019 
Mexico 7,059 2,259 1,976 
Philippines 6,119 1,958 1,713 
Thailand 5,572 1,783 1,560 
Afghanistan 4,774 1,528 1,337 
Uganda 4,620 1,478 1,294 
South Africa 4,245 1,359 1,189 
Venezuela 4,172 1,335 1,168 
Kenya 4,029 1,289 1,128 
Tanzania 3,969 1,270 1,111 
Iran 3,921 1,255 1,098 
 
The largest numbers of deaths from haemorrhage and consequently the largest numbers of 
deaths averted are in Asia. The largest numbers of premature deaths averted are in India (TXA≤1 
hr ≈ 19,000; TXA≤3 hrs ≈ 16,500) and China (TXA≤1 hr ≈ 17,000; TXA≤3 hrs ≈ 15,000). When 
ranked by the number of premature deaths potentially averted, nine of the top ten countries 
are low or middle income, the exception being the USA where approximately 4,000 and 3,500 
deaths would be averted by TXA given within one hour and three hours of injury, respectively.  
Sensitivity analyses 
When the analyses were repeated using the values of the lower and upper 95% CIs of the pooled 
parameter estimates, the global number of deaths averted ranged from approximately 76,000 
to 198,000 if TXA is given within one hour of injury and from 67,000 to 173,000 if given with 
three hours of injury. When the analysis was carried out using the relative risk estimate for all-
cause mortality if TXA is given within one hour (RR=0.87; 0.78 to 0.97) and within three hours 
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(RR=0.87; 0.80 to 0.94) of injury, the number of premature deaths averted was 52,000 (TXA≤1 
hr ≈ 12,000 to 88,000; TXA≤3 hrs ≈ 24,000 to 80,000). When the analysis was repeated using 
relative risk estimate for death due to bleeding when TXA is given at any time within eight hours 
of injury (RR=0.85; 0.76 to 0.96), the number of premature deaths averted was 60,000 (UR ≈ 
16,000 to 96,000). Finally, using the relative risk estimate for all-cause mortality when TXA is 
given within eight hours of injury (RR=0.91; 0.85 to 0.97), an estimated 36,000 (UR ≈ 12,000 to 
60,000) premature deaths could be averted. 
Discussion 
Based on WHO mortality data and a systematic review of the literature we estimate that there 
are about 400,000 in-hospital deaths from bleeding each year worldwide. If all hospitalised 
bleeding trauma patients could be treated with TXA within an hour of injury then up to 128,000 
of these premature deaths could be averted. If they could be treated within three hours of injury 
then up to 112,000 premature deaths could averted. Although there is considerable uncertainty 
in the estimates even the most conservative suggest that tens of thousands of deaths could be 
averted every year. 
We found no compelling evidence that the effect of TXA on death due to bleeding varies by 
geographical region. Our conclusion is based on a statistical test of interaction which is 
considered to be the most appropriate way to evaluate subgroup effects.30 As recommended by 
methodologists, we pre-specified that unless there was strong evidence against the null 
hypothesis of homogeneity of effects (i.e. p<0.001), that the overall risk ratio (RR) would be 
considered to be the most reliable guide to the approximate RRs in all regions. We found no 
statistical basis to reject the null hypothesis.  
The data sources used to parameterise the model are subject to a number of limitations which 
may have affected our results. First, although the WHO database provides the best available 
country-level mortality data, poor coverage and coding of mortality registration systems may 
affect the accuracy of the number of trauma deaths for some countries. Second, our 
classification of trauma deaths into blunt or penetrating trauma based on the cause of death 
categories in the WHO data was somewhat arbitrary and would have resulted in some 
misclassification. However, in the absence of accurate country-specific data, we judged that this 
approach would provide the most reliable estimates. Third, due to the absence of country-
specific data for the proportions of deaths occurring in hospital and the proportion of deaths 
caused by haemorrhage, we chose to apply average global estimates. We were therefore unable 
to incorporate between-country variations in these parameter estimates into our analysis. 
Nevertheless, our estimates were derived from a systematic review of the recent literature and 
data from the CRASH-2 trial, and thus represent the most accurate estimates available. We also 
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performed sensitivity analyses to assess the impact of uncertainty around the parameter 
estimates.  
Since many deaths from self-inflicted injuries are not usually associated with life-threatening 
haemorrhage (e.g. self-poisoning, hanging) we excluded this category to avoid over-estimating 
the number of deaths due to bleeding. However, this is likely to have led to the exclusion of 
some self-inflicted deaths that were associated with haemorrhage, in which case we may have 
underestimated the potential of TXA administration. 
Our analysis was based on a number of assumptions. We have assumed that there was no use 
of TXA as a treatment for traumatic bleeding prior to publication of the CRASH-2 trial results. It 
is possible that a small proportion of the trauma deaths in our sample did receive TXA prior to 
their death, which may over-estimate the number of deaths averted. However, given that any 
such prior use of TXA would have been minimal it is unlikely to have greatly affected our overall 
estimates.  
The objective of our analysis was to estimate the potential number of deaths that could be 
averted assuming TXA use under optimal conditions, that is, when administered appropriately 
and within three hours of injury, to all eligible bleeding trauma patients. It is unrealistic that such 
conditions are consistently and fully achieved in clinical practice. For example, the opportunity 
to treat some eligible patients will be missed and errors in the dose used or its administration 
may reduce the beneficial effect of TXA.  
We assumed that the results of the CRASH-2 trial could be extrapolated to all hospitalised 
bleeding trauma patients. The CRASH-2 trial used clinical criteria to recruit a large number of 
patients from 274 hospitals in 40 countries, which helps the results to be generalised widely. 
Whilst we acknowledge that the underlying risk of death will vary in different settings, this does 
not necessarily imply that that the relative effect will vary. Indeed, relative effects are often 
remarkably homogeneous despite differences in underlying risk. This is supported by empirical 
evidence from a range of trials in which the relative effects are constant across variations in 
baseline risk.31 Furthermore, there is no reason to suppose that the mechanism of action of TXA 
would vary in different populations. However, we acknowledge that the appropriateness of such 
extrapolation is a matter of judgement. 
A further assumption is that all trauma patients reached hospital in time to receive early 
treatment with TXA; that is either within one hour or within three hours of injury. Such a time 
frame is unlikely to be realistic in many settings where long distances and other logistical 
difficulties may delay arrival at hospital. For this reason we performed sensitivity analyses based 
on the relative effect of TXA from a more conservative estimate of time-to-treatment of within 
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eight hours of injury, the results of which still suggest that up to 60,000 deaths could be averted. 
Besides, there is reason to predict that time between injury and treatment would be shorter in 
clinical practice than in the CRASH-2 trial as delays caused by consent procedures would be 
avoided.32  
In applying the RR of death due to bleeding in our primary analysis we assumed that all deaths 
in this group would be avoided. However, it is possible that whilst TXA may prevent death due 
to bleeding, some patients would die from other causes instead. If this is the case, then our 
primary analysis would over-estimate the number of death averted. To address this we 
performed a sensitivity analysis in which the effect of TXA on all-cause mortality was used. Even 
using this smaller relative reduction, up to 50,000 deaths could be averted.  
We restricted our analysis to the potential benefit of in-hospital use of TXA. However, our 
parameter estimate of the proportion of in-hospital trauma deaths indicates that most trauma 
deaths occur before arrival at hospital. TXA is a practicable treatment suitable for use in a range 
of health-care settings, including pre-hospital. If TXA was used in the pre-hospital setting then 
many more premature deaths might be averted. 
Conclusions 
Our analysis shows the potential of TXA to reduce trauma deaths worldwide. Realisation of this 
potential is likely to require further efforts in dissemination and implementation, particularly in 
low and middle income settings. 
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4.0 WHAT ARE THE EFFECTS OF TRANEXAMIC ACID FOR PREVENTING 
POSTPARTUM HAEMORRHAGE? 
4.1 INTRODUCTION TO RESEARCH PAPER 6 
This Chapter includes Research Papers 6viii and 7, which address Aim 3 of my thesis - the effects 
of TXA for preventing postpartum haemorrhage. Despite one of discoverers earmarking TXA as 
a potential intervention for PPH back in the 1960s, she was unable at the time to persuade 
obstetricians to initiate trials1 and it is only more recently that its effects for this indication have 
been explored.  
Despite reassuring evidence from trials in surgery and trauma, differences in the coagulation 
profile observed in women immediately before, during, and after childbirth,2 raises questions 
concerning the effectiveness and safety in this patient group.  
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4.2 DOES TRANEXAMIC ACID PREVENT POSTPARTUM HAEMORRHAGE? A SYSTEMATIC REVIEW OF 
RANDOMISED CONTROLLED TRIALS 
Katharine Ker, Haleema Shakur, Ian Roberts 
British Journal of Obstetrics & Gynaecology. 2016 Oct;123(11):1745-52.  
Introduction 
Postpartum haemorrhage (PPH), one of the most common obstetric emergencies, occurs in 
about 10% of deliveries.1 It is the leading cause of maternal mortality worldwide, responsible 
for about 50,000 deaths each year.2 Because hysterectomy is sometimes carried out to control 
the bleeding, PPH deprives thousands of women of their ability to bear children. Anaemia is 
another important consequence that limits a mother's wellbeing and her ability to work and 
care for children.3 
Tranexamic acid (TXA) reduces bleeding by inhibiting the breakdown of fibrin blood clots. The 
WOMAN trial is currently evaluating the effect of TXA on death and hysterectomy in women 
with established PPH.4 However, for many women, treatment of PPH is too late. Over one third 
of pregnant women in the world are anaemic and many are severely anaemic.5 In these 
women, even moderate bleeding can be life threatening and by worsening their anaemia, can 
cause disabling fatigue that limits their ability to care for themselves and their baby.6 TXA given 
at the time of delivery could prevent severe postpartum bleeding. Plasma t-PA (the main 
fibrinolytic activator) doubles within an hour of delivery, probably due to the trauma of 
childbirth.7  
We conducted a systematic review of randomised controlled trials to assess the effects of TXA 
on the risk of postpartum haemorrhage and other clinically relevant outcomes. 
Methods 
We specified the methods in advanced and registered the review on PROSPERO 
(CRD42015020670). 
Selection criteria and search strategy 
We searched for randomised controlled trials comparing TXA with no TXA or a placebo in 
women delivering vaginally or by caesarean section. The primary outcome was the number of 
women with a clinical diagnosis of postpartum haemorrhage. Trials of TXA for the treatment 
of established postpartum haemorrhage were not eligible. Secondary outcomes were death, 
blood loss, blood transfusion, thromboembolic events (myocardial infarction, stroke, deep vein 
thrombosis, and pulmonary embolism), surgical intervention, maternal wellbeing and quality 
of life, and adverse events in baby. 
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Eligible trials were identified from a register of randomised controlled trials of antifibrinolytic 
drugs maintained by the London School of Hygiene & Medicine’s Clinical Trials Unit (LSHTM 
CTU). The register contains records of trials identified through searches of MEDLINE, CENTRAL, 
EMBASE, PubMed, ClinicalTrials.gov and the WHO International Clinical Trials Registry 
Platform. Each database was searched using a combination of subject headings and keywords 
(Appendix DD). In addition, we checked reference lists of relevant articles and searched the 
internet using the Google search engine for further potentially eligible trials. The searches were 
run to 13th May 2015 and were not restricted by date, language or publication status.  
Procedures 
One author screened the titles and abstracts of the search output to identify potentially eligible 
trials. The full texts of these reports were then retrieved and assessed for eligibility. Data on 
the number of participants, type of delivery, dose and timing of TXA, type of comparator and 
outcome data were extracted by two authors using a form developed specifically for the 
review. We used the Cochrane Collaboration’s tool for assessing the risk of bias. The risk of bias 
assessments were based on the information presented in the trial report.8 We assessed the 
sequence generation, allocation concealment, blinding, incomplete outcome data and 
selective outcome reporting as being at low, high, or unclear risk of bias for each trial. 
Statistical analysis 
For dichotomous outcomes, we calculated risk ratios and 95% confidence intervals. For 
continuous outcomes, we calculated the mean difference and 95% confidence interval. 
However, for blood loss, we estimated the proportional change in blood loss with TXA. Full 
details of the method used are described elsewhere.9 In brief, we expressed the change in 
blood loss with TXA as a proportion of the blood loss in the control group. As estimates of 
average blood loss are not normally distributed, we transformed blood loss data into a 
logarithmic scale and conducted the analysis using the transformed values. A meta-analysis of 
the differences in means using the transformed data on blood loss corresponds to a meta-
analysis of the ratio of the geometric means on the original scale. The estimates were back-
transformed to give the blood loss ratios and 95% confidence intervals on the original scale. If 
sufficiently homogeneous in terms of patients, intervention and outcome measurement, we 
planned to pool the trial data using the fixed effect model.  
We planned to conduct subgroup analyses to examine whether the effect of TXA on the risk of 
PPH varied according to whether or not the women were anaemic at baseline (anaemic 
Hb<11g/dL, vs non-anaemic Hb≥11g/dL). We also planned a sensitivity analysis restricted to 
trials at low risk of bias for allocation concealment. Analyses were carried out using Stata 
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version 13 and RevMan version 5.3.5. We reported the review in accordance with the PRISMA 
Statement (Appendix EE). 
Results 
Trial characteristics 
We identified 31 reports10-40 describing 26 trials involving a total of 4,191 women (Appendix 
FF). The trial reports were published between 2001 and 2015. Five trials were Master’s degree 
projects that were later published in medical journals. Two trials were reported as conference 
abstracts only.  
The characteristics of the included trials are shown in Appendix GG. The median sample size 
was 120 (min-max=74-740). They were conducted in China (n=3), Egypt (n=2), India (n=9), Iran 
(n=5), Malaysia (n=1), Pakistan (n=2), Turkey (n=3) and the Ukraine (n=1). All but one were 
single-centre trials. Twenty-two trials assessed the effect of TXA in women giving birth by 
caesarean section and four in women giving birth vaginally. One trial was restricted to anaemic 
women (Hb 7-10g/dL).  
TXA was given within 30 minutes prior to incision in all of the caesarean delivery trials except 
for one in which TXA was administered at delivery of anterior shoulder. Of the four trials 
involving vaginal delivery, TXA was given at delivery of anterior shoulder in three and at 
delivery of the placenta in one. The TXA dose ranged from 0.5g to 1g. TXA was compared to 
placebo in 13 trials and to a no-TXA group in 13 trials.  
The number of patients allocated to each group was not reported in one trial and so the data 
could not be used. The frequency of PPH was reported in 13 (50%) trials, blood loss in 24 (92%), 
thromboembolic events in 16 (62%), death in six (23%), surgical intervention in five (19%), and 
blood transfusion in 10 (38%). None of the trials collected data on maternal wellbeing or quality 
of life. 
Risk of bias 
A summary of the risk of judgements is shown in Appendix HH. The method used to generate 
the allocation sequence was adequate in eight trials and inadequate in four. The remaining 14 
trials did not describe the method used and so the risk was unclear. Allocation concealment 
was adequate in four, inadequate in seven, and unclear in 15 trials. Blinding was adequate in 
eleven trials, inadequate in 13 and unclear in two trials. There were no missing outcome data 
in four trials (low risk of bias). However, there were post-randomisation exclusions in three 
trials (high risk of bias). For the remaining 19 trials insufficient information was reported to 
judge the risk of bias from missing outcome data. In the one trial that was prospectively 
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registered, comparison of pre-specified and reported outcomes suggested selective outcome 
reporting. We could not determine the risk of bias for the remaining trials which were either 
retrospectively registered (n=5) or not registered (n=20). 
Data reliability 
Several reports raised concerns about the data and prompted further investigations. Eight 
reports contained sections of identical or very similar text despite purporting to be different 
trials (Appendix II), in addition, many of the results sections contained discrepancies and other 
errors. We therefore sought further information from the authors of all trial reports to reassure 
ourselves about the reliability of the data. We identified contact information for as many 
authors as possible. Each author was contacted and asked to provide the dates when the first 
and last patients were randomised; a copy of the ethics committee approval; and the 
anonymised individual patient data. Where possible we also contacted the ethics committee 
for confirmation of their approval.  
We received responses for 13 (50%) trials (Appendix JJ). One author declined to provide the 
information requested. Authors of nine trials confirmed recruitment dates, one did not have a 
record of the dates and one did not include this information in the response. We received a 
copy of the ethics approval for 10 trials, one of which was granted after the start of 
recruitment. Two trials did not receive ethics approval. In one case, an author explained that 
the trial was undertaken for a student thesis and formal approval from the ethics committee 
was not required (this was confirmed in a separate response from the ethics committee). In 
the other, although the trial report stated that ethics approval had been obtained, the author 
stated this was not in fact the case. This was confirmed by the ethics committee who said that 
they had no record of the trial. No explanation was offered as to why approval was not 
obtained.  
Seven of the 13 trials for which we received a response sent individual patient data. The 
authors of two trials did not respond to this part of our request and one author of two trials 
explained that he was unable to send us the data due to the theft of the laptop on which the 
data for both trials were stored. 
We then explored the success of the randomisation process by conducting meta-analyses of 
selected baseline variables. As recommended by Clark et al,41 we meta-analysed age as well as 
baseline haemoglobin (Hb) which we identified as another relevant prognostic covariate. The 
premise of this analysis is that if the trials are properly randomised, there will be no 
heterogeneity, i.e. I2=0% and any difference in baseline variables will be minimal and the result 
of random error.41 The results of the meta-analyses of age and baseline Hb are shown in 
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Appendix KK and Appendix LL. There was no heterogeneity (I2=0%) observed for age. However, 
there was a statistically significant difference between groups suggesting that women allocated 
to the TXA group were younger than those in the control (p=0.01), although this difference was 
not observed when the analysis was restricted to adequately concealed trials (P=0.59). There 
was substantial heterogeneity between trials for baseline Hb (I2=67%) and a statistically 
significant difference between groups indicating that women allocated to the TXA group had a 
lower Hb at baseline than those in the control (p=0.02). Substantial heterogeneity remained 
when the analysis was restricted to adequately concealed trials (I2=62%), although the 
difference in Hb between groups was no longer statistically significant (p=0.79). 
Data analysis 
Although the patients, interventions and outcomes were sufficiently homogeneous to pool the 
data, because of our concerns about trial quality and data reliability we did not conduct a meta-
analysis. However, effect estimates and 95% CIs were calculated and presented as Forest plots 
(Figure 4.1,Figure 4.2,Figure 4.3). We stratified the trials according to whether or not the final 
report contained similar text. Thirteen trials presented data on the number of women who 
developed postpartum haemorrhage (PPH). There was variation in the threshold used to 
diagnose PPH. Four trials applied the usual definition of blood loss ≥1000 ml after caesarean 
delivery or ≥500 ml after vaginal delivery. The remaining trials used other, lower thresholds 
including ≥500 ml after caesarean delivery or ≥400 ml after vaginal delivery. Because none of 
the trials were prospectively registered, we cannot discount the possibility that the selection 
of these thresholds was post hoc and data driven. In all trials fewer women in the TXA group 
developed PPH than in the control group. 
Figure 4.1 Results of trial assessing the effect of TXA on postpartum haemorrhage 
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Figure 4.2 Results of trials assessing the effect of TXA on blood loss 
 
 
Figure 4.3 Results of trials assessing the effect of TXA on blood transfusion 
 
Twenty-four trials presented data on average blood loss in both groups. All of the effect 
estimates are consistent with less blood loss in the TXA group; the difference is statistically 
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significant in all but one trial. There is notable variation in the magnitude of the effect 
estimates. 
Nine trials reported blood transfusion data. There were no events in two trials. In all of the 
remaining seven trials, fewer women in the TXA group received a blood transfusion than those 
in the control group. There were no deaths, surgical interventions, or cases of myocardial 
infarction, stroke or pulmonary embolism in any of the trials reporting these outcomes. In one 
trial, four women suffered a deep vein thrombosis, there was no difference in risk between the 
groups (TXA 2/88 vs control 2/86; RR=0.98, 95% CI 0.14 to 6.78). 
Discussion 
Main findings 
Worldwide, over 10 million women experience a postpartum haemorrhage each year. About 
50,000 women die, many more lose their ability to bear children and hundreds of thousands 
suffer debilitating fatigue from anaemia. TXA is an inexpensive, widely available medicine that 
has been shown to reduce bleeding in surgery and reduce the risk of death in bleeding trauma 
patients.42, 43 It is therefore unsurprising that there is interest in its role in the prevention of 
postpartum haemorrhage. However, our review shows that most trials of TXA are small, low 
quality, single-centre studies. We found that many trial reports shared similar or identical text, 
and contained important errors or inconsistencies. Two trials were conducted without ethics 
committee approval and only one was prospectively registered.  
Strengths and limitations 
Due to concerns about data quality and reliability we did not conduct a meta-analysis. When 
examined separately, the results of the individual trials were largely consistent with evidence 
from surgical bleeding, with most reporting less bleeding with TXA. However, the criteria used 
to diagnose PPH varied between trials and the absence of blinded outcome assessment in many 
trials may have introduced bias. Also, because the trials are too small to assess the effect of 
TXA on maternal health outcomes and none measured maternal wellbeing, the clinical 
importance of any reduction in bleeding is uncertain.  
Most systematic reviews assume that trial reports provide an accurate description of the 
methods and results. However, after finding that eight trials contained identical text and that 
some of the trial results were also similar, we were obliged to question this assumption. We 
therefore asked the authors of all trials to provide dates of recruitment, a copy of the ethics 
committee approval and the anonymised individual patient data in an attempt to assess their 
reliability. We received a response for only half of the included trials and less than half of these 
provided all the information requested. Moreover, the meta-analysis of baseline variables 
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suggests that the randomisation process was inadequate in many trials. Although our review 
aimed to include only randomised controlled trials, many of the included trials were not 
properly randomised and were imbalanced for key prognostic variables. 
Interpretation (in the light of other evidence) 
Other systematic reviews have assessed the effect of TXA on obstetric bleeding.44-46 However, 
ours is the first to describe the scale and nature of deficiencies in the evidence that go beyond 
the standard risk of bias assessment. Unless these deficiencies are brought to the attention of 
the maternal health community, treatment decisions could be based on unsound evidence, 
putting women at risk. Indeed, some of the trials have already informed the WHO’s 
recommendations on the use of TXA for the treatment of postpartum haemorrhage. 
As well as highlighting the poor quality of trial research in this area, the process of conducting 
this review has brought to our attention the lack of guidance on how systematic reviewers 
should deal with trial quality concerns that go beyond those assessed by the standard risk of 
bias approach.  
Furthermore, because we were unwilling to ignore these concerns, we devised our own 
approach to investigating them. We do not claim that our approach is the best and welcome 
ideas on more effective ways to deal with similar situations in the future. 
Conclusions  
Although reducing maternal mortality has been a development goal for 15 years, this review 
suggests that in some areas the quantity and quality of the research needed to support this 
humanitarian aspiration is inadequate and is not commensurate with the level of political 
ambition. We do not doubt that most of the included trials were conducted in good faith with 
the patients' interests in mind. However, a problem of such global health importance requires 
a strategic response from professional research teams rather than the efforts of concerned 
clinicians at a single hospital. Large, high quality, multi-centre trials with end points that matter 
to women are urgently needed.  
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4.3 INTRODUCTION TO RESEARCH PAPER 7 
The results of the systematic review presented in Research Paper 6 show that the existing trial 
evidence for the effects of TXA for preventing PPH is inadequate. 
Since I completed the review, two important randomised placebo-controlled trials have been 
completed - the TRAAP trial and the WOMAN trial. The TRAAP trial assessed the effect of TXA 
for preventing postpartum bleeding in 4079 women giving birth vaginally in hospitals in France. 
At the time of writing this thesis, the TRAAP trial results have not been published in full, although 
selected results were presented at the Society for Maternal-Fetal Medicine 38th Annual Meeting 
in February 2018.1 These show that fewer women in the TXA group experienced postpartum 
blood loss of ≥500 mL compared to those in the placebo group, although the difference was not 
statistically significant (RR=0.83, 95% CI 0.68 to 1.01; p=0.07). The WOMAN trial assessed the 
effects of TXA in 20,060 women with PPH in 193 hospitals in 21 countries.2 The results showed 
that TXA reduces the risk of bleeding to death after PPH (RR=0.81, 95% CI 0.65 to 1.00; p=0.045). 
However, data from the WOMAN trial also suggests that for many women treatment of PPH is 
too late. Most women who bled to death from PPH, did so very quickly, many within the first 
two hours after giving birth. A way of preventing excessive bleeding from occurring in the first 
place would therefore appear to be crucial in the effort to reduce mortality and morbidity from 
PPH. 
Although the results of my systematic review (Research Paper 6) was that there is no reliable 
evidence for the effects of TXA for preventing PPH, the subsequently published evidence from 
the TRAAP and WOMAN trials, provide reason to hope that TXA may be effective, especially in 
women at high risk of PPH. 
In response to this, the LSHTM CTU is embarking the WOMAN-2 trial, a randomised, placebo-
controlled trial to assess the effects of TXA for preventing postpartum bleeding in 10,000 women 
with anaemia. I am a member of the Protocol Committee, a multidisciplinary team that has 
designed the WOMAN-2 trial building on the experience of CRASH-2 and WOMAN trials, which 
were also co-ordinated by the LSHTM CTU. I have taken a lead in the drafting of the protocol 
and am first author of the version submitted for publication in Trials. I am also a named co-
applicant on the funding applications.  
The trial is funded by Wellcome and the Bill & Melinda Gates Foundation and is due to randomise 
the first women by January 2019. Research Paper 7 is an abridged version of the trial protocol, 
which I have submitted for publication in Trials.  
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4.4 TRANEXAMIC ACID FOR THE PREVENTION OF POSTPARTUM BLEEDING IN WOMEN WITH ANAEMIA: 
AN INTERNATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL 
Ker K, Roberts I , Chaudhri R, Fawole B, Beaumont D, Balogun E, Prowse D, Pepple T, Javaid K, 
Kayani A, Arulkumaran S, Bates I, Shakur-Still H, on behalf of the WOMAN-2 trial collaborators 
Trials (submitted) 
Background 
Postpartum haemorrhage (PPH) is a leading cause of maternal mortality and morbidity. PPH 
follows 6% to 10% of all births and accounts for around 100,000 maternal deaths every year.1-3 
Ninety-nine percent of deaths are in low and middle income countries (LMICs).4 Many women 
who survive experience severe morbidity. Some women need surgery to control the bleeding 
(e.g. exploratory laparotomy, uterine artery ligation, brace sutures) and many require a 
hysterectomy, thus removing the possibility of having more children. Severe morbidity due to 
PPH interferes with breastfeeding and bonding.5 PPH is a frightening experience and some 
women develop post-traumatic stress disorder.6  
Many women with PPH are given a blood transfusion. However, blood is a scarce and costly 
resource in LMICs and access to safe blood is limited. The blood donation rate in Africa is 5 per 
1000 population compared to 47 per 1000 population in the USA and it is estimated that 35 of 
the 40 sub-Saharan countries collect less than half of the donor blood required to meet their 
population needs.7 Even when blood is available, because of problems with screening, recipients 
are at risk of blood borne infections and adverse transfusion reactions are common.  
Anaemia is a cause and consequence of PPH. A cohort study in Assam, India found that women 
with moderate or severe anaemia had a greatly increased risk of PPH.8 Women with moderate 
anaemia had a 50% increased risk of PPH, whereas those with severe anaemia had a ten-fold 
increased risk. The reason for the increased risk is unclear but some researchers think that 
anaemic women are more susceptible to uterine atony due to impaired oxygen transport to the 
uterus. Anaemic women experience worse outcomes after PPH. An international survey of 
275,000 women found that severe maternal outcomes after PPH were nearly three times more 
common in anaemic than in non-anaemic women.9 Even moderate bleeding can be life 
threatening in anaemic women. Excessive bleeding after childbirth worsens maternal anaemia, 
raising the possibility of a vicious circle of bleeding and adverse outcomes. Fatigue due to 
anaemia limits a mother’s wellbeing and her ability to care for her children.10 Despite efforts to 
prevent anaemia, many women labour with low haemoglobin levels. Worldwide, over one third 
of pregnant women are anaemic and many are severely anaemic.11 The prevalence is highest in 
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countries in central and West Africa as well as in South Asia where about half of pregnant woman 
are anaemic and it poses a severe public health problem.11, 12 There is an urgent need to find an 
effective way to reduce postpartum bleeding in anaemic women. 
Tranexamic acid (TXA) is a synthetic analogue of the amino acid lysine, which inhibits fibrinolysis 
by blocking the lysine binding sites on plasminogen. TXA reduces surgical bleeding and death 
due to bleeding in trauma patients. The WOMAN trial assessed the effects of TXA in 20,060 
women with PPH.13 TXA significantly reduced death due to bleeding with no adverse effects. 
When given within three hours of birth, TXA reduced death due to bleeding by nearly one third 
(RR=0.69, 95% CI 0.52 to 0.91; p=0.008). However, for many women, treatment is too late to 
prevent death from PPH. Most PPH deaths occur in the first hours after giving birth and women 
with anaemia are at increased risk. Whilst there have been some trials of TXA for the prevention 
of PPH, most have serious flaws and very few collected data on maternal wellbeing. There is very 
little reliable evidence about the effectiveness and safety of TXA for preventing postpartum 
bleeding, especially in high risk anaemic women.  
The WOMAN-2 trial will determine the effects of TXA in women with moderate or severe 
anaemia who give birth vaginally. For pregnant women, the WHO defines moderate anaemia as 
haemoglobin levels of 70-99 g/L and severe anaemia as haemoglobin levels lower than 70 g/L.14 
Women with anaemia are at increased risk of PPH and experience worse outcomes should PPH 
occur. By including women with moderate or severe anaemia, participating women have the 
potential to benefit from the trial treatment. Results from clinical trials of TXA in elective surgery 
show that TXA reduces blood loss by about one third irrespective of baseline blood loss.15 In 
other words, TXA treatment seems to move the entire distribution of bleeding towards reduced 
blood loss. If this is also the case in postpartum anaemic women, then trial participants have the 
potential to benefit whether or not they experience PPH, since even moderate or mild blood 
loss can have adverse health consequences in anaemic women.  
Around 10,000 women with moderate or severe anaemia giving birth in hospitals primarily in 
Africa and Asia will be randomly allocated to receive TXA or matching placebo after the umbilical 
cord is cut or clamped. Although there is no evidence of any adverse effects on the baby, by 
randomising women after cutting or clamping the umbilical cord, any risk associated with 
placental transfer of the trial treatment to the baby is removed. The umbilical cord will be cut 
or clamped in the usual way and the timing will not be affected by the trial. TXA passes into 
breast milk in very low concentrations and so an antifibrinolytic effect in the baby is highly 
unlikely.  
The ability to form a blood clot depends on fibrinogen levels. In both trauma and PPH, a low 
serum fibrinogen is a strong predictor of life threatening bleeding. Fibrinogen declines rapidly 
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during bleeding due to its consumption in fibrin clot formation. However, fibrinolysis due to the 
activation of plasmin by tissue plasminogen activator worsens fibrinogen depletion by breaking 
down clots. Tissue plasminogen activator mediated fibrinogenolysis also depletes fibrinogen 
levels. Early TXA administration has the potential to prevent excessive blood loss by interrupting 
the vicious circle of fibrinolysis and fibrinogen depletion. Women with anaemia are at increased 
risk of bleeding soon after delivery. If they can be treated with TXA before their fibrinogen levels 
fall, severe postpartum bleeding and its consequences may be prevented.  
Rationale for trial 
For some women the treatment of PPH is too late to prevent death and severe morbidity. 
Despite efforts to increase the availability of antenatal care, many women are anaemic at the 
time of giving birth and blood for transfusion is often unavailable. There is an urgent need to 
reduce postpartum bleeding and its adverse impacts on mothers, especially in anaemic women 
in LMICs. Knowing that TXA reduces deaths due to bleeding after PPH provides reason to believe 
that it might also prevent PPH. However, the evidence to date is insufficient to support the 
prophylactic use of TXA in routine clinical practice. Most of the available trials of TXA for 
preventing PPH are small and unreliable, and few collect information on maternal health and 
wellbeing.16, 17 One exception is the TRAAP trial18 which enrolled 4079 women who were giving 
birth vaginally in French hospitals. Women were randomised to receive 1 g TXA or matching 
placebo within two minutes after delivery. Although women who received TXA were less likely 
to experience a blood loss of ≥500 mL (the primary end point) the difference was not statistically 
significant (RR=0.83, 95% CI 0.68 to 1.01; p=0.07). Fewer woman in the TXA group received 
additional uterotonics (RR=0.75, 95% 0.61 to 0.92; p=0.006) however, there were no statistically 
significant differences in transfusion, change in haemoglobin or surgical intervention. The 
WOMAN-2 trial will provide reliable evidence on the effects of TXA when used to prevent PPH 
in anaemic women in LMICs. Although there was no increase in thrombotic events with TXA in 
the WOMAN or TRAPP trials, the administration of TXA to all women who give birth vaginally 
may be inappropriate. There is an increased risk of venous thrombosis in the postpartum 
period19 and maternal anaemia is an established risk factor.20 Treating all mothers would involve 
treating all women when only a proportion would benefit. However, in anaemic women the 
benefits could outweigh any harms so that a trial is justified. Inclusion in the trial will be limited 
to women giving birth vaginally. For women who give birth by caesarean section, especially for 
placenta abnormalities, the interval between cord clamping and PPH onset is short, often a 
matter of minutes, so the potential of TXA to prevent coagulopathy and PPH is limited. 
Safety of tranexamic acid 
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TXA is a widely used treatment with a good safety profile. Although on pathophysiological 
grounds we might expect an increased risk of thrombosis with antifibrinolytic drugs, randomised 
trials including over 50,000 participants show no increased risk. High doses of TXA (doses from 
7.5 g up to 20 g) have been associated with seizures in cardiac surgery but there was no increase 
in seizures in the CRASH-2 or WOMAN trials, which used a 1-2 g dose. TXA passes into breast 
milk in very low concentrations, approximately one hundredth of the concentration in maternal 
blood. An antifibrinolytic effect in the breast-fed infant is highly unlikely at this low 
concentration.21, 22 No adverse events in breastfed babies were found in the WOMAN trial. 
Because TXA will be given after cutting or clamping the umbilical cord, there will be no risk of 
placental transfer to the baby. Nevertheless, we will collect data on nausea, vomiting, diarrhoea, 
maternal thrombotic events, seizures and thromboembolic events in breastfed babies, in all 
participants as outcomes. These outcome events will not be reported using the adverse event 
reporting procedure.  
Objective 
To determine the effects of TXA on postpartum bleeding and other health outcomes in women 
with moderate or severe anaemia. 
Methods/Design 
This protocol has been prepared in accordance with the SPIRIT 2013 statement.23 
Overview 
The WOMAN-2 trial is a randomised, parallel group, double-blind, placebo controlled trial of the 
effects of TXA in women with moderate or severe anaemia who are giving birth vaginally. Ten 
thousand women with moderate or severe anaemia who are giving birth in hospitals will be 
randomised to receive 1 g of TXA or matching placebo (sodium chloride 0.9%) by intravenous 
injection immediately and no later than 15 minutes after the umbilical cord is cut or clamped 
(Figure 4.4). 
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Figure 4.4 Trial overview  
 
Setting 
Women from hospitals where anaemia in pregnancy is common, primarily Africa and Asia will 
be enrolled. All participating hospitals will have the facilities to provide comprehensive essential 
obstetric care as defined by the World Health Organization. 
Number of participants needed 
For the purpose of the sample size calculation, a baseline risk of PPH of 10% was assumed. A 
trial with 10,000 women would have over 90% power (two sided alpha=5%) to detect a clinically 
important 25% reduction from 10% to 7.5% in PPH. The sample size estimate is based on two 
key assumptions (1) the baseline event rate and (2) the size of the treatment effect. The primary 
endpoint is PPH. The prevalence of PPH is estimated at 6% world-wide but 10% in Africa and 
Asia. If the event rate is 10% then the trial has 99% power. However, if the event rates is lower, 
the study will have less power. For example if the 6% estimate applies, the trial would have just 
over 90% power. Planning for the possibility that the event rate may be lower than anticipated 
is a sensible precaution. It is also possible that the treatment effect is not as large as predicted. 
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Although a 25% reduction would be clinically important, a more modest reduction would also 
be worthwhile. The additional power also reduces the chance that a more modest treatment 
effect will be missed. Experience from the WOMAN trial shows that loss to follow-up will be 
minimal (less than 1%) and will not influence trial power. The LSHTM CTU has successfully 
recruited large sample sizes for previous international trials and is experienced at managing 
recruitment at sites to ensure that target recruitment is achieved. The main anticipated risk to 
recruitment to the WOMAN-2 trial is political instability in the participating countries. The main 
resource for mitigating this risk is the large international network of obstetric clinical trialists 
that was established during the WOMAN trial. If political instability prevents the recruitment of 
patients in any of the planned settings, recruitment in other sites will be initiated, thereby 
reducing the risk.  
Identification of participating investigators and trial sites 
Participating investigators and trial sites will be identified from the international network of 
obstetricians that was established during the WOMAN trial and includes hospitals where 
anaemia in pregnancy is common. Before the trial can start at any site, all relevant regulatory 
and ethics approvals must be in place and the site principal investigator must agree to conduct 
the trial according to the Protocol, Good Clinical Practice guidelines and all the relevant 
regulations. Names of participating sites will be listed on the trial website 
(http://woman2.lshtm.ac.uk/). 
Eligibility of Participants 
Inclusion criteria 
Women with moderate or severe anaemia (haemoglobin level <100 g/L or packed cell volume 
<30%), who have given birth vaginally and for who the responsible clinician is substantially 
uncertain whether to use TXA. 
Exclusion criteria 
• Women who are not legally adult (<18 years) and permission not provided by a guardian.  
• Women with a known allergy to TXA or its excipients. 
• Women who develop PPH before umbilical cord is clamped/cut. 
Screening and enrolment procedures 
Routine clinical screening: Many pregnant women are likely to arrive to give birth at a 
participating hospital without antenatal care, or with low compliance with treatments for 
anaemia. It is important for her clinical care that her haemoglobin (Hb) or Packed Cell Volume 
(PCV) value is known before giving birth. If no test has been done on admission to give birth, 
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women planning to give birth vaginally will be offered a standard point of care haemoglobin 
assessment (HemaCue®) on arrival at hospital. Pregnant women will be informed about the 
purpose of the test before it is performed and they will have the right to accept or decline in line 
with any clinical care being offered. The test will be provided free of charge. Information on 
patients screened will be recorded on a Screening Log. 
Women with a moderate or severe anaemia (haemoglobin level <100 g/L or PCV <30%) will be 
offered the opportunity to participate in the WOMAN-2 trial.  
Baseline screening and eligibility confirmation: Following completion of the appropriate 
informed consent procedure, data on demographics, anthropometry, clinical signs, pregnancy 
and medical history, risk factors for postpartum haemorrhage, about the birth, about the 
baby/ies and baseline treatment plan for the anaemia, will be collected in the Case Report Form 
Booklet. Some data will be collected before a woman gives birth which will assess potential 
eligibility. Final eligibility will be confirmed at delivery of the baby’s anterior shoulder up to when 
the cord is clamped or cut. This is because some women who plan to deliver vaginally and have 
provided consent may need a caesarean section or may develop PPH before the cord is cut or 
clamped which will make them ineligible for the trial. 
Randomisation 
An IT coding expert supported by a statistician who are not involved in the conduct of the trial 
will prepare the randomisation codes. They will give a copy to the Sponsor’s representative, who 
is also not associated with the conduct of the trial, for manual back-up. The IT coding expert will 
also send the codes to the trial drug manufacturer so that treatment packs can be prepared in 
accordance with the randomisation list. Trial staff (coordinating centres and sites) and patients 
will not have access to the randomisation codes until final database lock or unless un-blinding 
of an individual patient is requested.  
Women who are eligible for inclusion will be randomised to receive active (tranexamic acid) or 
placebo (sodium chloride 0.9%) by intravenous injection.  
Once eligibility has been confirmed at delivery of the baby’s anterior shoulder and up to when 
the cord is clamped/cut, the next lowest consecutively numbered pack will be taken from a box 
of 20 treatment packs. The participant is considered randomised to the trial once administration 
of the trial treatment has started. Each site will keep a log of women they randomise to the trial. 
Site investigators will need to explain any out-of-sequence use of the trial treatment. 
Trial treatment  
Name and description of investigational medicinal product 
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Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that exerts an 
antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen 
molecules. TXA is sold under a variety of trade names for the treatment of bleeding due to 
general or local fibrinolysis in adults and children from one year of age.24 TXA would be given in 
addition to all the usual interventions for preventing PPH thus WOMAN-2 will compare its 
effects with matching placebo (sodium chloride 0.9%) to ensure blinding. 
Drug administration and dosage schedule 
A single dose of 1 gram of TXA or placebo (sodium chloride 0.9%) by intravenous injection will 
be given immediately after the umbilical cord is cut or clamped, and no more than 15 minutes 
later. There should be no delay in administering the trial medication after the umbilical cord is 
cut or clamped. Each treatment pack contains two ampoules each containing 500 mg (5 mL) of 
TXA or placebo (5 mL), and one sterile 10 mL syringe and 21G needle. Appropriately qualified 
staff will prepare the treatment to be administered by drawing up the contents of both 
ampoules into the 10 mL syringe using the 21G needle provided. Before administration, the 
expiry date will be checked and the randomisation number confirmed. The contents of both 
ampoules (total volume 10 mL) will be administered as a slow intravenous injection at rate of 
about 1 mL/minute using standard local intravenous administration procedure.  
In the event of multiple births, the trial drug will be given after cutting or clamping the umbilical 
cord of the last baby.  
Outcome measures 
Once randomised, we will collect follow-up data even if the trial treatment is not completed. 
Data will be collected within the first 24 hours after administration of the trial treatment and 
final outcome data will be collected when a woman is discharged from the randomising hospital, 
at death or 42 days post randomisation, whichever occurs first. In the event a woman is 
discharged or dies within 24 hours, all outcomes will be assessed at the same time. Adverse 
events will be collected from administration of the trial medication up to day 42.  
Primary outcome:  
The primary outcome is a clinical diagnosis of primary PPH. This may be an estimated blood loss 
of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 
24 hours of administration of trial medication. Haemodynamic instability is based on clinical 
judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced 
urine output). The cause of PPH will be described. 
Secondary outcomes:  
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Maternal blood loss and its consequences: 
• Postpartum blood loss (clinical estimation) 
• Haemoglobin  
• Haemodynamic instability  
• Shock index  
• Receipt of blood transfusion  
• Use of interventions to control postpartum bleeding (medical and surgical)  
Maternal health and wellbeing: 
• Symptoms of anaemia (e.g. fatigue, headache, dizziness, palpitations, breathlessness) 
• Exercise tolerance (short 6-minute walk test) 
• Quality of Life (overall wellbeing, ability to care for herself and her baby, breastfeeding)  
Other health outcomes: 
• Vascular occlusive events (pulmonary embolism (PE), deep vein thrombosis (DVT), 
stroke, myocardial infarction (MI)).  
• Organ dysfunction 
• Sepsis 
• Expected side effects (nausea, vomiting, diarrhoea, seizure) 
• Adverse events 
• Death (cause and time to death will be described)  
• Length of hospital stay 
• Admission to and time spent in higher level facility 
• Status of baby/ies and any thromboembolic events 
Definition of end of trial 
The end of trial will be day 42 of the last participant randomised.  
Statistics and data analysis 
A detailed Statistical Analysis Plan will be drafted and agreed with the DMC for their ongoing 
review and will be finalised before the trial database is locked for final analysis. 
Main analysis 
Analyses will be on an ‘intention-to-treat’ basis. Data will be analysed by randomised group, 
irrespective of whether they received the intervention. Demographic and other baseline 
characteristics will be tabulated. Descriptive statistics for continuous variables will include the 
mean, standard deviation, median, range, and the number of observations. Categorical variables 
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will be presented as numbers, and as percentages of those participants who had the assessment. 
All statistics will be presented by treatment group. Effect measures will be relative risk and 
absolute risk reduction. Precision will be quantified using 95% confidence intervals. Planned 
subgroup analyses include analyses based on the severity of anaemia (moderate versus severe) 
and type of labour (induced or augmented versus spontaneous). In a large trial such as WOMAN-
2, baseline characteristics of participants that may influence the outcome are expected to be 
evenly distributed between the treatment and placebo groups, so that any difference in 
outcome can be attributed to the intervention. However, it is still possible that a chance 
imbalance in important prognostic factors could influence the results. To investigate this 
possibility, an analysis of the effect of treatment that is adjusted for baseline risk will be 
conducted. A prognostic model will be built based on pre-specified baseline variables and use it 
to estimate the predicted risk of the outcome at baseline. Checks will be made to ensure that 
there are sufficient patients in the severe anaemia subgroup by limiting recruitment to these 
patients if necessary. For subgroups, relative risks and confidence intervals with two-sided p-
values will be reported. Test of homogeneity of effect across the subgroups will be done and a 
p-value reported. Unless there is evidence against the null hypothesis of homogeneity of effects 
the overall RR will be taken as the most reliable guide to the approximate RR in all subgroups.  
Sponsor 
The London School of Hygiene & Tropical Medicine (LSHTM) will act as the Sponsor for this trial.  
Funding 
Wellcome and the Bill & Melinda Gates Foundation are funding this study.  
Discussion 
The WOMAN-2 trial will provide reliable evidence for the effects of TXA for preventing 
postpartum bleeding in women with anaemia. If the WOMAN-2 trial shows that TXA reduces 
PPH in anaemic women, we would have identified a way of improving the wellbeing of 
thousands of women world-wide. 
Trial status 
The protocol was approved by the London School of Hygiene & Tropical Medicine’s Ethics 
Committee (ref: 15194). National ethics and regulatory approvals are in progress in three 
countries. Patient recruitment is planned to start by January 2019. End of recruitment is planned 
for January 2021 with end of follow-up in March 2021. Further information is available at 
http://woman2.lshtm.ac.uk/ 
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5.0 DISCUSSION, SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
This thesis comprises a series of studies critically analysing the evidence from randomised trials 
for the effects of the antifibrinolytic drug, tranexamic acid (TXA) in patients with surgical 
bleeding, traumatic bleeding, and for preventing postpartum haemorrhage. 
In this final Chapter, I summarise the principal findings of these studies and consider their 
implications for practice and future research. I will also reflect on the strengths and weaknesses 
of the methods used in the thesis before drawing my overall conclusions.  
5.1 EFFECTS OF TRANEXAMIC ACID FOR SURGICAL BLEEDING 
5.1.1 Principal findings 
Chapter 1 included Research Papers 1-3 in which I evaluated the evidence from randomised 
trials for the effects of TXA in patients with surgical bleeding (Aim 1). On the basis of my results, 
I drew four main conclusions: 1) that TXA reduces the risk of receiving a blood transfusion by 
about one third; 2) that strong evidence that TXA reduces blood transfusion in surgery has been 
available for many years; 3) that the effects of TXA on the risk of death and thromboembolic 
events are uncertain; and 4) that trials continue to be conducted assessing the effect of TXA on 
bleeding despite awareness of the evidence. I consider these in more detail below. 
Evidence from randomised trials of the effect of TXA on blood transfusion and blood loss in 
surgery 
The pooled estimates from the meta-analyses were consistent with relative reductions in risk of 
blood transfusion and blood loss of 38% and 34% respectively. However, many trials were 
methodologically weak and fewer than half had adequate allocation concealment. When the 
analyses were restricted to adequately concealed trials, the estimated relative risk reductions 
were somewhat smaller; 32% and 30% respectively. They were also less precise albeit both 
remained statistically significant. There were also concerns about selective reporting and only 
two of the adequately concealed trials were prospectively registered and had pre-specified 
receipt of blood transfusion as an outcome. The pooled estimate of the effect on blood 
transfusion from these two trials was still consistent with a statistically significant relative risk 
reduction of 21% although, as suggested by the results of the trial sequential analysis (Research 
Paper 3), this may be a spurious result. Despite these shortcomings, due to the number of trials 
and the magnitude of the effect that remained when restricted to adequately concealed trials, I 
concluded that there was reliable evidence that TXA reduces bleeding in surgery. Furthermore, 
based on the results of the cumulative meta-analysis presented in Research Paper 1, I also 
concluded that the evidence that TXA reduces the risk of blood transfusion had been available 
for many years. 
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However, since I completed Research Papers 1-3, there have been two important developments 
which oblige me to reconsider these conclusions. First, are the serious deficiencies in the quality 
and integrity of the studies included in my systematic review of trials investigating TXA for 
preventing postpartum haemorrhage (Research Paper 6), which raise the possibility that similar 
deficiencies also affect the surgical trials. Whilst I did not have the same suspicions about the 
surgical trials when extracting data, it would be remiss of me not to consider that the same 
concerns could affect these trials at least to some extent. There seems no reason why such issues 
would be confined to the PPH prevention trials, so there is now a further question mark over 
the reliability of the trials in surgery. 
The second development is the publication of the results of the ATACAS trial, a large, high quality 
trial of the effects of TXA in over 4000 cardiac surgery patients, in January 2017.1 The ATACAS 
trial assessed the effects of TXA in patients undergoing coronary-artery surgery who were at risk 
of perioperative complications.1 The trial was at low risk of bias (adequately concealed, double-
blind, prospectively registered) and provided outcome data for 4631 patients (2311 in the TXA 
group and 2320 in the placebo group). Fewer patients in the TXA group received a blood 
transfusion than in the placebo group (37.9% vs. 54.7%; RR=0.69, 95% CI 0.65 to 0.74). To 
understand how these results contribute to the wider evidence from surgery trials, I have 
repeated the meta-analyses conducted for the systematic review to include data from the 
ATACAS trial. Table 5.1 (below) shows the results of the meta-analysis of the risk of receiving a 
blood transfusion, before and after the inclusion of data from the ATACAS trial. 
Table 5.1 Meta-analysis of effect of TXA on receipt blood transfusion reported in Chapter 2 with 
and without the addition of data from the ATACAS trial.  
 Pooled RR without ATACAS Pooled RR with ATACAS 
Blood transfusion 
All trials 0.62 (0.58 to 0.65); p<0.001 0.65 (0.62 to 0.68); p<0.001 
Adequately concealed trials 0.68 (0.62 to 0.74); p<0.001 0.69 (0.65 to 0.73); p<0.001 
Prospectively registered, 
blood transfusion pre-
specified 
0.79 (0.71 to 0.87); p<0.001 0.71 (0.67 to 0.75); p<0.001 
 
The magnitude of the effect after the inclusion of the ATACAS trial data is smaller although more 
precise. When data from the ATACAS trial are included in the pooled analysis based on 
adequately concealed trials, which were also prospectively registered and prespecified receipt 
of blood transfusion as an outcome, the pooled estimate is consistent with a 29% relative risk 
reduction. Although the required information size (n=10,888) is still not achieved, the results of 
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the updated trial sequential analysis show that the z-curve crosses the monitoring boundary 
after the addition of the ATACAS trial (Figure 5.1), thus I can be more confident that this is a 
reliable effect estimate.  
Figure 5.1 Results of trial sequential analyses for trials at low risk of bias trials with transfusion 
pre-specified on prospective registration record, reported in Research Paper 3, updated to 
include data from the ATACAS trial.  
 
In summary, due to further concerns about the quality of trials arising out of the systematic 
review of TXA trials for preventing PPH, my original conclusions regarding the reliability of the 
evidence for the effect on surgical bleeding were arguably too strong. Moreover, my statement 
that reliable evidence had existed for many years was incorrect. Rather it is only since the 
publication of the ATACAS trial in 2017 that reliable evidence has been available. Furthermore, 
the magnitude of the effect on blood transfusion (RR=0.62) estimated by the pooled analysis of 
all trials was inflated and a smaller effect (RR=0.71) seems likely to be closer to the true effect.  
Evidence from randomised trials of the effect of TXA on risk of death and thromboembolic 
events in surgery 
My third conclusion was that the effect of TXA on death and thromboembolic events in surgical 
patients is uncertain. Although there is no evidence that TXA increases the risk of death or 
thrombosis (indeed the effect estimates are consistent with a reduced risk), the estimates are 
imprecise. Whilst most trials reported data on bleeding or blood transfusion, data on mortality 
and thromboembolic events were only available for about half (even after contact with the 
original investigators) raising concerns about the potential for selective reporting bias. This, 
coupled with the concerns about the quality of trials arising from the PPH prevention systematic 
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review, further exacerbate these uncertainties. However, once again the ATACAS trial has since 
made a useful contribution to the evidence (Table 5.2). 
Table 5.2 Meta-analysis of effect of TXA on risk of death and myocardial infarction conducted in 
Research Paper 1 before and after the addition of data from the ATACAS trial. 
 Pooled RR without ATACAS Pooled RR with ATACAS 
Death 
All trials 0.61 (0.38 to 0.98); p=0.04 0.69 (0.49 to 0.97); p=0.04 
Adequately concealed trials 0.67 (0.33 to 1.34); p=0.25 0.75 (0.50 to 1.13); p=0.16 
Myocardial infarction 
All trials 0.68 (0.43 to 1.09); p=0.11 0.87 (0.76 to 1.01); p=0.07 
Adequately concealed trials 0.70 (0.39 to 1.25); p=0.22 0.88 (0.76 to 1.03); p=0.11 
 
The ATACAS trial data support a reduction in the risk of death although the magnitude of the 
effect is reduced when the data are added to the pooled analysis. The effect is no longer 
statistically significant at the 5% level, when restricted to adequately concealed trials and 
therefore remains open to question. Due to the relative rarity of events, the pooled effect 
estimate for myocardial infarction is uncertain even after the addition of the ATACAS trial data, 
although the lack of evidence for an increased risk from ATACAS provides some reassurance that 
TXA is safe. However, a high quality randomised trial, powered to detect the effect of TXA on 
death and thromboembolic events is still needed to resolve these uncertainties. 
The continuation of trials assessing the effects of TXA on bleeding outcomes in surgery 
My forth conclusion was that trials assessing the effect on bleeding in surgery continue to be 
conducted despite investigators being aware of existing evidence for effectiveness. This is 
contrary to a widely held view that the failure to systematically review the evidence prior to 
starting a trial is the main cause of research waste. Instead, much of the continuation of trial 
activity appears to be as a result of inappropriate trial design and the reluctance to generalise 
the existing evidence across surgery types.  
Inappropriate study design typically described trials in which the investigators cited existing 
evidence for the effectiveness of TXA and sought to assess different dose regimens of TXA, yet 
also included a placebo group. A key justification for the use of a placebo in a clinical trial is that 
no proven intervention exists.2 If the investigators truly believe that there is evidence that TXA 
is effective for reducing bleeding, the decision to include a placebo group is ethically 
inappropriate.  
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Another main motivation for embarking on new a trial was to ascertain if TXA was also effective 
in patients undergoing types of surgery yet to be investigated by the existing trials. The result 
has been the expansion in the number of trials into increasingly specific subtypes of surgery. 
Investigators appear to be unwilling to generalise results from one form of surgery (e.g. cardiac) 
to another (e.g. orthopaedic) or even to generalise within surgical areas (e.g. from hip to knee 
arthroplasty). It is of course appropriate that careful consideration is given before generalising 
trial results from one setting to another. However, it could be that investigators are confusing 
scientific and statistical inference.3 This argument by Kenneth J Rothman, suggests that rather 
than seeking to replicate results in every subgroup of surgery, it is necessary to consider what is 
known about the mechanism of action of TXA and asking whether there is good reason to think 
that it would work differently between surgical types. Such scientific reasoning appeared to be 
absent when investigators outlined their rationale for initiating a new trial of TXA. One such 
example is the trial by MacGillivray et al which assessed the effect of TXA on bleeding in 60 
patients undergoing bilateral total knee arthroplasty.4 When describing the trial rationale in the 
final report, the authors cited the evidence from two meta-analyses of trials in patients 
undergoing total knee replacement, that TXA “appears safe and effective in reducing allogeneic 
blood transfusion and blood loss”. However, because the effect had not been assessed in 
patients undergoing concurrent, bilateral total knee replacement (a procedure typically 
associated with greater blood loss) MacGillivray et al embarked on a new trial in which 40 
patients received TXA and 20 participants were randomised to receive placebo. The authors 
offer no biological reasoning why TXA might have a different effect in bilateral knee 
replacement. They note the greater blood loss associated with bilateral knee replacement, 
which is likely to mean that the absolute effect of TXA differs, but in most cases the relative 
effects of a treatment are consistent across different baseline risks.5 The unwillingness of 
MacGillivray et al to generalise the evidence from the previous trials in knee arthroplasty meant 
that one third of their trial participants, who were undergoing a procedure known to be 
associated with greater blood loss than others, were denied treatment that the trial 
investigators themselves described as being effective for reducing bleeding.  
5.1.2 Strengths and weaknesses 
The Discussion sections of each Research Paper that make up this thesis, include consideration 
of the strengths and weaknesses of each paper. I will not repeat these here, but I will reflect on 
some further points. 
The systematic review described in Research Papers 1 and 2 is not the first to assess the evidence 
of TXA in surgery patients, although I am only aware of one other review with broad inclusion 
criteria to include trials irrespective of surgery type. This is the Cochrane systematic review by 
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Henry et al, first published in 19996 and most recently updated with new trials in 20117 which 
assesses the effects of antifibrinolytic drugs in adult patients undergoing elective surgery. Unlike 
the review by Henry et al, I included trials involving paediatric and emergency surgery and 
focussed only on trials of TXA. I also identified and included a larger number of trials (129 versus 
60). My review is also the first to estimate the proportional effect of TXA on blood loss and to 
conduct a meta-regression to explore the effect of total dose, using data from trials conducted 
across a range of surgery types. Furthermore, I am not aware of any other review that has 
undertaken detailed investigation into the evidence of effect of TXA on blood transfusion by 
conducting trial sequential analyses or cumulative meta-analyses. 
The systematic review of randomised trials assessing the effects of TXA in surgery is a 
comprehensive review conducted in adherence to recommended methodology. Thus, at the 
time of its completion, it provided the most rigorous examination of the randomised trials and 
was deemed to be of sufficiently high quality to inform clinical practice. Indeed, the results have 
been used in the preparation of clinical guidelines, such as those prepared by NICE, and the Task 
Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for 
Cardio-Thoracic Surgery and the European Association of Cardiothoracic Anaesthesiology, both 
of which recommend the use of TXA in surgery.8, 9  
However, as is typical of systematic reviews based on aggregate data, my systematic review is 
largely based on information as presented by the investigators in the original trial reports. 
Although I contacted authors to obtain additional outcome data, I did not seek individual patient 
data or additional information to ensure that the information presented was accurate. Nor did 
I undertake additional analyses to assess the integrity of the data such as a meta-analysis of 
baseline information to assess the adequacy of randomisation. I cannot therefore be confident 
that the trials included in the meta-analysis were conducted as reported or indeed, if they were 
conducted at all. Although I cannot predict how this may have affected the results of the review, 
the publication of the ATACAS trial does provide reassurance that TXA does reduce bleeding in 
surgery.  
5.1.3 Implications for future research 
The publication of the ATACAS trial confirms the findings of my systematic review that TXA 
reduces bleeding in surgery although the magnitude of the effect may be somewhat smaller 
than estimated in my meta-analysis. It is, however, a relatively large treatment effect that is 
clinically relevant.  
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Without sound, biological reasoning why the effect would vary between different types of 
surgical patients, it is difficult to see how further trials of TXA designed to assess the effect on 
bleeding or blood transfusion in surgery can be justified.  
Although clinically important questions may remain regarding optimal dose and timing of TXA 
that necessitate further trials, such questions do not require the inclusion of an inactive 
comparison group and it is difficult to see how such trials can be ethically justified. However, 
uncertainties regarding the effects of TXA on other outcomes in surgical patients remain. 
Indeed, it seems likely that concerns regarding a possible increase in thrombotic risk will 
somewhat limit the uptake of TXA into clinical practice, since an increase in thrombosis could 
outweigh the benefits of reduced blood use. In the Discussion section of Research Paper 1, I 
suggested that to resolve the uncertainties over the effect on death and thromboembolic events 
there is a “need for a large pragmatic clinical trial of the effect of the routine administration of 
TXA in a heterogeneous group of surgical patients”. Since this was published, a team of 
researchers based at the Population Health Research Institute in Canada have initiated a new 
trial of TXA (the POISE-3 trial) in 10,000 non-cardiac surgical patients to ascertain its effect on 
thromboembolic events.10 The trial is expected to be completed by December 2022. 
5.2 EFFECTS OF TRANEXAMIC ACID FOR TRAUMATIC BLEEDING 
5.2.1 Principal findings 
Chapter 2 included Research Papers 4 and 5 in which I evaluated the evidence from randomised 
trials for the effects of TXA in patients with traumatic bleeding (Aim 2). On the basis of my 
results, I drew four main conclusions: 1) that TXA reduces the risk of death to bleeding; 2) that 
the relative effect is largest when TXA is administrated within three hours of injury; 3) that there 
is no apparent increase in risk of thromboembolic events; and 4) that over 100,000 bleeding 
trauma deaths could be averted every year if all patients were given TXA within three hours of 
injury. 
Effect of TXA in patients with traumatic bleeding 
There is a marked difference in the nature of the evidence from randomised trials for the effects 
of TXA in traumatic bleeding compared with that for surgery. Instead of over one hundred small, 
generally poor quality trials conducted over decades as found for surgery, there are just two 
trials in trauma and the bulk of the evidence originates from one of these, the CRASH-2 trial. The 
CRASH-2 trial was a high quality trial involving a heterogeneous group of 20,211 adult trauma 
patients recruited from 274 hospitals in 40 countries. It provides reliable evidence that is not 
subject to the quality concerns affecting the surgery trials. The results suggest that TXA reduces 
the risk of death due to bleeding by 15% (RR=0.85; 95% CI 0.76 to 0.96). There is also evidence 
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for an important time to treatment interaction. Although not pre-specified in the systematic 
review, a pre-specified subgroup analysis of the trial data showed that early treatment (within 
three hours) was most effective. There was no apparent increase in the risk of thromboembolic 
events which is reassuring, although due to the relative rarity of events (<2%) the effect 
estimates are imprecise and neither an increase nor decrease in risk can be discounted. 
Nevertheless, the evidence for the effect on death due to bleeding is strong and as a result TXA 
has been implemented into trauma protocols worldwide and is now listed on the WHO List of 
Essential Medicines.11 
Potential number of deaths averted 
Applying the relative effect of TXA on death due to bleeding in trauma patients, to the data on 
the number of trauma death worldwide provides an indication of the enormous health impact 
that the routine use of TXA could have. Using data from the WHO and the literature, I estimated 
that worldwide about 400,000 trauma patients die in hospital from bleeding every year. 
Although subject to wide uncertainty intervals, the estimates in Research Paper 5 are consistent 
with up to 100,000 deaths potentially averted every year, by the routine, early use of TXA. Most 
of these potentially averted deaths are found in LMICs. These estimates have been useful for 
supporting the efforts to disseminate the results of the CRASH-2 trial, such as the Trauma 
Promise initiative.12 
5.2.2 Strengths and limitations 
As described in the Discussion section of Research Paper 5, the estimates of the number of 
deaths that could potentially be averted with TXA were based on a simple mathematical model, 
subject to several assumptions and were limited by a lack of data on the epidemiology of trauma 
deaths. Another limitation was that the information used to estimate the model parameters 
primarily originated from high income countries. There is therefore a question regarding the 
extent to which these apply to the situation in low income countries. Indeed, it is quite likely 
that the proportion of trauma deaths in hospital would be lower in low income countries where 
a lack of pre-hospital care may mean that fewer people survive to reach hospital.  
5.2.3 Implications for research 
The CRASH-2 trial provides reliable evidence for the effects of TXA in trauma patients, there is 
therefore no need for further trials. Efforts instead should be focussed on the dissemination of 
the evidence and implementation of early TXA use into trauma protocols worldwide. 
There are uncertainties regarding its effects in isolated traumatic brain injury and these are 
currently being investigated by the ongoing CRASH-3 trial.13 Another important research 
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opportunity is exploring ways to facilitate the pre-hospital use of TXA. As suggested by the 
estimates used to calculate the number of deaths that could be averted in Research Paper 5, 
most trauma deaths (approximately 60%) occur before arrival at hospital. Research into 
alternative routes of administering TXA that are amenable to use outside of hospital, such as 
intramuscular administration, would therefore be a worthwhile area for future research.  
5.3 EFFECTS OF TRANEXAMIC ACID FOR PREVENTING POSTPARTUM HAEMORRHAGE 
5.3.1 Principal findings 
Chapter 3 focussed on assessing the evidence from randomised trials for the effects of TXA for 
preventing postpartum haemorrhage (Aim 3). Research Paper 6 described a systematic review 
including 26 trials involving 4191 women. There were serious deficiencies in the quality and 
integrity of the trials that meant that no reliable inferences on the effects of TXA for this 
indication could be made. Research Paper 7 presented the protocol for a new trial (WOMAN-2), 
which by randomising 10,000 women with moderate or severe anaemia after they have given 
birth vaginally, will address the existing uncertainties and provide reliable evidence for the 
effects of TXA in this patient group. 
There is no reliable evidence for the effects of TXA for preventing PPH 
Despite identifying 26 randomised trials involving a total of 4191 women, I concluded that there 
was no reliable evidence for the effects of TXA due to serious concerns about the quality and 
integrity of the trials. A crucial aspect of a systematic review is thorough assessment of 
methodological quality of the included trials, with Cochrane’s risk of bias tool being a preferred 
approach. However, there were concerns and deficiencies affecting the included trials that were 
not captured by this assessment. The near identical sections of text shared by a number of the 
reports, alongside errors and inconsistencies, forced me to question the reported data and 
indeed, to question whether the trials were carried out as reported at all. Obtaining additional 
information from authors did not reassure me, rather it raised further concerns. The meta-
analysis of baseline variables supported my concerns that these trials were unreliable by 
suggesting that the randomisation process may have been subverted.  
The WOMAN-2 trial 
The trials assessing the effect of TXA on preventing postpartum haemorrhage included in the 
systematic review described in Research Paper 6, provide no reliable evidence. However, the 
subsequently published TRAAP14 and WOMAN15 trials, coupled with the wider evidence from 
surgery and trauma, give reason to hope that it could be effective for reducing postpartum 
bleeding. The WOMAN-2 trial outlined in Research Paper 7, should provide a definitive answer 
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to the question of the effect of TXA on postpartum bleeding and wellbeing in women with 
anaemia. 
5.3.2 Strengths and limitations 
My systematic review is the first to highlight the wider deficiencies affecting trials assessing the 
effect of TXA for preventing PPH. The investigations I undertook to explore these concerns were 
not pre-specified but were initiated in response to issues observed during data extraction. Nor 
were the investigations based on a recommended approach. However, in the absence of 
guidelines, I believe that my approach was preferable to ignoring the concerns.  
The planned WOMAN-2 trial is a large, multicentre, randomised trial that is designed to minimise 
bias (prospectively registered, adequately concealed, double-blind). It has been designed by a 
multidisciplinary team that has a proven track record in the delivery of large clinical trials of TXA, 
having previously co-ordinated the CRASH-216 and WOMAN15 trials. The planned sample size of 
10,000 women provides over 90% power to detect a 25% reduction from 10% to 7.5% in PPH. 
The large sample size also allows for reliable assessment of the effects of other patient-centred 
outcomes such as those pertaining to maternal wellbeing. 
5.3.3 Implications for research 
A key implication for research is being addressed by the WOMAN-2 trial, which will provide 
reliable evidence for the effects of TXA on postpartum bleeding and wellbeing in women with 
anaemia. Patient recruitment is expected to start by January 2019 and the trial will be completed 
by January 2022. 
The results of the systematic review of trials has implications for the conduct of systematic 
reviews more generally. Many of the weaknesses of the trials such as near-identical texts of 
published reports, lack of ethics committee approval, apparent subversion of the randomisation 
process, alongside errors and inconsistencies in the results data, go beyond the standard checks 
and assessment of methodological quality typically used by systematic reviewers. This raises a 
fundamental question of the extent to which we can take the information presented in trial 
reports on trust. Most systematic reviews are based on aggregate data extracted from trial 
reports, with contact (if any) with the original trial investigators largely limited to seeking 
clarification of methods or obtaining unreported data. Rarely do systematic reviewers request 
basic information about the conduct of the trial such as proof of ethics approval or 
randomisation dates. However, the results of the systematic review described in Research Paper 
6, highlight the potential problem with such an approach and the need for thorough 
investigations into the basic integrity of the data. There are previous examples of trials being 
included in systematic reviews and informing conclusions about intervention effectiveness, only 
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to be found at a later date to be fraudalent.17, 18 As mentioned previously, there is no guidance 
for systematic reviewers on how to identify research misconduct or how to manage it when 
suspected. Given the influence that results of systematic reviews can have on clinical practice 
and policy, I believe that research to inform guidance that systematic reviewers can use to 
identify and manage research misconduct is urgently required. 
5.4 IMPLICATIONS FOR MY RESEARCH INTO THE EFFECTS OF TRANEXAMIC ACID  
I intend to continue participating in research to reliably assess the effects of TXA. In my role 
within the LSHTM CTU, I will be part of the team working over the next four years to ensure the 
successful completion of the WOMAN-2 trial.  
Another project I plan to take forward is the establishment of the Antifibrinolytics Trialists 
Collaboration. As described in earlier sections, there are some unanswered questions regarding 
the effects of TXA, such as the effect on thromboembolic events. There are also other questions 
such as effects of TXA by time to treatment and by baseline risk. These cannot be answered 
reliably by the existing trials, either individually or by combining their aggregate data. However, 
such questions could be answered by individual patient data (IPD) meta-analyses. Systematic 
reviews and meta-analyses of IPD are the ‘gold standard’ for systematic reviews.19 IPD 
systematic reviews can reduce the problem of selective reporting, which would reduce bias and 
increase statistical power. The increased statistical power also facilitates more reliable subgroup 
analyses. They also allow a detailed check of the primary data, which in light of the concerns 
raised by my systematic review of PPH prevention trials (Research Paper 6), may be crucial. In 
the context of the safety and effectiveness of TXA, an IPD systematic review can overcome 
several of the limitations of reviews based solely on aggregate patient data. This is an 
opportunity for future research that I am taking forward. On the 10-11th June 2018, I hosted the 
first meeting of the Antifibrinolytics Trialists Collaboration, supported by the LSHTM CTU. 
Investigators of completed and ongoing trials of TXA from all over the world, attended and 
agreed participate in an IPD meta-analysis to resolve the remaining uncertainties. Together 
these trials could provide data on over 100,000 bleeding patients and the results could provide 
the most reliable evidence for the effects of TXA.  
5.5 CONCLUSIONS 
Most of the randomised trials assessing the effects of TXA for surgical bleeding and for 
preventing PPH are small and poor quality. Although together they provide promising evidence 
that TXA reduces bleeding, large, well-conducted trials at low risk of bias are required to 
determine reliably the effects of TXA. Two additional trials of TXA in surgery, the recently 
completed ATACAS trial in coronary-artery surgery and the ongoing POISE-3 trial in non-cardiac 
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surgery, in addition to the ongoing WOMAN-2 trial of TXA for preventing PPH, should contribute 
importantly to resolving the uncertainties about the effects of TXA in these indications.  
The evidence for the effects of TXA for traumatic bleeding originates from the CRASH-2 trial, a 
large, high quality trial in 20,000 bleeding trauma patients. It provides reliable evidence that TXA 
given soon after injury reduces the risk of death due to bleeding by about one third. The 
implication of this is that TXA has the potential to prevent thousands of trauma deaths 
worldwide.  
There is remaining uncertainty regarding the effect of TXA on risk of thromboembolic events. 
There are also questions regarding the effects of TXA by time to treatment and baseline risk. An 
IPD meta-analysis could answer some of the questions about the effects of TXA that cannot be 
answered by systematic reviews and meta-analyses based on aggregate data. 
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Appendix E. Research Paper 1: PRISMA Checklist 
Section/topic  # Checklist item  Reported on pageix 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
web appendix 2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
4 
                                                            
ixCorresponds to page numbers within the manuscript submitted to the journal 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
4-5 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis.  
5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
5 
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Appendix F. Research Paper 1: MEDLINE (Ovid) search strategy, 1950 to September 2011 
1. exp Antifibrinolytic Agents/ 
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or 
antiplasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti. 
3. exp Aprotinin/ 
4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or 
bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal or 
kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin or 
pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or 
kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or 
antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin 
inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type 
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or 
(pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or 
traskolan or trazylol or zymofren or zymophren).ab,ti. 
5. exp Tranexamic Acid/ 
6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethylcyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or 
exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino 
methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or 
frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti. 
7.  exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/ 
8.  (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or 
amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n 
hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine 
or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon 
or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or 
epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or 
ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti. 
9.  1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10.  randomi?ed.ab,ti. 
11.  randomized controlled trial.pt. 
12.  controlled clinical trial.pt. 
13.  placebo.ab. 
14.  clinical trials as topic.sh. 
15.  randomly.ab. 
16.  trial.ti. 
17.  10 or 11 or 12 or 13 or 14 or 15 or 16 
18.  (animals not (humans and animals)).sh. 
19.  17 not 18 
20.  9 and 19 
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Appendix H. Research Paper 1: Forest plots of the effects of TXA in surgery on risk of blood 
transfusion, thromboembolic events and mortality 
Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of blood 
transfusion
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Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of 
myocardial infarction 
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Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of 
stroke 
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Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of deep 
vein thrombosis 
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Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of 
pulmonary embolism 
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Meta-analysis and cumulative meta-analysis of the effect of TXA in surgery on the risk of death 
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Appendix K. Research Paper 2: Further detail of statistical methods 
Bayesian model for linear regression of means in the two groups 
Ideally the population means for each group in each trial would be used for the regression 
however, in this case only the sample means were available. According to the Central Limit 
Theorem, the means of random samples should be normally distributed centred on the 
population mean. The standard error of the sample mean with the sample variance was 
estimated using the Student’s t distribution as follows. 
So: yc[i] ~ Student-T(mc[i] , sec[i], nc[i]) and  yt[i] ~ Student-T( mt[i] , set[i], nt[i])  
And: sec[i] = sdc[i] / sqrt(nc[i]) and set[i] = sdt[i] / sqrt(nt[i]) 
Where: ‘yc[i]’ is sample mean of controls, ‘mc[i]’ is population mean of controls and ‘sec[i]’ is 
standard error of yc[i] estimated with the sample standard deviation sdc[i] and sample size nc[i], 
all in trial[i]. Also yt[i], mt[i], set[i], sdt[i] and nt[i] have the same meaning for the treatment 
group in trial[i].  
The linear model is: mt[i] <- intercept + slope*mc[i] + e[i] 
    e[i] ~ dnorm(0, sde[i]) 
    sde[i] <- e0 + e1*mc[i] 
Where e[i] is the random error in the regression that is assumed to be distributed normally and 
independently for each trial. However, as it is not realistic to think of an error of constant 
standard deviation (sde[i]) the standard deviation was allowed to vary with the mean of the 
control group. 
Interpretation: The ‘intercept’ is expected to be 0 if there is a constant proportional effect of 
TXA. The ‘slope’ is the coefficient that estimates the proportional reduction in blood loss in 
intervention compared to control group.  
Priors: Non informative priors to mc[i], intercept, slope, e0 and e1 were assigned. 
 
Transformation of blood loss data into the logarithmic scale  
Ideally, individual patient data would be available and the natural logarithm of the estimated 
blood loss in each patient is taken and the mean and standard deviation calculated using the 
transformed data. Because individual patient data were not available, the summary statistics 
from the trials were used to estimate the log-transformed values.  
It was assumed that the variable blood loss ( X ) followed a log-normal distribution
),(~ σµLogNormalX , thus ),(~)( LLNormalXLn σµ and the equations linking the means 
( µ ) and standard deviation (σ ) of the distributions were: 


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For trials that reported average blood loss as means with standard deviations, the equations 
above were used to estimate the log means and standard deviations. 
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Appendix L. Research Paper 2: Characteristics of included trials 
Trial Participants Intervention and comparator Risk of bias judgements 
Alvarez 2008 
 
Spain 
95 patients undergoing knee arthroplasty 
TXA group (n=46):  
M/F=7/39; mean age(sd)=71(9) 
Control group (n=49): 
M/F=10/39; mean age(sd)=72(7) 
 
TXA group: bolus 10mg/kg before 
deflation of tourniquet, then infusion 
1mg/kg/hr 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
unclear 
Armellin 2001 
 
Italy 
283 patients undergoing aortic valve 
replacement 
TXA group (n=143): 
M/F=71/72; mean age(sd)=65.7(11.7) 
Control group (n=140):  
M/F=90/50; mean age(sd)=65.9(12.8) 
 
 
TXA group: 2.5g before skin incision, 
further 2.5g added to pump prime 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
unclear 
Auvinen 1987 
 
Finland 
76 patients undergoing surgery of the thyroid 
gland 
TXA group (n=39):  
M/F=4/35; mean age(sd)=50(16.4) 
Control group (n=37): 
M/F=2/35; mean age(sd)=51(13.5) 
 
 
TXA group: 0.5g at induction of 
anaesthesia then 0.5g during each 8h of 
the intra- and post-op period 24 hrs 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Benoni 1996 
 
Sweden 
96 patients undergoing knee arthroplasty 
TXA group (n=43):  
M/F=13/30; mean age(sd)=76(7) 
Control group (n=43):  
M/F=10/33; mean age(sd)=74(7) 
 
 
TXA group: 10mg/kg given as slow 
injection towards end of operation, before 
deflation of tourniquet 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
unclear 
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Trial Participants Intervention and comparator Risk of bias judgements 
Benoni 2001 
 
Sweden 
38 patients undergoing hip arthroplasty 
TXA group (n=18):  
M/F=9/9; mean age(sd)=66(9.5) 
Control group (n=20):  
M/F=10/10; mean age(sd)=68(9.4) 
 
TXA group: 10 mg/kg immediately before 
operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
unclear 
Blauhut 1994 
 
Austria/Switzerland 
30 patients undergoing cardiac surgery 
TXA group (n=16):  
M/F=13/3; mean age(sd)=62.5(2.2) 
Control group (n=14):  
M/F=11/3; mean age(sd)=62.7(2.6) 
 
TXA group: 10 mg/kg 30 mins before skin 
incision, then 1mg/kg per hr for 10 hr after 
the beginning of surgery 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
unclear 
Bulutcu 2005 
 
Turkey 
50 paediatric patients undergoing cardiac 
surgery 
TXA group (n=25):  
M/F=15/10; mean age(sd)=4.1(2.0) 
Control group (n=25):  
M/F=12/13; mean age(sd)=3.8(2.4) 
 
TXA group: 100mg/kg after anaesthesia, 
100mg/kg in pump prime and 100mg/kg 
after weaning from CPB until skin closure 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
unclear 
Caglar 2008 
 
Turkey 
100 patients undergoing myomectomy 
TXA group (n=50):  
All F; mean age(sd)=34.2(5.5) 
Control group (n=50):  
All F; mean age(sd)=36.5(2.6) 
 
TXA group: Bolus of 10mg/kg during 10 
min, 15 mins before incision, then 
continuous infusion of 1mg/kg/h 10 hrs 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
Casati 2004a 
 
Italy 
51 patients undergoing cardiac surgery 
TXA group (n=26):  
M/F=24/2; mean age(sd)=64(9) 
Control group (n=25):  
M/F=21/4; mean age(sd)=60(9) 
 
TXA group: Bolus 1g in 20 mins after 
induction anaesthesia before skin incision 
then continuous infusion of 400mg/h 
during operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
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Casati 2004b 
 
Italy 
 
51 patients undergoing cardiac surgery 
TXA group (n=26):  
M/F=20/6; mean age(sd)=64(12) 
Control group (n=25):  
M/F=21/4; mean age(sd)=61(11) 
 
 
TXA group: 1g in 20 mins after induction 
anaesthesia before skin incision then 
infusion of 400mg/h during operation plus 
500mg added to priming 
Control group: placebo 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Chauhan 2003 
 
India 
120 paediatric patients undergoing cardiac 
surgery 
TXA group (n=96):  
M/F=71/25; mean age(sd)=4.4(3.6) 
Control group (n=24):  
M/F=20/4; mean age(sd)=4.2(3.3) 
 
 
TXA group: 10mg/kg after anaesthetic 
induction, 10mg/kg on CPB and 10mg/kg 
after protamine reversal of heparin 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
high 
unclear 
low 
Chauhan 2004a 
 
India 
100 paediatric patients undergoing cardiac 
surgery 
TXA group (n=50):  
M/F=36/14; mean age(sd)=4.1(2.4) 
Control group (n=50):  
M/F=35/15; mean age(sd)=4.2(2.1) 
 
 
TXA group: 10mg/kg after anaesthetic 
induction, 10mg/kg on CPB and 10mg/kg 
after protamine reversal of heparin 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
high 
unclear 
low 
Chauhan 2004b 
 
India 
Paediatric patients undergoing cardiac surgery 
TXA group (n=30):  
M/F=24/6; mean age(sd)=3.3(2.9) 
Control group (n=30):  
M/F=20/10; mean age(sd)=4.3(3.3) 
 
 
TXA group: single dose of 50mg/kg given 
over 30 mins after anaesthetic induction  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
high 
unclear 
low 
Chauhan 2004c 
 
India 
Paediatric patients undergoing cardiac surgery 
TXA group (n=30):  
M/F=25/5; mean age(sd)=4.2(4.0) 
Control group: as for Chauhan 2004b 
 
TXA group: 10mg/kg given over 30 mins 
after anaesthetic induction, followed by 
infusion of 1mg/kg for 8 hours  
Control group: as for Chauhan 2004b 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
high 
unclear 
low 
Chauhan 2004d Paediatric patients undergoing cardiac surgery  • Sequence generation unclear 
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India 
TXA group (n=30):  
M/F=26/4; mean age(sd)=3.0(4.3) 
Control group:  
as for Chauhan 2004b 
 
TXA group: 10mg/kg given over 30 mins 
after anaesthetic induction, 10mg/kg on 
CPB, and 10mg/kg after protamine 
administration 
Control group: as for Chauhan 2004b 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
high 
unclear 
low 
Chauhan 2004e 
 
India 
Paediatric patients undergoing cardiac surgery 
TXA group (n=30):  
M/F=25/5; mean age(sd)=2.9(5.0) 
Control group: as for Chauhan 2004b 
 
 
TXA group: 20mg/kg after anaesthetic 
induction and 20mg/kg after protamine 
Control group: as for Chauhan 2004b 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
high 
unclear 
low 
Chen 2008 
 
Taiwan 
 
55 patients undergoing head and neck surgery 
TXA group (n=26):  
M/F=15/11; mean age(sd)=49.8(13.0) 
Control group (n=29):  
M/F=16/13; mean age(sd)=46.4(14.8) 
 
 
TXA group: Bolus 10mg/kg before incision, 
then continuous infusion of 1mg/kg/h 
during the operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment  
• Blinding 
• Incomplete outcome data 
low 
low 
low 
high 
Choi 2009 
 
Hong Kong 
 
61 patients undergoing head and neck surgery 
TXA group (n=32):  
M/F=10/22; mean age(sd)=23.9(6.1) 
Control group (n=29):  
M/F=11/18; mean age(sd)=22.8(4.5) 
 
 
TXA group: 20mg/kg bolus just before 
surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
high 
Claeys 2007 
 
Belgium 
 
40 patients undergoing hip arthroplasty 
TXA group (n=20):  
M/F=5/15; mean age(sd)=73(8) 
Control group (n=20):  
M/F=7/13; mean age(sd)=68(11) 
 
 
TXA group: Single pre-op dose of 15mg/kg 
as slow infusion 15 mins before surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Coffey 1995 
 
USA 
 
30 patients undergoing cardiac surgery 
TXA group (n=16):  
M/F=5/11; mean age=63.94 
Control group (n=14):  
M/F=5/9; mean age=64.75 
 
TXA group: Single pre-op dose of 15mg/kg 
as slow infusion 15 mins before surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
low 
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Corbeau 1995 
 
USA 
 
61 patients undergoing cardiac surgery 
TXA group (n=41):  
M/F=26/15; mean age(sd)=62.46(14.33) 
Control group (n=20):  
M/F=16/4; mean age(sd)=63(15.59) 
 
 
TXA group: 15 mg/kg between heparin 
injection and beginning of extracorporeal 
circulation, 15mg/kg after protamine 
injection 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
unclear 
Crescenti 2011 
 
Italy 
200 patients undergoing prostatectomy 
TXA group (n=100):  
All M; mean age(sd)=64(7.4) 
Control group (n=100):  
All M; mean age(sd)=64(7.8) 
 
 
TXA group: 500mg, then infusion of 
250mg/h during operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Dadure 2011 
 
France 
39 paediatric patients undergoing head and 
neck surgery 
TXA group (n=19):  
M/F=17/2; median age(range)=7 months (4-
15) 
Control group (n=20):  
M/F=17/3; median age(range)=6 months(3-9) 
 
 
TXA group: 15mg/kg over 15 mins after 
induction of anaesthesia, before skin 
incision, then continuous infusion of 
1ml/kg/hr until skin closure  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Diprose 2005 
 
UK 
123 patients undergoing cardiac surgery 
TXA group (n=62):  
M/F=49/11; median age(range)=65 (40-81) 
Control group (n=61):  
M/F=52/8; median age(range)=65(32-82) 
 
 
TXA group: 5g IV in 200ml volume at start 
of surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
high 
Durán de la Fuente 
2003 
 
Spain 
20 paediatric patients undergoing cranial 
surgery 
TXA group (n=10):  
M/F=3/7; mean age(sd)=6(1) 
Control group (n=10):  
M/F=3/7; mean age(sd)=7(3) 
 
TXA group: 15mg/kg IV on anaesthetic 
induction, every 4 hrs during surgery and 
every 8 hrs for 48 hrs after surgery 
Control group: no TXA 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
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Ekback 2000 
 
Sweden 
40 patients undergoing hip arthroplasty 
TXA group (n=20):  
M/F=9/11; mean age(sd)=66.4(9.0) 
Control group (n=20):  
M/F=11/9; mean age(sd)=65.6(8.8) 
 
 
TXA group: bolus of 10mg/kg before 
surgical incision, continuous infusion of 
1mg/kg/hr during 10 hr started 
immediately after 1st bolus dose, 2nd 
bolus dose of 10mg/kg given 3 hr later 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Elwatidy 2008 
 
Saudi Arabia 
64 patients undergoing spinal surgery 
TXA group (n=32):  
M/F=21/11; mean age(sd)=51.56(19.08) 
Control group (n=32):  
M/F=18/14; mean age(sd)=49.75(21.04) 
 
 
TXA group: loading dose of 2g followed by 
continuous infusion of 100mg/h during 
surgery and for 5 hrs after operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
high 
low 
low 
low 
Gai 2004 
 
China 
180 patients undergoing caesarean section 
TXA group (n=91):  
All F; mean age(sd)=29.71(4.18) 
Control group (n=89):  
All F; mean age(sd)=29.75(4.01) 
 
 
TXA group: 1g Iv infused over 5 mins, 10 
mins before incision 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Garneti 2004 
 
UK 
50 patients undergoing hip arthroplasty 
TXA group (n=25):  
M/F=NR; mean age(sd)=69.6(11.99) 
Control group (n=25):  
M/F=NR; mean age(sd)=67.6(11.4) 
 
 
TXA group: 10mg/kg as a bolus at 
anaesthesia 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
Gobbur 2010 
 
India 
100 patients undergoing caesarean section 
TXA group (n=50):  
All F=NR; mean age(sd)=NR 
Control group (n=50):  
All F; mean age(sd)=NR 
 
 
TXA group: 1g 20 mins before surgery 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
unclear 
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Gohel 2007 
 
India 
100 patients undergoing caesarean section 
TXA group (n=50):  
All F=NR; mean age(sd)=24.30(3.65) 
Control group (n=50):  
All F; mean age(sd)=24.89(3.99) 
 
 
TXA group: 1g over 5 minutes, 20 mins 
before incision 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
 
high 
high 
high 
low 
 
Goobie 2011 
 
USA 
46 paediatric patients undergoing head and 
neck surgery 
TXA group (n=23):  
M/F=15/8; mean age(sd)=23 months(19) 
Control group (n=20):  
M/F=11/9; mean age(sd)=25 months(20) 
 
 
TXA group: after induction of anaesthesia 
and before skin incision, loading dose of 
50mg/kg as infusion over 15 mins, 
followed by infusion of 5mg/kg/hr 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
high 
Greiff 2011 
 
Norway 
63 patients undergoing cardiac surgery 
TXA group (n=30):  
M/F=18/12; mean age(sd)=77(4) 
Control group (n=33):  
M/F=19/14; mean age(sd)=77(5) 
 
 
TXA group: 10mg/kg bolus injection 
before surgery, then 1mg/kg/h as infusion 
during surgery 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
low 
Gungorduk 2010 
 
Turkey 
660 patients undergoing caesarean section 
TXA group (n=330):  
All F=18/12; mean age(sd)=26.3(3.5) 
Control group (n=330):  
All F=19/14; mean age(sd)=26.6(3.6) 
 
 
TXA group: 1g over 5 mins at least 10 mins 
prior to skin incision 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Hiippala 1995 
 
Finland 
29 patients undergoing knee arthroplasty 
TXA group (n=15):  
M/F=2/12; mean age(range)=70(56-82) 
Control group (n=13):  
M/F=3/10; mean age(range)=70(63-78) 
 
 
TXA group: 15mg/kg , 2/5 minutes before 
tourniquet was deflated 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
 
low 
unclear 
unclear 
high 
 
Hiippala 1997 
 
77 patients undergoing knee arthroplasty 
TXA group (n=39):  
 
• Sequence generation 
unclear 
unclear 
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Finland M/F=4/35; mean age(sd)=70(7) 
Control group (n=38):  
M/F=8/30; mean age(sd)=69(5) 
 
TXA group: 15mg/kg just before 
tourniquet was deflated, further 2 doses 
of 10mg/kg given during the operation day 
Control group: placebo 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
Horrow 1990 
 
USA 
38 patients undergoing cardiac surgery 
TXA group (n=18):  
M/F=NR; mean age(sd)=62(9) 
Control group (n=20): 
M/F=NR; mean age(sd)=66(10) 
 
 
TXA group: 10 mg/kg infusion over 20 min 
period followed by infusion of 1mg/kg for 
10 hours 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Horrow 1991a 
 
USA 
81 patients undergoing cardiac surgery 
TXA group (n=37):  
M/F=NR; mean age(sd)=65(11) 
Control group (n=44):  
M/F=NR; mean age(sd)=64(10) 
 
 
TXA group: loading dose 10mg/kg over 30 
mins after induction of anaesthesia, 
followed by 12 hr infusion of 1 mg/kg/hr 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Horrow 1991b  
 
USA 
78 patients undergoing cardiac surgery 
TXA group (n=40):  
M/F=NR; mean age(sd)=63(9) 
Control group (n=38): 
M/F=NR; mean age(sd)=63(11) 
 
 
TXA group: loading dose 10mg/kg over 30 
mins after induction of anaesthesia, 
followed by 12 hr infusion of 1 mg/kg/hr + 
desmopressin 
Control group: placebo + desmopressin 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Horrow 1995a 
 
USA 
Patients undergoing cardiac surgery 
TXA group (n=24):  
M/F=18/6; mean age(sd)=67(9.8) 
Control group (n=38):  
M/F=23/4; mean age(sd)=63(10.4) 
 
 
TXA group: loading dose of 2.5mg/kg after 
the induction of anaesthesia over a period 
of 30 mins followed by a 12 hour 
continuous infusion of 0.25mg/kg/hr 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Horrow 1995b 
 
USA 
Patients undergoing cardiac surgery 
TXA group (n=22):  
M/F=19/3; mean age(sd)=61(9.4) 
Control group: as for Horrow 1995a 
 
 
TXA group: loading dose of 5.0mg/kg after 
the induction of anaesthesia over a period 
of 30 mins followed by a 12 hour 
continuous infusion of 0.5mg/kg/hr 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
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Control group: as for Horrow 1995a 
 
Horrow 1995c 
 
USA 
Patients undergoing cardiac surgery 
TXA group (n=21):  
M/F=18/3; mean age(sd)=66(9.2) 
Control group: as for Horrow 1995a 
 
 
TXA group: loading dose of 10mg/kg after 
the induction of anaesthesia over a period 
of 30 mins followed by a 1 hr continuous 
infusion of 1.0mg/kg/hr 
Control group: as for Horrow 1995a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Horrow 1995d 
 
USA 
Patients undergoing cardiac surgery 
TXA group (n=21):  
M/F=18/3; mean age(sd)=66(9.2) 
Control group: as for Horrow 1995a 
 
 
TXA group: loading dose of 20mg/kg after 
the induction of anaesthesia over a period 
of 30 mins followed by a 12 hr continuous 
infusion of 2.0mg/kg/hr 
Control group: as for Horrow 1995a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Horrow 1995e 
 
USA 
Patients undergoing cardiac surgery 
TXA group (n=27):  
M/F=21/6; mean age(sd)=65(10.4) 
Control group: as for Horrow 1995a 
 
 
TXA group: loading dose of 40mg/kg after 
the induction of anaesthesia over a period 
of 30 mins followed by a 12 hr continuous 
infusion of 4.0mg/kg/hr 
Control group: as for Horrow 1995a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Husted 2003 
 
Denmark 
 
 
40 patients undergoing hip arthroplasty 
TXA group (n=20):  
M/F=7/13; mean age=65 
Control group: (n=20):  
M/F=6/14; mean age=67 
 
 
TXA group: 10mg/kg bolus followed by 
continuous infusion of 1mg/kg/hr for 10 
hrs 
Control group: as for Horrow 1995a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Isetta 1993 
 
France 
 
140 patients undergoing cardiac surgery 
TXA group (n=70):  
M/F=NR; age=NR 
Control group: (n=70):  
 
TXA group: 15mg/kg before injection of 
heparin prior to CPB 
• Sequence generation 
• Allocation concealment 
• Blinding 
unclear 
unclear 
unclear 
low 
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M/F=NR; age=NR  
 
Control group: no intervention (standard 
care) 
 
• Incomplete outcome data 
Jansen 1999 
 
Belgium 
42 patients undergoing knee arthroplasty 
TXA group (n=21):  
M/F=5/16; median age(range)=70.7(62-80) 
Control group (n=21):  
M/F=3/18; median age(range)=71.0(64-84) 
 
 
TXA group: 15mg/kg 30 min before 
inflation of the tourniquet and surgery, 
and again every 8 hrs for 3 days 
Control group: placebo 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
Jimenez 2007 
 
Spain 
50 patients undergoing cardiac surgery 
TXA group (n=24):  
M/F=12/12; mean age(95% CI)=66(63-70) 
Control group (n=26):  
M/F=15/11; mean age(95% CI)=67(62-71) 
 
 
TXA group: 2g pre and post surgery 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
low 
Johansson 2005 
 
Sweden 
100 patients undergoing hip arthroplasty 
TXA group (n=47):  
M/F=25/22; mean age(sd)=68(8) 
Control group (n=53):  
M/F=28/25; mean age(sd)=69(7) 
 
 
TXA group: 15mg/kg before start of the 
operation  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Kakar 2009 
 
India 
50 patients undergoing knee arthroplasty 
TXA group (n=25):  
M/F=7/18; mean age(sd)=62.78(13.48) 
Control group (n=25):  
M/F=7/18; mean age(sd)=66.69(5.88) 
 
 
TXA group: 10mg/kg just before 
tourniquet inflation followed by 
1mg/kg/hr until closure of wound 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Karski 1995a 
 
Canada 
Patients undergoing cardiac surgery 
TXA group (n=49):  
M/F=NR; mean age(sd)=59(3) 
Control group (n=48):  
M/F=NR; mean age(sd)=58(2) 
 
 
TXA group: 10g over 20 minutes 
Control group: placebo 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
high 
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Karski 1995b 
 
Canada 
Patients undergoing cardiac surgery 
TXA group (n=50):  
M/F=NR; mean age(sd)=63(1) 
Control group: as for Karski 1995a 
 
 
TXA group: 10g over 20 minutes and 
another 10g infused over 5 hours  
Control group: placebo 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
high 
Karski 2005 
 
Canada 
312 patients undergoing cardiac surgery 
TXA group (n=25):  
M/F=7/18; mean age(sd)=62.78(13.48) 
Control group (n=25):  
M/F=7/18; mean age(sd)=66.69(5.88) 
 
 
TXA group: 100 mg/kg over 20 minutes 
after induction of anaesthesia 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Katoh 1997a 
 
Japan 
Patients undergoing cardiac surgery 
TXA group (n=31):  
M/F=22/9; mean age(sd)=63.7(1.5) 
Control group (n=31):  
M/F=22/9; mean age(sd)=64.7(2.1) 
 
 
TXA group: infusion 100mg/kg over 20 
mins after induction of anaesthesia and 
before CPB 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Katoh 1997b 
 
Japan 
Patients undergoing cardiac surgery 
TXA group (n=31):  
M/F=21/10; mean age(sd)=62.9(1.7) 
Control group: as for Katoh 1997b 
 
TXA group: infusion 100mg/kg over 20 
mins after induction of anaesthesia and 
before CPB and 50mg/kg infused over 20 
mins after being weaned from CPB 
Control group: as for Katoh 1997b 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Katsaros 1996 
 
USA 
 
210 patients undergoing cardiac surgery 
TXA group (n=104):  
M/F=68/36; mean age(sd)=65(0.91) 
Control group (n=106):  
M/F=80/26; mean age(sd)=63(1.2) 
 
 
 
TXA group: 10g over 20 mins before 
incision 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
 
unclear 
unclear 
low 
low 
 
Kazemi 2010 
 
Iran 
64 patients undergoing hip arthroplasty 
TXA group (n=32):  
M/F=23/9; mean age(sd)=46.6(16.2) 
 
TXA group: 15mg/kg given 5 mins pre-op  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
unclear 
unclear 
low 
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Control group (n=32):  
M/F=20/12; mean age(sd)=45.4(17.2) 
 
• Blinding  
• Incomplete outcome data 
low 
Kojima 2001 
 
Japan 
22 patients undergoing hip arthroplasty 
TXA group (n=11):  
M/F=6/5; mean age(sd)=56(4) 
Control group (n=11): 
 M/F=8/3; mean age(sd)=60(2) 
 
 
TXA group: bolus 100mg/kg over 20 mins 
after anaesthesia induction and prior to 
skin incision  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Kuitunen 2005 
 
Finland 
40 patients undergoing cardiac surgery 
TXA group (n=20):  
M/F=NR; mean age(sd)=63(2) 
Control group (n=20):  
M/F=NR mean age(sd)=65(2) 
 
 
TXA group: 15mg/kg after induction of 
anaesthesia then infusion of 15mg/kg until 
end of surgery and 15mg/kg added to 
pump prime of CPB circuit 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
low 
Kuitunen 2006 
 
Finland 
30 patients undergoing cardiac surgery 
TXA group (n=15):  
M/F=12/3; mean age(sd)=57(16) 
Control group (n=15):  
M/F=11/4; mean age(sd)=61(11) 
 
 
TXA group: 10 min bolus of 1g in 100ml 
saline, given after operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
high 
Leelahanon 2002 
 
Thailand 
101 patients undergoing cardiac surgery 
TXA group (n=50):  
M/F=NR; age=NR 
Control group (n=15):  
M/F=NR; age=NR 
 
 
TXA group: 1000mg before sternotomy 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Lemay 2004 
 
Canada 
39 patients undergoing hip arthroplasty 
TXA group (n=20):  
M/F=12/8; mean age(sd)=59.7(10.3) 
Control group (n=19):  
M/F=13/6; mean age(sd)=53.6(12.8) 
 
 
TXA group: 10mg/kg bolus before surgery 
plus 1mg/kg/hr infusion until wound 
closure  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
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Lin 2011 
 
Taiwan 
100 patients undergoing knee arthroplasty 
TXA group (n=50):  
M/F=6/44; mean age(sd)=69.2(6.3) 
Control group (n=50):  
M/F=9/41; mean age(sd)=58.3(8.4) 
 
 
TXA group: 10mg/kg before deflation of 
tourniquet usually at end of wound 
closure 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
high 
high 
unclear 
high 
MacGillivray 2010a 
 
Dubai 
Patients undergoing knee arthroplasty 
TXA group (n=20):  
M/F=7/13; mean age(sd)=69.2(6.3) 
Control group (n=20):  
M/F=5/15; mean age(sd)=66(7.3) 
 
 
TXA group: 1 dose of 10mg/kg over 10 
mins before deflation of tourniquet, 2nd 
dose of 10mg/kg given 3 hrs later  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
MacGillivray 2010b 
 
Dubai 
Patients undergoing knee arthroplasty 
TXA group (n=20):  
M/F=8/12; mean age(sd)=65(4.3) 
Control group: as for MacGillivray 2010a 
 
 
TXA group: 1 dose of 15mg/kg over 10 
mins before deflation of tourniquet, 2nd 
dose of 15mg/kg given 3 hrs later  
Control group: as for MacGillivray 2010a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Maddali 2007 
 
Oman 
222 patients undergoing cardiac surgery 
TXA group (n=111):  
M/F=80/31; mean age(sd)=57.1(8.9) 
Control group (n=111):  
M/F=72/39; mean age(sd)=58.2(8.3) 
 
 
TXA group: loading dose of 10mg/kg 
before incision, then continuous infusion 
of 1mg/kg/hr until end of CPB 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
low 
Mehr-Aein 2007 
 
Iran 
66 patients undergoing cardiac surgery 
TXA group (n=33):  
M/F=NR; mean age(sd)=44(10) 
Control group (n=33):  
M/F=NR; mean age(sd)=45(10) 
 
 
TXA group: loading dose of 15mg/kg at 
beginning of surgery, same dose before 
infusion of heparin at the end of surgery, 
and after protamine infusion  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Menichetti 1996 
 
Italy 
48 patients undergoing cardiac surgery 
TXA group (n=24):  
M/F=12/12; mean age(sd)=55.2(8.6) 
 
• Sequence generation 
• Allocation concealment 
unclear 
unclear 
high 
192 
 
Trial Participants Intervention and comparator Risk of bias judgements 
Control group (n=24):  
M/F=13/11; mean age(sd)=61.0(9.7) 
 
TXA group: 10mg/kg bolus then 
continuous infusion of 3mg/kg/hr plus 
10mg/kg in the CPB priming  
Control group: no intervention (standard 
care) 
• Blinding 
• Incomplete outcome data 
low 
Misfeld 1998 
 
Germany 
24 patients undergoing cardiac surgery 
TXA group (n=14):  
M/F=14/0; mean age(sd)=56(7) 
Control group (n=14):  
M/F=11/3; mean age(sd)=59(10) 
 
 
TXA group: 10mg/kg as bolus after 
heparinization then continuous infusion of 
1mg/kg/hr over 10 hrs  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
high 
low 
Molloy 2006 
 
UK 
100 patients undergoing knee arthroplasty 
TXA group (n=50):  
M/F=NR; age=NR 
Control group (n=50):  
M/F=NR; age=NR 
 
 
TXA group: 500mg 5mins before deflation 
of tourniquet and repeat dose 3 hrs later 
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Moret 2006a 
 
Spain 
Patients undergoing cardiac surgery 
TXA group (n=70):  
M/F=NR; age=NR 
Control group (n=70):  
M/F=NR; age=NR 
 
 
TXA group: 1g bolus after anaesthetic 
induction then constant infusion of 
400mg/h iv until end of surgery and 
500mg on bypass  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
unclear 
Moret 2006b 
 
Spain 
Patients undergoing cardiac surgery 
TXA group (n=69):  
M/F=NR; age=NR 
Control group: as for Moret 2006a 
 
 
TXA group: 30mg/kg bolus after heparin 
administration 
Control group: as for Moret 2006a 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
unclear 
Movafegh 2011 
 
Iran 
100 patients undergoing caesarean section 
TXA group (n=50):  
All F; mean age(sd)=37 (3.4) 
Control group (n=50):  
All F; mean age(sd)=27.6(4.1) 
 
TXA group: 10mg/kg in 200ml saline 
infused over 10 mins, 20 mins before 
beginning spinal anaesthesia 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
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Murphy 2006 
 
Italy 
100 patients undergoing cardiac surgery 
TXA group (n=50):  
M/F=42/8; mean age(sd)=64.9 (7) 
Control group (n=50):  
M/F=37/13; mean age(sd)=65.8(8.7) 
 
 
TXA group: 2g as a bolus before 
sternotomy  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
low 
Neilipovitz 2001 
 
Canada 
40 adolescent patients undergoing spinal 
surgery 
TXA group (n=22):  
M/F=12/10; mean age(sd)=14.1 (2.1) 
Control group (n=18):  
M/F=5/13; mean age(sd)=13.7(2.5) 
 
 
TXA group: 10mg/kg initial dose then 
infusion of 1mg/kg/hr until skin closure 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
Niskanen 2005 
 
Finland 
39 patients undergoing hip arthroplasty 
TXA group (n=19):  
M/F=6/13; mean age(sd)=66 (9.1) 
Control group (n=20):  
M/F=7/13; mean age(sd)=65(8.2) 
 
 
TXA group: 3 doses of 10mg/kg, one given 
over 5-10 mins immediately before 
operation, next 2 given 8 and 16h after 1st 
injection 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
unclear 
Oertli 1994 
 
Switzerland 
160 patients undergoing surgery for breast 
cancer 
TXA group (n=79):  
All F; mean age(sd)=58.1 (10.4) 
Control group (n=81):  
All F; mean age(sd)=59.4(14.6) 
 
 
TXA group: Post-operative administration 
of 1g every 8 hrs for 5 days 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Orpen 2006 
 
UK 
30 patients undergoing knee arthroplasty 
TXA group (n=50):  
M/F=8/7; mean age(95% CI)=73 (70-80) 
Control group (n=50):  
M/F=3/11; mean age(95% CI)=69(63-74) 
 
 
TXA group: 15mg/kg at the time that 
cement mixing commenced 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
low 
low 
unclear  
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Özal 2002 
 
Turkey 
100 patients undergoing cardiac surgery 
TXA group (n=15):  
M/F=35/15; mean age(sd)=59 (4) 
Control group (n=14):  
M/F=38/12; mean age(sd)=61(7) 
 
 
TXA group: Desmopressin + 10mg/kg 
loading dose over 30 mins before skin 
incision then 12 hrs of 1mg/kg/hr  
Control group: Desmopressin only 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Penta de Peppo 
1995 
 
Italy 
30 patients undergoing cardiac surgery 
TXA group (n=15):  
M/F=12/3; mean age(sd)=60 (12) 
Control group (n=14):  
M/F=13/2; mean age(sd)=63(7) 
 
 
TXA group: 10mg/kg within 30 mins of 
induction of anaesthesia then infusion of 
1mg/kg/hr for 10 hrs  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Pfizer 2011 
 
India 
80 patients undergoing surgery for long bone 
fracture 
TXA group (n=40):  
M/F=“mostly male”; age range=18-44 
Control group (n=40):  
M/F=“mostly male”; age range=18-44 
 
 
TXA group: 15mg/kg 15 mins before 
surgery, followed by 2nd dose at 3 hrs 
later and a 3rd dose 3 hrs later  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Pinosky 1997 
 
USA 
39 patients undergoing cardiac surgery 
TXA group (n=20):  
M/F=12/8; mean age(sd)=62.6(2.1) 
Control group (n=19):  
M/F=15/4; mean age(sd)=60.6(2.5) 
 
TXA group: 15mg/kg loading dose then 
continuous infusion of 1mg/kg/hr for 6 hrs 
immediately after induction of anaesthesia 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Pleym 2003 
 
Norway 
79 patients undergoing cardiac surgery 
TXA group (n=40):  
M/F=34/6; mean age(sd)=63.6(9.9) 
Control group (n=39):  
M/F=32/7; mean age(sd)=62.0(9.2) 
 
 
TXA group: 30mg/kg as bolus in injection 5 
mins before start of CPB 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
high 
Sadeghi 2007 
 
Iran 
67 patients undergoing hip arthroplasty 
TXA group (n=32):  
M/F=3/29; mean age(sd)=51.81(25.7) 
 
TXA group: bolus of 15mg/kg at beginning 
of surgery 
• Sequence generation 
• Allocation concealment 
low 
low 
low 
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Control group (n=35):  
M/F=4/31; mean age(sd)=44.4(26.16) 
 
Control group: placebo • Blinding 
• Incomplete outcome data 
unclear 
Sekhavat 2009 
 
Iran 
90 patients undergoing caesarean section 
TXA group (n=45):  
All F; mean age(sd)=26.2(4.7) 
Control group (n=45):  
All F; mean age(sd)=27.1(4.1) 
 
 
TXA group: 10 mins before incision 
1g/10mL infused over 5 mins  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
Senghore 1999 
 
UK 
52 patients undergoing dental surgery 
TXA group (n=45):  
M/F=8/18; age range=16-39 
Control group (n=45): 
M/F=8/18; age range=16-39 
 
 
TXA group: single dose 25mg/kg at 
induction of anaesthesia 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
high 
Sethna 2005 
 
USA 
44 adolescent patients undergoing spinal 
surgery 
TXA group (n=23):  
M/F=17/6; mean age(sd)=13.6(1.8) 
Control group (n=21): 
M/F=13/8; mean age(sd)=14.0(2.0) 
 
 
TXA group: 100mg/kg before incision then 
infusion of 10mg/kg/hr during surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Shore-Lesserson 
1996 
 
USA 
30 patients undergoing cardiac surgery 
TXA group (n=17):  
M/F=10/7; mean age(sd)=68(13) 
Control group (n=13): 
M/F=10/3; mean age(sd)=63(6) 
 
 
TXA group: 20mg/kg at skin incision then 
infusion of 2mg/kg/hr for duration of 
operation 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
high 
Speekenbrink 1995 
 
The Netherlands 
30 patients undergoing cardiac surgery 
TXA group (n=15):  
M/F=1/14; mean age(sd)=61(11) 
Control group (n=15): 
M/F=1/14; mean age(sd)=57(12) 
 
TXA group: After induction of anaesthesia 
given bolus of 10mg/kg in 20 mins and 
infusion of 1mg/kg up to total dose of 
1000mg  
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
 
unclear 
unclear 
unclear 
low 
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 Control group: no intervention (standard 
care) 
 
Taghaddomi 2009a 
 
Iran 
100 patients undergoing cardiac surgery 
TXA group (n=50):  
M/F=38/12; mean age(sd)=54.7(10.9) 
Control group (n=50): 
M/F=34/16; mean age(sd)=60.3(10.2) 
 
 
TXA group: bolus 1g before incision then 
maintenance dose of 400mg/h during 
surgery  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Taghaddomi 2009b 
 
Iran 
40 patients undergoing spinal surgery 
TXA group (n=20):  
M/F=10/10; mean age(sd)=40.4(7.64) 
Control group (n=20):  
M/F=9/11; mean age(sd)40.5(12.48) 
 
 
TXA group: 15mg/kg 20-30 mins before 
skin incision then continued for 
0.1mg/kg/min during the operation  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
low 
Taghaddomi 2009c 
 
Iran 
41 patients undergoing spinal surgery 
TXA group (n=20):  
M/F=15/5; mean age(sd)=68.0(11.0) 
Control group (n=21):  
M/F=16/4; mean age(sd)=65.8(11.8) 
 
 
TXA group: 15mg/kg, 20-30 mins before 
skin incision then continued for 
0.1mg/kg/min during the operation  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Tsutsumimoto 
2011 
 
Japan 
40 patients undergoing spinal surgery 
TXA group (n=20):  
M/F=8/12; mean age(sd)=42.0(17.31) 
Control group (n=20):  
M/F=9/12; mean age(sd)=42.6(10.42) 
 
 
TXA group: 15mg/kg in 100ml saline over 
15 mins before skin incision  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
high 
high 
unclear 
unclear 
Uozaki 2001 
 
Japan 
14 patients undergoing cardiac surgery 
TXA group (n=7):  
M/F=1/5; mean age(sd)=72.3(4.1) 
Control group (n=7):  
M/F=3/3; mean age(sd)=63.3(5.3) 
 
 
TXA group: 50mg/kg before skin incision 
and after the start of CPB 
Control group: NR 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
low 
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Vanek 2005 
 
Czech Republic 
62 patients undergoing cardiac surgery 
TXA group (n=32): M/F=16/16; mean 
age(range)=68.4(64.6-72.2) 
Control group (n=32): M/F=22/8; mean 
age(range)=68.9(65.8-72.0) 
 
 
TXA group: 1g before skin incision then 
continuous infusion of 200mg/h  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
high 
Veien 2002 
 
Denmark 
30 patients undergoing cardiac surgery 
TXA group (n=15):  
M/F=4/11; mean age(sd)=70.5(9.5) 
Control group (n=15):  
M/F=1/14; mean age(sd)=69.5(9.0) 
 
 
TXA group: 10mg/kg given at conclusion of 
surgery and again at 3 hrs later  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Wang 2011 
 
China 
231 patients undergoing cardiac surgery 
TXA group (n=116):  
M/F=93/23; mean age(sd)=60.5(8.0) 
Control group (n=115):  
M/F=102/13; mean age(sd)=60.0(8.5) 
 
 
TXA group: bolus 1g before surgical 
incision, then infusion 400mg/h during 
surgery 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
low 
high 
Wong 2008 
 
Canada 
147 patients undergoing spinal surgery 
TXA group (n=73):  
M/F=21/52; mean age(sd)=56.8(16.2) 
Control group (n=74):  
M/F=26/48; mean age(sd)=50.0(16.2) 
 
 
TXA group: bolus of 10mg/kg after 
induction then maintenance infusion of 
1mg/kg/hr until skin closure 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
low 
low 
unclear 
Yamasaki 2004 
 
Japan 
40 patients undergoing hip arthroplasty 
TXA group (n=20):  
M/F=19/1; mean age(sd)=55.5(14.2) 
Control group (n=20):  
M/F=18/2; mean age(sd)=61.2(6.9) 
 
 
TXA group: 1000mg administered 5 mins 
before start of operation  
Control group: no intervention (standard 
care) 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Yassen 1993 
 
UK 
20 patients undergoing hepatic surgery 
TXA group (n=10):  
M/F=5/5; mean age(sd)=44.8(12.2) 
 
• Sequence generation 
• Allocation concealment 
unclear 
unclear 
unclear 
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Control group (n=10):  
M/F=4/6; mean age(sd)=49.6(14.2) 
 
TXA group: 10mg/kg loading dose at start 
of operation then infusion of 3mg/kg/h 
until transfer to ITU 
Control group: placebo 
• Blinding 
• Incomplete outcome data 
low 
Zabeeda 2002 
 
Israel 
50 patients undergoing cardiac surgery 
TXA group (n=25):  
M/F=20/5; mean age(sd)=65.6(9) 
Control group (n=25):  
M/F=18/7; mean age(sd)=65(13) 
 
 
TXA group: 10mg/kg after induction of 
anaesthesia followed by infusion of 
1mg/kg per hr during the operation  
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding  
• Incomplete outcome data 
unclear 
unclear 
low 
low 
Zhang 2007 
 
China 
102 patients undergoing knee arthroplasty 
TXA group (n=51):  
M/F=NR; mean age(sd)=68.14(9.05) 
Control group (n=51):  
M/F=NR; mean age(sd)=67.64(8.33) 
 
 
TXA group: 1g infused before deflation of 
tourniquet, then administration of 1g 3 hrs 
later 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
unclear 
unclear  
Zohar 2004 
 
Israel 
40 patients undergoing knee arthroplasty 
TXA group (n=20):  
M/F=6/14; mean age(sd)=73(8) 
Control group (n=20):  
M/F=7/13; mean age(sd)=73(7) 
 
TXA group: 30 mins before limb 
tourniquet deflated, bolus of 15mg/kg 
administered over 30 mins then constant 
infusion of 10mg/kg/hr until 12 hrs after 
final deflation of limb tourniquet 
Control group: no intervention (standard 
care) 
 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
low 
unclear 
unclear 
low 
Zonis 1996 
 
Canada 
82 paediatric patients undergoing cardiac 
surgery 
TXA group (n=40):  
M/F=19/21; mean age(sd)=62.8 months(58.1) 
Control group (n=42):  
M/F=21/21; mean age(sd)=52.6 months(51.2) 
 
 
TXA group: single dose 50mg/kg 
Control group: placebo 
• Sequence generation 
• Allocation concealment 
• Blinding 
• Incomplete outcome data 
unclear 
unclear 
low 
high 
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Appendix N. Research Paper 2: Results of random effects meta-analysis of the effect of TXA on 
blood loss stratified by type of surgery, timing of TXA administration, adequacy of allocation 
concealment and type of comparator 
 Ratio* (95% CI) 
*back-transformed ratio 
of geometric means 
Test for effect  
(p value) 
  
Type of surgery  
Orthopaedic 0.64 (0.58 to 0.70) <0.0001 
Cardiac 0.67 (0.64 to 0.70) <0.0001 
Head & neck 0.75 (0.68 to 0.82) <0.0001 
Obs & gynae 0.74 (0.63 to 0.86) <0.0001 
Urological 0.72 (0.59 to 0.87) 0.001 
Breast cancer 0.68 (0.56 to 0.82) <0.0001 
Hepatic 0.55 (0.30 to 1.03) 0.060 
 
Timing 
Pre-incision 0.69 (0.66 to 0.71) <0.0001 
Post-incision 0.64 (0.57 to 0.71) <0.0001 
 
Allocation concealment 
Yes 0.68 (0.64 to 0.72) <0.0001 
Unclear 0.66 (0.63 to 0.70) <0.0001 
No 0.73 (0.64 to 0.84) <0.0001 
 
Comparator 
Placebo 0.67 (0.64 to 0.71) <0.0001 
No TXA 0.66 (0.65 to 0.67) <0.0001 
   
Overall 0.67 (0.65 to 0.70) <0.0001 
Heterogeneity: χ2=592.79, df=103, p<0.001;I2=83%  
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Appendix P. Research paper 3: Published article 
 
203 
 
 
204 
 
 
205 
 
 
206 
 
 
207 
 
 
208 
 
 
209 
 
Appendix Q. Research Paper 3: MEDLINE (Ovid) search strategy, 1950 to May 2014 
1. exp Antifibrinolytic Agents/ 
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or 
antiplasmin* or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti. 
3. exp Aprotinin/ 
4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* 
or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or 
contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or 
traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or 
antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or 
rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128 
or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox 
or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or 
midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?52g or 
rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or 
zymophren).ab,ti. 
5. exp Tranexamic Acid/ 
6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* 
or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino 
methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or 
frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti. 
7. exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/ 
8. (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon 
or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or 
amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest 
or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or 
ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon 
aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or 
emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti. 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. randomi?ed.ab,ti. 
11. randomized controlled trial.pt. 
12. controlled clinical trial.pt. 
13. placebo.ab. 
14. clinical trials as topic.sh. 
15. randomly.ab. 
16. trial.ti. 
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17. 10 or 11 or 12 or 13 or 14 or 15 or 16 
18. (animals not (humans and animals)).sh. 
19. 17 not 18 
20. 9 and 19 
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Appendix R. Research Paper 3: Results of random effects meta-analysis of the effect of TXA on 
blood loss stratified by type of surgery, timing of TXA administration, adequacy of allocation 
concealment and type of comparator 
 
 Ratio* (95% CI) 
*back-transformed ratio 
of geometric means 
Test for effect  
(P value) 
  
Type of surgery  
Orthopaedic 0.64 (0.58 to 0.70) <0.0001 
Cardiac 0.67 (0.64 to 0.70) <0.0001 
Head & neck 0.75 (0.68 to 0.82) <0.0001 
Obs & gynae 0.74 (0.63 to 0.86) <0.0001 
Urological 0.72 (0.59 to 0.87) 0.001 
Breast cancer 0.68 (0.56 to 0.82) <0.0001 
Hepatic 0.55 (0.30 to 1.03) 0.060 
 
Timing 
Pre-incision 0.69 (0.66 to 0.71) <0.0001 
Post-incision 0.64 (0.57 to 0.71) <0.0001 
 
Allocation concealment 
Yes 0.68 (0.64 to 0.72) <0.0001 
Unclear 0.66 (0.63 to 0.70) <0.0001 
No 0.73 (0.64 to 0.84) <0.0001 
 
Comparator 
Placebo 0.67 (0.64 to 0.71) <0.0001 
No TXA 0.66 (0.65 to 0.67) <0.0001 
   
Overall 0.67 (0.65 to 0.70) <0.0001 
Heterogeneity: χ2=592.79, df=103, p<0.001;I2=83%  
 
 
  
212 
 
Appendix S. Research Paper 4: Retention of copyright/permission to publish 
 
 
  
213 
 
Appendix T. Research Paper 4: Published article 
 
214 
 
 
215 
 
 
216 
 
 
  
217 
 
 
218 
 
 
  
219 
 
 
220 
 
 
  
221 
 
 
222 
 
 
223 
 
 
224 
 
Appendix U. Research Paper 4: Search strategies 
Cochrane Injuries Group Specialised Register (searched July 2010) 
(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or 
bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal 
or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin 
or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or 
kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or 
antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin 
inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type 
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or 
(pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or 
traskolan or trazylol or zymofren or zymophren) or (tranexamic or Cyclohexanecarboxylic 
Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or 
cyklokapron or ugurol oramino methylcyclohexane carboxylate or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA 
or amchafibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl 
cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid or 
aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or 
aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclocapron or 
cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or 
TXA) or (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or 
amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n 
hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine 
or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon 
or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or 
epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or 
ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan) 
Cochrane Central Register of Controlled Trials 2010, Issue 3 (The Cochrane Library) 
#1 MeSH descriptor Antifibrinolytic Agents explode all trees  
#2 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or 
antiplasmin* or anti-plasmin* ):ab,ti or ((plasmin or fibrinolysis) near3 inhibitor*):ab,ti  
#3 MeSH descriptor Aprotinin explode all trees  
#4 (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* 
or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or 
contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan 
or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or 
kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or 
antilysin or antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic 
secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin 
inhibitor* or kazal type trypsin inhibitor or riker?52g or rp?9921or tracylol or trascolan or 
trasilol or traskolan or trazylol or zymofren or zymophren or midran):ab,ti or ((Kunitz near3 
inhibitor*) or (pancrea* near3 antitrypsin) or (pancrea* near3 trypsin next inhibitor*)):ab,ti  
#5 MeSH descriptor Tranexamic Acid explode all trees  
#6 (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or 
exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino 
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methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or 
frenolyse or hexacapron or hexakapron or tranex or TXA):ab,ti  
#7 MeSH descriptor Aminocaproic Acids explode all trees  
#8 MeSH descriptor 6-Aminocaproic Acid explode all trees  
#9 (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or 
Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or acikaprin or afibrin 
or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 
10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or 
epsilcapramin or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or 
etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or 
neocaprol or nsc?26154 or tachostyptan):ab,ti  
#10 (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic):ab,ti  
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10) 
MEDLINE(Ovid) 1950 to July Week 2 2010  
1.exp Antifibrinolytic Agents/  
2.(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* 
or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti.  
3.exp Aprotinin/  
4.(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or 
bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal 
or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin 
or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or 
kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or 
antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin 
inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type 
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or 
(pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or 
traskolan or trazylol or zymofren or zymophren).ab,ti.  
5.exp Tranexamic Acid/  
6.(tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or 
exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino 
methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or 
frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.  
7.exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/  
8.(((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or 
amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n 
hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine 
226 
 
or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon 
or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or 
epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or 
ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti.  
9.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10.randomi?ed.ab,ti.  
11.randomized controlled trial.pt.  
12.controlled clinical trial.pt.  
13.placebo.ab.  
14.clinical trials as topic.sh.  
15.randomly.ab.  
16.trial.ti.  
17.10 or 11 or 12 or 13 or 14 or 15 or 16  
18.(animals not (humans and animals)).sh.  
19.17 not 18  
20.9 and 19  
 
EMBASE (Ovid) 1980 to 2010 (Week 28)  
1.exp Antifibrinolytic Agent/  
2.(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* 
or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti.  
3.exp Aprotinin/  
4.(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or 
bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal 
or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin 
or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or 
kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or 
antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin 
inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type 
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or 
(pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or 
traskolan or trazylol or zymofren or zymophren).ab,ti.  
5.exp Tranexamic Acid/  
6.(tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or 
exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino 
methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or 
frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.  
7.exp Aminocaproic Acid/  
8.(((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or 
amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n 
hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine 
or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon 
or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or 
epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or 
ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti.  
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9.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10.exp Randomized Controlled Trial/  
11.exp controlled clinical trial/  
12.randomi?ed.ab,ti.  
13.placebo.ab.  
14.*Clinical Trial/  
15.randomly.ab.  
16.trial.ti.  
17.10 or 11 or 12 or 13 or 14 or 15 or 16  
18.exp animal/ not (exp human/ and exp animal/)  
19.17 not 18  
20.9 and 19 
  
228 
 
Appendix V. Research Paper 4: Characteristics of included studies 
Auer 1979 
Methods Probable RCT: “Twenty patients were included in 
a double-blind study; nine patients were treated 
with Trasylol. Eleven received a placebo drug.” 
Five additional (non-randomly allocated) patients 
were added to the study and received aprotinin 
treatment. These patients were not separated 
out in the analysis. 
Participants Patients with severe head injury who had 
remained comatose for seven days. Most of them 
had clinical brain stem signs. 
 
Interventions Aprotinin group: 500,000 IE initially thereafter 
200,000 IV every four hours 
 
Outcomes Death. 
Range of biochemical end points. 
Notes Notes Because it was not possible to separate the 
5 non-randomised patients from the 20 probably 
randomised patients, this study provides no 
useable outcome data 
Risk of bias 
Bias Authors’ judgement Support for judgement 
Allocation concealment (selection bias) Unclear risk Unclear. 
 
CRASH-2 2010 
Methods RCT: Randomisation was balanced by centre, with 
an allocation sequence based on a block size of 
eight, generated with a computer random 
number generator. Participants and study staff 
were blind to treatment allocation 
Participants 20,211 adult (>16 years) trauma patients with, or 
at risk of, significant bleeding 
 
Interventions Tranexamic acid group: loading dose 1g over 10 
minutes then infusion of 1g over 8 hours 
Matching placebo. 
Outcomes Death. 
Vascular occlusive events. 
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Blood transfusion requirements. 
Disability. 
Notes  
Risk of bias 
Bias Authors’ judgement Support for judgement 
Allocation concealment (selection bias) Low risk TXA and placebo were 
packaged in identical 
ampoules. Hospitals 
with a reliable 
telephone 
access used a 
telephone 
randomisation 
service, hospitals 
without used a local 
pack system 
 
McMichan 1982 
Methods RCT: Aprotinin and placebo were supplied in 
identical coded ampoules. Ampoules were in 
boxes of 50 with a code number assigned to each 
box. These numbers were randomised in groups 
of 20 and each batch was assigned in numerical 
order. The codes were not broken until the end of 
the study. 
Patients excluded after randomisation were those 
who died within the first 24 hours or refused 
continuing investigation. 
Participants Patients with a combination of hypovolaemic 
shock and major fractures of the lower limb and 
or pelvis. Patients seen 12 or more hours after 
injury and those with major head or chest injuries 
were excluded. 
Interventions Aprotinin group: 500,000 Kallikrein Inhibitor Units 
(KIU) IV statim followed by 300,000 
KIU at 6-hour intervals for 96 hours. 
Outcomes Death. 
Mean blood transfusion. 
Respiratory function. 
Notes 77 patients were randomised but there were 7 
post-randomisation exclusions. Among the 
7 excluded patients, there were 3 deaths within 
the first 24 hours of injury. One patient was 
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transferred to another hospital because of 
quadriplegia and died later, and three patients 
refused investigation. 
It was noted in the results that the data on 
transfusion requirement was found to have a 
non-normal distribution. Nevertheless, the mean 
and standard deviation were presented. 
Risk of bias 
Bias Authors’ judgement Support for judgement 
Allocation concealment (selection bias) Low risk Aprotinin and placebo 
were prepared in 
“similar ampoules”. All 
ampoules were in 
boxes of 50, with a 
code number assigned 
to each box. The nature 
of the content of the 
ampoules was not 
known to any of the 
investigators nor to the 
attending physicians. 
The codes were not 
broken until the end of 
the study 
 
Yutthakasemsunt 2010  
Methods RCT 
Participants 240 adults patients (>16 years) with moderate to 
severe traumatic brain injury (Glasgow 
Coma Scale 4 to 12) within 8 hours of injury 
Interventions Tranexamic acid group: 2g. 
Matching placebo. 
Outcomes Death. 
Progressive intracranial haemorrhage. 
Disability (GOS). 
Thromboembolic events. 
Notes  
Risk of bias 
Bias Authors’ judgement Support for judgement 
Allocation concealment (selection bias) Unclear risk Unclear 
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Appendix W. Research Paper 4: Characteristics of excluded studies 
Study Reason for exclusion 
Gierhake 1971 Types of patients: general surgery patients not 
trauma. 
Husted 2003 Types of patients: orthopaedic patients not 
trauma. 
Klobow 1977a Types of interventions: trasylol compared with 
heparin. 
Klobow 1977b Types of interventions: trasylol compared with 
heparin. 
Kuiian 1999 Types of studies: After Dr Vasiliy Vlassov, Director 
of the Russian Branch of the Nordic Cochrane 
Centre kindly 
translated the methods section it was clear that 
this study was not randomised 
Loew 1970 Types of studies: alternation used not random 
allocation. 
Nissen 1989 Types of studies: review article not randomised 
controlled trial 
Schneider 1976 Types of studies: randomisation in this trial was 
by allocating patients to the treatment group 
according to the day of admission. However, this 
procedure was subverted for large numbers (813) 
of patients in which case the study 
cannot be considered to be a randomised 
controlled trial 
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Appendix X. Research Paper 4: Characteristics of ongoing studies 
CRASH-3 
Trial name or title Clinical Randomisation of an Antifibrinolytic in 
Significant Head Injury (CRASH-3) 
Methods Large, international, randomised, placebo 
controlled trial. 
Participants Adults with traumatic brain injury, who are within 
eight hours of injury, with any intracranial 
bleeding on CT scan or who have a GCS of 12 or 
less, and have no significant extra-cranial 
haemorrhage, are eligible for inclusion, except 
those for whom antifibrinolytic agents are 
thought to be clearly indicated or clearly 
contraindicated 
Interventions Loading dose of tranexamic acid (1 gram by 
intravenous injection) or placebo (sodium 
chloride 0.9%) given as soon as possible after 
randomisation. Maintenance dose of tranexamic 
acid (1 gram by intravenous injection) or placebo 
(sodium chloride 0.9%) given after the loading 
dose is finished 
Outcomes Primary outcome is death in hospital within 28 
days of injury. Secondary outcomes are vascular 
occlusive events (myocardial infarction, 
pulmonary embolism, clinical evidence of deep 
vein thrombosis), stroke, disability, seizures, 
neurosurgical intervention, days in intensive care, 
other adverse events 
Starting date July 2012 
Contact information crash@Lshtm.ac.uk 
Notes Current Controlled Trials ISRCTN15088122; 
Clinicaltrials.gov NCT01402882 
The JP Moulton Charitable Trust, UK, is funding 
the run-in costs for the trial and up to 500 
patients’ 
recruitment. Full funding is being sought from 
public funding organisations for the main trial 
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Appendix Y. Research Paper 5: Retention of copyright/permission to publish 
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Appendix Z. Research Paper 4: Published article 
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Appendix AA. Research Paper 5: Summary of data extracted from studies included in systematic review 
Author, year Country Design Deaths (n) Deaths occurring in-
hospital (n) 
Blunt trauma deaths 
due to haemorrhage (n) 
Penetrating trauma 
deaths due to 
haemorrhage (n) 
Boulanger 2007 USA Trauma-registry based study; 2000-
2004 
7362 - 19.6 56.3 
CRASH-2 2010 Worldwide Randomised controlled trial; 2005-2010 1618* - 28.2 59.6 
Demetriades 2004 USA Trauma-registry based study; 1993-
2002 
2648 33.4 - - 
Demetriades 2005 USA Trauma registry and emergency 
medical services records based study; 
Jan 2000-Dec 2002 
4151 79.6 - - 
Di Barolomeo 2004 Italy Prospective population-based study; 
March 1998-Feb 1999 
286 37.8 - - 
Dutton 2010 USA Trauma-registry based study; July 1996-
June 2008 
2327 - 18.5 46.6 
Evans 2010 Australia Prospective study of autopsies reports 
and medical records; Feb 2005-Jan 
2006 
175 61.1 - - 
Gilroy 2005 UK Retrospective study of in-hospital 
deaths; 2001 
94** - 13.8 - 
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Author, year Country Design Deaths (n) Deaths occurring in-
hospital (n) 
Blunt trauma deaths 
due to haemorrhage (n) 
Penetrating trauma 
deaths due to 
haemorrhage (n) 
Gomez de Segura 
Nieva 2009a 
Spain Prospective study of severe multiple 
injury patients; April 2001-March 2002 
165 27.3 - - 
Gomez de Segura 
Nieva 2009b 
France Prospective study of severe multiple 
injury patients; April 2001-March 2002 
151 33.8 - - 
Gomez 2010 Canada Retrospective population-based study; 
2002-2003 
3486 46.2 - - 
Masella 2008 Brazil Retrospective population based study; 
Jan 2000 – Dec 2001 
787 43.1 - - 
Meel 2004 South Africa Retrospective study of medico-legal 
autopsies; 1997-1998 
274 25.9 - - 
Meisler 2010 Denmark Prospective population based study; 
2006 
2068 41.7 - - 
Nizamo 2006 Mozambique Respective review of registered deaths; 
2000 
1135 38.8 - - 
Potenza 2004 USA Retrospective population based study; 
1987-1997 
14,767 27.9 - - 
Singh 2008 India Retrospective study of autopsy reports; 
Jan 2001-Dec 2003 
344 75.8 - - 
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Author, year Country Design Deaths (n) Deaths occurring in-
hospital (n) 
Blunt trauma deaths 
due to haemorrhage (n) 
Penetrating trauma 
deaths due to 
haemorrhage (n) 
Soreide 2007 Norway Retrospective review of autopsy 
reports; 1996-2004 
260 48.1 - - 
Tien 2007 Canada Retrospective study of in-hospital 
deaths; 1999-2003 
558 - 8.5 61.6 
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Appendix DD. Research Paper 6: MEDLINE (Ovid) search strategy 
1 exp Antifibrinolytic Agents/ 
2 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or 
antiplasmin* or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti.  
3 exp Aprotinin/  
4 (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin 
inhibitor* or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or 
BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren 
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or 
antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or 
rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer 
a?128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or 
gordox or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor* or (Kunitz adj3 
inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) 
or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or 
zymofren or zymophren).ab,ti.  
5 exp Tranexamic Acid/ 
6 (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-
aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or 
transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol 
oramino methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or 
aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or 
aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or 
aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or 
aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or 
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or 
anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl 
or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti. 
7 exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/ 
8 (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-
aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or 
epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino 
caproic or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel 
or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche 
or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino 
caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or 
ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 
or tachostyptan).ab,ti.  
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10 randomi?ed.ab,ti. 
11 randomized controlled trial.pt. 
12 controlled clinical trial.pt. 
13 placebo.ab.  
14 clinical trials as topic.sh. 
15 randomly.ab. 
16 trial.ti. 
17 10 or 11 or 12 or 13 or 14 or 15 or 16 
18 (animals not (humans and animals)).sh. 
19 17 not 18 
20 9 and 19 
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Appendix EE. Research Paper 6: PRISMA Checklist 
Section/topic  # Checklist item  
Reported on 
pagex  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
4-5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
Table S1 
                                                            
xCorresponds to page numbers within the manuscript submitted to the journal 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
4-5 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis.  
5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  5-6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
5-6 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Figure S1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
6-7, Table S3 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  7, Figure S2 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9, Figures 1-3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
256 
 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
n/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
9-11 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
9-11 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
9-11 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
12 
 
 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097  
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Appendix FF. Research Paper 6: Flow diagram of the selection of trials 
 
Records identified through database 
searching (n=10024) 
Additional records identified through 
other sources (n=16) 
Records excluded (n=9990) Records screened (n=10040) 
Articles assessed for eligibility (n=34) 
Articles excluded (n=3)  
ineligible patient group n=2 
ineligible comparator n=1 
Trials included in qualitative synthesis 
(n=26, reported in 31 articles) 
Trials included in quantitative synthesis 
(n=25) 
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Appendix GG. Research Paper 6: Characteristics of included trials. 
Trial Participants Intervention and comparator Outcomes 
Abdel-Aleem 
2013 
 
Single-centre, 
Egypt 
740 women delivering by caesarean section 
TXA group (n=373)  
Age mean(sd)= 26.62(5.05)  
Baseline Hb<11g/dL=55% 
Control group (n=367) 
Age mean(sd)=26.34(5.16) 
Baseline Hb<11g/dL=46% 
 
TXA group 
1g IV given over 10 mins before incision 
 
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥1000ml) 
Blood loss 
Thromboembolic events 
Surgical intervention 
Death 
 
Gai 2004 
 
Multi-centre, 
China 
180 women delivering by caesarean section 
TXA group (n=91) 
Age mean(sd)=29.71(4.18) 
Baseline Hb=NR 
Control group (n=89) 
Age mean(sd)=29.75(4.01) 
Baseline Hb=NR 
 
 
TXA group 
1g IV over 5 mins, 10 mins before incision 
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥400ml) 
Blood loss 
Thromboembolic events 
 
Gobbur 2014 
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=23.62(3.43) 
Baseline Hb=NR 
Control group (n=50)  
Age mean(sd)=24.5(3.98) 
Baseline Hb=NR 
 
 
TXA group 
1g IV 20 mins before incision  
 
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
Thromboembolic events 
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Trial Participants Intervention and comparator Outcomes 
Gohel 2007  
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=24.30(3.65) 
Baseline Hb=NR 
Control group (n=50) 
Age mean(sd)=24.89(3.99) 
Baseline Hb=NR 
 
 
TXA group 
1g IV over 5 mins, 20 mins before incision  
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
Thromboembolic events 
 
Goswami 2013 
 
Single-centre, 
India 
90 women delivering by caesarean section 
TXA group 1* (n=30) 
Age mean(sd)=23.6(2.5) 
TXA group 2* (n=30) 
Age mean(sd)=22.8(2.2) 
Control group (n=30) 
Age mean(sd)=24.3(2.6) 
All women were anaemic at baseline (Hb 7-10g/dL) 
[*combined for purpose of this review] 
 
TXA group 1 
10mg/kg IV 20 mins before incision  
TXA group 2 
15mg/kg IV 20 mins before incision  
Control group 
Placebo 
 
All groups received oxytocin 
Postpartum haemorrhage (not defined) 
Blood loss 
Thromboembolic events 
Blood transfusion 
Gungorduk 
2010 
 
Single-centre, 
Turkey 
660 women delivering by caesarean section 
TXA group (n=330) 
Age mean(sd)=26.3(3.5) 
Baseline Hb mean(sd)=11.4(0.8)g/dL 
Control group (n=330) 
Age mean(sd)=26.6(3.6) 
Baseline Hb mean(sd)=11.3(0.6)g/dL 
 
 
TXA group 
1g IV over 5 mins, 10 mins before incision 
Control group 
Placebo 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥1000ml) 
Blood loss 
Thromboembolic events 
Surgical intervention 
Death 
Blood transfusion 
Gungorduk 
2012 
 
Single-centre, 
Turkey 
454 women delivering vaginally 
TXA group (n=228) 
Age mean(sd)=27.9(4.9) 
Baseline Hb mean(sd)=9.9(1.4)g/dL 
Control group (n=226) 
Age mean(sd)=27.6(4.8) 
Baseline Hb mean(sd)=9.3(0.9)g/dL 
 
 
TXA group 
1g IV at delivery of anterior shoulder 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
Thromboembolic events 
Surgical intervention 
Death 
Blood transfusion 
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Trial Participants Intervention and comparator Outcomes 
Halder 2013 
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=26.06(2.51) 
Baseline Hb=NR 
Control group (n=50) 
Age mean(sd)=26.04(2.50) 
Baseline Hb=NR 
 
 
TXA group 
1g 30 mins before incision 
 
Control group 
No TXA 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events 
 
Mirghafourvand 
2015 
Single-centre, 
Iran 
120 women delivering vaginally 
TXA group (n=60) 
Age mean(sd)=26.2(4.8) 
Baseline Hb mean(sd)=12.9(0.9)g/dL 
Control group (n=60) 
Age mean(sd)=26.1(4.9) 
Baseline Hb mean(sd)=13.0(0.9)g/dL 
 
 
TXA group 
1g IV at delivery of anterior shoulder 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
 
Movafegh 2011 
 
Single-centre, 
Iran 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=27.0(3.4) 
Baseline Hb mean(sd)=12.5(1.4)g/dL 
Control group (n=50) 
Age mean(sd)=27.6(4.1) 
Baseline Hb mean(sd)=12.8(1.0)g/dL 
 
TXA group 
10mg/kg IV over 10 mins, 20 mins before 
anaesthesia 
Control group 
Placebo 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events 
 
Poonia 2012 
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age=NR 
Baseline Hb mean(sd)=10.2(0.73)g/dL 
Control group (n=50) 
Age=NR 
Baseline Hb mean(sd)=10.1(0.91)g/dL 
 
 
TXA group 
1g IV given 10 mins before incision 
 
Control group 
No TXA 
 
Both groups received oxytocin 
Blood loss 
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Trial Participants Intervention and comparator Outcomes 
Ramani 2014 
 
Single-centre, 
India 
120 women delivering by caesarean section 
TXA group (n=NR) 
Age mean(sd)=24.9(3.9) 
Baseline Hb mean(sd)=10.5(1.15)g/dL 
Control group (n=NR) 
Age mean(sd)=24.4(3.7) 
Baseline Hb mean(sd)=10.1(2.14)g/dL 
 
TXA group 
1g IV prior to incision plus 2nd 500mg dose at 
end of CS if bleeding continued 
Control group 
No TXA 
 
Both groups received oxytocin 
No useable outcome data (number 
allocated to each group NR). 
Ramesh 2015 
 
Single-centre, 
India 
200 women delivering by caesarean section 
TXA group (n=100) 
Age mean(sd)=23.62(3.43) 
Baseline Hb mean(sd)=10.84(0.75)g/dL 
Control group (n=100) 
Age mean(sd)=24.5(3.89) 
Baseline Hb mean(sd)=11.4(0.89)g/dL 
 
TXA group 
1g IV given 10 mins before incision  
 
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
Thromboembolic events 
 
Rashmi 2012 
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=25.7(3.7) 
Baseline Hb=NR 
Control group (n=50) 
Age mean(sd)=25.1(4.73) 
Baseline Hb=NR 
 
 
TXA group 
1g IV over 5 mins, 30 mins before incision 
Control group 
No TXA 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events 
 
Safdarian 2015 
 
Single-centre, 
Iran 
200 women delivering by caesarean section 
TXA group (n=100) 
Age mean(sd)=26.3(5.97) 
Baseline Hb mean(sd)=11.96(1.00)g/dL  
Control group (n=100) 
Age mean(sd)=26.83(6.31) 
Baseline Hb mean(sd)=12.28(1.26)g/dL  
 
TXA group 
10mg/kg IV 20 mins before incision 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Blood loss 
Blood transfusion 
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Trial Participants Intervention and comparator Outcomes 
Samini 2003 
 
Single-centre, 
Iran 
200 women delivering vaginally 
TXA group (n=100) 
Age(sd)=23.93(4.29) 
Baseline Hb mean(sd)=12.73(0.9) 
Control group (n=100) 
Age(sd)=24.28(4.82) 
Baseline Hb mean(sd)=12.92(1.51) 
 
 
TXA group 
1g IV given at placental delivery 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Surgical intervention 
Death 
Blood transfusion 
Sekhavat 2009 
 
Single-centre, 
Iran 
90 women delivering by caesarean section 
TXA group (n=45) 
Age(sd)=26.2(4.7) 
Baseline Hb mean(sd)=13.6(1.4)g/dL 
Control group (n=45) 
Age(sd)=27.1(4.1) 
Baseline Hb mean(sd)=14.0(1.9)g/dL 
 
 
TXA group 
1g IV over 5 mins, 10 mins before incision 
Control group 
Placebo 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events 
 
Senturk 2012 
 
Single-centre, 
Turkey 
223 women delivering by caesarean section 
TXA group (n=101) 
Age mean(sd)=30.2(6.83) 
Baseline Hb mean(sd)=11.66(1.02)g/dL 
Control group (n=122) 
Age mean(sd)=29.22(6.93) 
Baseline Hb mean(sd)=11.86(1.32)g/dL 
 
 
TXA group 
1g IV over 5 mins, 10 mins before incision 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events (DVT, PE) 
Surgical intervention 
Death 
Blood transfusion 
Shahid 2012 
 
Single-centre, 
Pakistan 
74 women delivering by caesarean section 
TXA group (n=38) 
Age mean(sd)=24.18(3.93) 
Baseline Hb mean(sd)=9.76(0.85)g/dL 
Control group (n=36)  
Age mean(sd)=24.89(4.16) 
Baseline Hb mean(sd)=9.88(1.26)g/dL 
 
 
TXA group 
1g IV 10 mins before incision 
 
Control group 
Placebo 
 
Both groups received oxytocin 
Blood loss 
Thromboembolic events 
Blood transfusion 
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Trial Participants Intervention and comparator Outcomes 
Sharma 2011 
 
Single-centre, 
India 
100 women delivering by caesarean section 
TXA group (n=50) 
Age mean(sd)=25.63(3.72) 
Baseline Hb=NR 
Control group (n=50)  
Age mean(sd)=25.88(3.89) 
Baseline Hb=NR 
 
 
TXA group 
1g IV immediately before CS 
 
Control group 
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥500ml) 
Blood loss 
 
Taj 2014 
 
Single-centre, 
Pakistan 
120 women delivering by caesarean section 
TXA group (n=60) 
Age mean(sd)=23.56(3.82) 
Baseline Hb=NR 
Control group (n=60)  
Age mean(sd)=24.18(3.47) 
Baseline Hb=NR 
 
 
TXA group 
1g IV 20 mins before incision 
 
Control group 
Placebo 
 
Blood loss 
Thromboembolic events 
Blood transfusion 
Tarabrin 20121, 
21, 21, 21, 2 
 
Single-centre, 
Ukraine 
37 women delivering by caesarean section 
TXA group (n=19) 
Age=NR 
Baseline Hb=NR 
Control group (n=18)  
Age=NR 
Baseline Hb=NR 
 
 
TXA group 
10mg/kg IV 30 mins before incision 
 
Control group 
Placebo 
Blood loss 
Thromboembolic events 
 
Xu 2012 
 
Single-centre, 
China 
176 women delivering by caesarean section 
TXA group (n=88) 
Age mean(sd)=26.7(3.7) 
Baseline Hb mean(sd)=12.4(1.3)g/dL 
Control group (n=86)  
Age mean (sd)=27.1(4.1) 
Baseline Hb mean(sd)=12.6(1.2)g/dL 
 
 
TXA group 
10mg/kg IV 10-20 mins before incision 
 
Control group 
Placebo 
Postpartum haemorrhage (≥500ml) 
Blood loss 
Thromboembolic events (DVT) 
Death 
Blood transfusion 
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Trial Participants Intervention and comparator Outcomes 
Yang 2001 
 
Single-centre, 
China 
400 women delivering vaginally 
TXA group 1* (n=94) 
Age mean(sd)=27.6(2.9) 
Baseline Hb=NR 
TXA group 2* (n=92) 
Age mean(sd)=27.0(2.6) 
Baseline Hb=NR 
Control group (n=87) 
Age mean(sd)=28.0(2.6) 
Baseline Hb=NR 
 
[*combined for purpose of this review] 
 
TXA group 1 
1g IV after delivery of shoulders 
 
TXA group 2 
0.5g IV after delivery of shoulders 
 
Control group  
No TXA 
 
All groups received oxytocin 
Postpartum haemorrhage (≥400ml) 
Blood loss 
 
Yehia 2014 
 
Single-centre, 
Egypt 
223 women delivering by caesarean section 
TXA group (n=106) 
Age mean(sd)=28.4(4.9) 
Baseline Hb mean(sd)=11.8(1.5)g/dL 
Control group (n=106)  
Age mean (sd)=28.6(4.7) 
Baseline Hb mean(sd)=11.9(1.2)g/dL 
 
 
TXA group 
1g IV at induction of anaesthesia 
 
Control group  
No TXA 
 
Both groups received oxytocin 
Postpartum haemorrhage (≥400ml) 
Blood loss 
Thromboembolic events 
Blood transfusion 
Zizi 2013 
 
Single-centre, 
Malaysia 
174 women delivering by caesarean section 
TXA group (n=93) 
Age mean(sd)=NR 
Baseline Hb=NR 
Control group (n=81) 
Age mean(sd)=NR 
Baseline Hb=NR 
 
 
TXA group 
1g IV given immediately before incision 
 
Control group 
No TXA 
Blood loss 
 
TXA=tranexamic acid 
sd=standard deviation 
Hb=haemoglobin 
NR=not reported 
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Appendix HH. Research Paper 6: Summary of the risk of bias judgement for each methodological quality 
domain (‘L’ = Low, ‘U’ = unclear, ‘H’ = High) 
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Appendix II. Research Paper 6: Selected extracts from eight included trials containing identical or similar text. 
[Gai et al was the first trial to be published.] 
 
Gai 2004 
 
Gobbur 2014 
 
Gohel 2005 
 
Halder 2014 Ramesh 2015 
 
Rashmi 2012 
 
Sekhavat 2009 
 
Shahid 2013 Sharma 2011 
Clinical 
observation of 
blood loss reduced 
by tranexamic acid 
during and after 
caesarian section: a 
multi-center, 
randomized trial. 
Efficacy of 
tranexamic acid in 
reducing blood loss 
during lower 
segment caesarean 
section. 
Efficacy of 
tranexamic acid in 
decreasing blood loss 
during and after 
cesarean section: A 
randomized case 
controlled 
prospective study. 
Tranexamic acid used 
before caesarean 
section reduces 
blood loss based on 
pre- and 
postoperative 
haemoglobin level: a 
case-control study 
Efficacy of 
tranexamic acid in 
decreasing blood loss 
during and after 
caesarean section: a 
randamized case 
controlled 
prospective study 
Role of Tranexamic 
acid in reducing 
blood loss during and 
after cesarean 
section: A 
randomized case 
control prospective 
study. 
Efficacy of 
tranexamic acid in 
reducing blood loss 
after cesarean 
section. 
Tranexamic acid in 
decreasing blood loss 
during and after 
caesarean section 
Efficacy of 
tranexamic acid 
in decreasing 
blood loss 
during and after 
caesarean 
section 
Caesarian section 
(CS) rates have 
increased to as high 
as 40–50% in many 
areas of China. 
Cesarean section 
rates have increased 
to as high as 25 - 30% 
in many areas of the 
world.1  
Cesarean section (CS) 
rates have increased 
to as high as 25 to 
30% in many areas of 
the world1.  
Caesarean section 
(CS) rates have 
increased all over 
India.  
Cesarean section (CS) 
rates have increased 
to as high as 25 to 30 
% in many areas of 
the world. (1) 
Cesarean Section (CS) 
rates have increased 
to as high as 25-30% 
in many areas of the 
world1. 
Cesarean section (CS) 
rate has increased to 
as high as 25 to 30% in 
many areas of the 
world [1].  
Caesarean section 
(CS) rates have 
increased to as high 
as 25-30% in many 
areas of the world.  
 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
hemorrhaging, 
which can be life 
threatening. In 
order to reduce 
maternal mortality 
and morbidity 
caused by bleeding, 
it is important to 
reduce the extent 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
primary or secondary 
hemorrhage. In order 
to reduce maternal 
mortality and 
morbidity caused by 
bleeding it is 
important to reduce 
the maternal bleeding 
during and after 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
primary or secondary 
postpartum 
hemorrhage (20%). It 
leads to increased 
maternal mortality 
and morbidity. In 
order to reduce 
maternal mortality 
and morbidity caused 
 
 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
primary or secondary 
postpartum 
hemorrhage (20%). It 
leads to increased 
maternal mortality 
and morbidity. In 
order to reduce 
maternal mortality 
and morbidity caused 
Delivery by cesarean 
section can cause 
more complication 
than normal vaginal 
delivery and one of 
the most common 
complication is 
primary or secondary 
postpartum 
hemorrhage (20%)1. 
It leads to increased 
maternal mortality 
and morbidity. In 
order to reduce 
maternal mortality 
and morbidity caused 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
postpartum bleeding, 
which can be life-
threatening. To 
reduce maternal 
mortality and 
morbidity caused by 
bleeding, it is 
important to reduce 
the extent of bleeding 
Delivery by CS can 
cause more 
complications than 
normal vaginal 
delivery and one of 
the most common 
complications is 
primary or secondary 
postpartum 
haemorrhage (20%).3 
Obstetric 
haemorrhage can be 
life threatening, 
therefore, to reduce 
the morbidity and 
mortality due to 
The incidence of 
complications is 
much higher as 
compared with 
normal vaginal 
delivery. Out of 
these 
complications 
primary and 
secondary 
postpartum 
haemorrhage is 
most common. 
It leads to 
increased 
maternal 
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of bleeding during 
and after CS. 
 
 
 
 
 
 
lower segment 
cesarean section.1 
by bleeding, it is 
important to reduce 
the amount of 
bleeding during and 
after lower segment 
cesarean section 
(LSCS) 1. 
by bleeding, it is 
important to reduce 
the amount of 
bleeding during and 
after lower segment 
cesarean section 
(LSCS).1 
by bleeding, it is 
important to reduce 
the amount of 
bleeding during lower 
segment cesarean 
section. 
during and after CS 
[2].  
 
 
 
 
 
obstetric 
haemorrhaging we 
need to reduce the 
bleeding at caesarean 
sections. 
morbidity and 
mortality. Effect 
of this 
complication is 
reduced by 
reducing the 
amount of blood 
loss during and 
after cesarean 
section.  
Tranexamic acid is 
an inhibitor of 
fibrinolysis.  
 
 
 
 
 
 
 
 
 
Tranexamic acid is a 
synthetic derivative 
of the amino acid 
lysine that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine binding 
sites on the 
plasminogen 
molecules.3,4  
Tranexamic acid is a 
synthetic derivative 
of the amino acid 
lysine that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine binding 
sites on plasminogen 
molecules 2.  
Tranexamic acid is a 
synthetic derivative 
of the amino acid 
lysine that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine binding 
sites on plasminogen 
molecules 1.  
Tranexamic acid is a 
synthetic derivative of 
the amino acid lysine 
that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine 
binding sites on 
plasminogen 
molecules.3,4  
 
Tranexamic acid is a 
synthetic derivative 
of the amino acid 
lysine that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine binding 
sites on plasminogen 
molecules 2.  
Tranexamic acid is a 
synthetic derivative of 
the amino acid lysine 
that exerts its 
antifibrinolytic effect 
through the 
reversible blockade of 
the lysine binding 
sites on plasminogen 
molecules [5].  
Tranexamic acid (TXA) 
is a synthetic 
derivative of the 
amino acid lysine that 
exerts its anti-
fibrinolytic effect 
through the 
reversible blockade of 
lysine binding sites on 
plasminogen 
molecules.  
 
Tranexamic acid 
(a synthetic 
derivative of the 
amino acid 
lysine) is an 
antifibrinolytic 
that 
competitively 
inhibits the 
activation of 
plasminogen to 
plasmin.  
It has been 
routinely used for 
many years to 
reduce 
hemorrhaging 
during and after 
surgical procedures 
[1] such as coronary 
artery bypass, 
scoliosis surgery, 
and knee 
arthroplasty. 
 
 
 
 
 
Intravenous 
administration of the 
tranexamic acid has 
been routinely used 
for many years to 
reduce hemorrhage 
during and after 
surgical procedures 
like coronary artery 
bypass, scoliosis 
surgery, oral surgery 
etc 
 
 
 
 
 
Intravenous 
administration of 
tranexamic acid has 
been routinely used 
for many years to 
reduce hemorrhage 
during and after 
surgical procedures 
like coronary artery 
bypass, scoliosis 
surgery, oral surgery, 
orthotopic liver 
transplantation, total 
hip or knee 
arthroplasty, and 
urinary tract surgery 
3,4.  
Intravenous 
administration of 
tranexamic acid has 
been routinely used 
for many years to 
reduce haemorrhage 
during and after 
surgical procedures. 
Intravenous 
administration of 
tranexamic acid has 
been routinely used 
for many years to 
reduce haemorrhage 
during and after 
surgical procedures 
like coronary artery 
bypass, scoliosis 
surgery, oral surgery, 
orthotopic liver 
transplantation, total 
hip or knee 
arthroplasty, and 
urinary tract surgery. 
Intravenous 
administration of 
tranexamic acid has 
been routinely used 
for many years to 
reduce hemorrhage 
during and after 
surgical procedures 
like coronary artery 
bypass, oral 
surgeries2. 
 
 
 
 
It has been routinely 
used for many years 
to reduce 
hemorrhage during 
and after surgical 
procedures, such as 
coronary artery 
bypass, scoliosis 
surgery and knee 
arthroplasty.  
 
 
 
 
 
It has been in used for 
many years for 
reducing the blood 
loss in surgeries like, 
cardiac surgery with 
cardiopulmonary 
bypass, orthotopic 
liver transplantation, 
transurethral 
prostatic surgery, 
total hip/knee 
arthroplasty, or 
urinary tract 
surgery,4…  
 
It has been shown 
to be very useful for 
reducing blood loss 
Tranexamic acid has 
been shown to be 
very useful in 
Tranexamic acid has 
been shown to be 
very useful in 
Tranexamic acid has 
been shown to be 
very useful in 
Tranexamic acid has 
been shown to be 
very useful in 
Tranexamic acid has 
been shown to be 
very useful in 
It has been shown to 
be very useful for 
reducing blood loss 
TXA has been shown 
to be very useful in 
reducing blood loss 
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and blood 
transfusion, but 
there has been no 
report on 
preventing blood 
loss at CS.  
reducing blood loss 
and incidence of 
blood transfusion in 
these surgeries.* 
 
reducing blood loss 
and incidence of 
blood transfusion in 
these surgeries. 
reducing blood loss 
and incidence of 
blood transfusion in 
these surgeries2. 
reducing blood loss 
and incidence of 
blood transfusion in 
these surgeries. 
reducing blood loss 
and incidence of 
blood transfusions in 
these surgeries 2. 
 
 
and blood transfusion 
[6].  
and incidence of 
blood transfusion in 
these surgeries… 
In this study, the 
efficacy and safety 
of tranexamic acid 
was investigated in 
the management of 
CS. 
In this study the 
efficacy of tranexamic 
acid in reducing the 
blood loss during and 
after LSCS… 
In this study, the 
efficacy and safety of 
tranexamic acid in the 
reducing the blood 
loss during and after 
LSCS was 
investigated. 
In this study, the 
efficacy and safety of 
tranexamic acid was 
studied in reducing 
blood loss during and 
after CS... 
In this study, the 
efficacy of tranexamic 
acid in the reducing 
the blood loss during 
and after LSCS was 
investigated. 
In this study the 
efficacy and safety of 
tranexaminc acid in 
reducing blood loss 
during cesarean 
section is 
investigated. 
In this study, the 
efficacy and safety of 
tranexamic acid in 
reducing blood loss 
after CS was 
investigated. 
In this study, the aim 
was to determine the 
efficacy and safety of 
TXA in reducing the 
blood loss during and 
after LSCS. 
 
A multi-center, 
prospective, 
randomized, case-
controlled clinical 
trial…  
It is prospective 
randomized case 
control study… 
This is a prospective 
randomized case 
controlled study.  
This is a prospective 
randomised case-
control study. 
A randomized, case 
controlled, 
prospective study… 
This is a prospective 
randomized case 
controlled study.  
A prospective, 
randomised, case-
controlled clinical 
trial…  
It was a prospectively 
conducted 
randomized double-
blind placebo 
controlled study… 
The present 
study in a 
prospective 
randomized case 
controlled study. 
 The study group 
comprise 50 subjects 
who received 
tranexamic acid and 
50 subjects who did 
not receive 
tranexamic acid 
formed the control 
group. 
One hundred subjects 
were enrolled in the 
study. In 50 subjects 
tranexamic acid was 
given immediately 
before LSCS and the 
blood loss was 
compared with that in 
50 others to whom 
tranexamic acid was 
not given 
 100 women 
comprised study 
group – subject who 
received tranexamic 
acid, & 100 women 
comprised control 
group – subject who 
did not received 
tranexamic acid. 
One hundred subjects 
are enrolled in the 
study. In fifty subjects 
tranexamic acid is 
given immediately 
before Lower 
Segment Cesarean 
Section (LSCS) and the 
blood loss is 
compared with that in 
50 others to whom 
tranexamic acid was 
not given. 
 
The women were 
randomly allocated 
into two groups: 
study group (n = 45) 
receiving tranexamic 
acid and control 
group (n = 45) 
receiving placebo. 
  
Inclusion criteria 
Term primipara 
with a singleton 
delivered by CS. 
Regular perinatal 
care. 
Adherence to 
research 
regulations. 
Inclusion criteria 
1. Full term 
primigravida or 
multigravida with 
singleton pregnancy 
delivered by CS. 
2. Normal or 
abnormal 
presentation 
 
Full term primiparas / 
multiparas with 
singleton pregnancy 
being delivered by 
LSCS were included in 
the study…  
 
Full term primiparas 
with singleton 
pregnancy and have 
regular antenatal 
check-up being 
delivered by lower 
segment caesarean 
section (LSCS) were 
included in the 
study… 
Inclusion criteria : 
• Term primipara with 
a singleton delivered 
by CS 
• Regular perinatal 
care 
• Adherence to 
research regulations 
• Informed consent 
obtained. 
Inclusion Criteria 
All singleton 
pregnancies being 
delivered by LSCS 
 
 
 
 
 
 
We enrolled only 
nuliparas because of 
risk of multiparity for 
uterine inertia after 
delivery.  
 
 
 
Full term primipara / 
multiparas (parity not 
more than two) with 
the singleton 
pregnancy being 
delivered by LSCS 
were included in the 
study. 
Subjects with 
full term 
primipara and 
multipara with 
single pregnancy 
being delivered 
by cesarean 
section were 
included in this 
study… 
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Informed consent 
obtained. 
 
 
 
 
 
Exclusion criteria 
Severe medical and 
surgical 
complications 
involving the heart, 
liver or kidney, 
brain disease and 
blood disorders. 
Allergy to 
tranexamic acid. 
History of thrombo-
embolic disorders. 
Abnormal placenta: 
such as placenta-
previa, placenta-
abruptio, placental 
adhesion caused by 
repeated artificial 
abortions. 
Severe pregnancy 
complications, such 
as severe 
preeclampsia. 
Multiple 
pregnancies, 
macrosomia, 
polyhydramnios. 
Complication with 
myoma. 
 
Exclusion criteria 
1 Medical or surgical 
problem involving 
heart, liver and 
kidney disease 
2 Allergy to 
tranexamic acid 
3 H/O thrombo 
embolic disorder 
4 Abnormal placenta 
such as placenta 
previa, placenta 
aburption, pregnancy 
complication such as 
pre-eclampsia 
5 Multiple pregnancy, 
macrosomia and 
polyhydraminos 
6 Complication with 
myoma 
7 Any blood 
dyscrasia* 
…while subjects 
having medical and 
problems involving 
the heart, liver, 
kidney and brain and 
having blood 
disorders were 
excluded from the 
study. 
Subjects having 
allergy to tranexamic 
acid, history of 
thromboembolic 
disorders, abnormal 
placentation, severe 
pre-eclampsia, 
multiple pregnancy, 
macrosomia, 
polyhydromnios and 
those requiring blood 
transfusion due to 
anemia were also 
excluded from the 
study. 
… while mothers 
having medical and 
surgical problems 
involving the heart, 
liver, kidney and 
having blood 
disorders were 
excluded from the 
study. 
Exclusion criteria : 
• Severe medical and 
surgical complications 
including the heart, 
liver and kidney, brain 
disease and blood 
disorders. 
• Allergy to 
tranexamic acid. 
• History of 
thromboembolic 
disorders. 
• Abnormal placenta : 
such as placenta 
previa, placenta 
abruption, placental 
adhesions caused by 
repeated artificial 
abortions. 
• Severe pregnancy 
complications such as 
severe pre-eclampsia.  
• Multiple 
pregnancies, 
macrosomia, poly 
hydromnios 
• Complication with 
myoma. 
Exclusion Criteria: 
Blood disorders, renal 
insufficiency, liver 
disorders, 
polyhydramnios, 
multiple gestation, 
imminent ecclampsia, 
ecclampsia, severe 
anemia, known 
hypersensitivity to 
drugs. 
 
Women with severe 
medical and surgical 
disorders, having 
blood disorders and 
anemia, allergy to 
tranexamic acid, 
history of thrombo-
embolic disorders, 
abnormal placenta 
such as placenta-
previa, placenta-
abruptia and 
pregnancy 
complications such as 
severe preeclampsia, 
multiple pregnancies, 
macrosomia, 
polyhydramnios and 
those requiring blood 
transfusion were 
excluded.  
 
Subjects having 
medical problems 
involving the heart, 
liver, kidney, brain 
and having blood 
disorders were 
excluded from the 
study. Subjects having 
allergy to TXA, history 
of thromboembolic 
disorders, abnormal 
placentation, severe 
pre-eclampsia, 
multiple pregnancy, 
macrosomia, 
polyhydromnios and 
those requiring blood 
transfusion due to 
anaemia were also 
excluded from the 
study. 
…and subjects 
with medical 
disorders and 
having blood 
disorders were 
excluded from 
this study. 
Subjects with a 
history of 
thromboembolic 
disorders, 
hypersensitivity 
to tranexamic 
acid, multiple 
pregnancy, 
polyhydromnios 
and those with 
anemia 
requiring blood 
transfusion were 
also excluded 
from this study. 
 Vital signs: heart 
rate (HR), 
respiratory rate 
(RR), blood 
pressure (BP) were 
checked 
immediately after 
placental delivery, 
1. Vital sign – BP, RR 
and heart rate were 
measured 
immediately after 
placental 
delivery and 1and 2 
hours after birth 
respectively* 
Heart rate, 
respiratory rate and 
blood pressure were 
checked and noted 
before the surgery, 
immediately after 
placental delivery and 
Heart rate, 
respiratory rate and 
blood pressure were 
checked and noted 
before the surgery, 
immediately after the 
operation and 1 and 2 
hours after birth.  
1. Vital signs : Heart 
rate (HR) : Respiratory 
rate (RR), Blood 
pressure 
(BP), were checked 
immediately after 
placental delivery and 
Vital signs (PR, RR, BP) 
are checked and 
noted before surgery, 
immediately after 
delivery of the 
placenta 1 hour, 2 
hour after birth 
respectively.  
Vital signs (heart rate, 
blood pressure and 
respiratory rate) were 
checked and noted 
before operation, 
immediately after 
placental delivery and 
 The vital 
parameters 
(blood pressure, 
heart rate and 
respiratory rate) 
were checked 
and noted 
before the 
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and 1 and 2 h after 
birth, respectively. 
 
1 and 2 hours after 
birth, respectively.  
 
1 and 2 hour after 
birth respectively. 
 1 and 2 h after birth, 
respectively.  
 
surgery, 
immediately 
after placental 
delivery and 1 
and 2 hrs after 
birth of the 
neonate.  
Tranexamic acid 
exerts its 
antifibrinolytic 
effect by blocking 
the lysine-binding 
locus of the 
plasminogen and 
plasmin molecules, 
thereby preventing 
the binding of 
plasminogen and 
plasmin to the 
fibrin substrate. 
Tranexamic acid 
also inhibits the 
conversion of 
plasminogen to 
plasmin by the 
plasminogen 
activators [2]. It has 
been used in the 
treatment of 
bleeding for many 
years. 
 
Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine 
binding locus of the 
plasminogen and 
plasmin molecules, 
thereby preventing 
the binding of the 
plasminogen and 
plasmin to the fibrin 
substrate. 
Tranexamic acid also 
inhibits conversion of 
plasminogen to 
plasmin by 
plasminogen 
activators.3,4  
Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine 
binding locus of the 
plasminogen & 
plasmin molecules, 
thereby preventing 
the binding of 
plasminogen & 
plasmin to the fibrin 
substrate. 
Tranexamic acid also 
inhibits conversion of 
plasminogen to 
plasmin by 
plasminogen 
activators. It has been 
used in the treatment 
of bleeding for many 
years. (3,4)* 
Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine 
binding locus of the 
plasminogen and 
plasmin molecules. It 
also inhibits the 
conversion of 
plasminogen to 
plasmin by the 
plasminogen 
activators. 
Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine 
binding locus of the 
plasminogen & 
plasmin molecules, 
thereby preventing 
the binding of 
plasminogen & 
plasmin to the fibrin 
substrate. 
Tranexamic acid also 
inhibits conversion of 
plasminogen to 
plasmin by 
plasminogen 
activators. It has 
been used in the 
treatment of bleeding 
for many years.3,4 
 
 Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine-
binding locus of the 
plasminogen and 
plasmin molecules, 
thereby preventing 
the binding of 
plasminogen and 
plasmin to the fibrin 
substrate. 
Tranexamic acid also 
inhibits the 
conversion of 
plasminogen to 
plasmin by the 
plasminogen 
activators [10]. It has 
been used in the 
treatment of bleeding 
for many years. 
 
Tranexamic acid 
exerts its 
antifibrinolytic effect 
by blocking the lysine-
binding locus of the 
plasminogen and 
plasmin molecules, 
thereby preventing 
the binding of 
plasminogen and 
plasmin to the fibrin 
substrate. TXA also 
inhibits the 
conversion of 
plasminogen to 
plasmin by the 
plasminogen 
activators. 
 
271 
 
During placental 
delivery, fibrinogen 
and fibrin are 
rapidly degraded, 
whereas 
plasminogen 
activators and fibrin 
degradation 
products (FDP) 
increase due to 
activation of the 
fibrinolytic system. 
This activation can 
last up to 6–10 h 
postpartum, 
causing more 
bleeding. It was 
because of this 
activation of the 
fibrinolytic system 
that we decided to 
use tranexamic acid 
in this trial. 
During placental 
delivery fibrinogen 
and fibrin are rapidly 
degraded whereas 
plasminogen 
activators and fibrin 
degradation products 
(FDP) increase due to 
activation of the 
fibrinolytic system. 
This activation can 
last upto 6-10 hours 
post-partum causing 
more bleeding. It was 
because of this 
activation of the 
fibrinolytic system 
that we decided to 
use tranexamic acid 
the trial. 
During placental 
delivery, fibrinogen 
and fibrin are rapidly 
degraded, whereas 
plasminogen 
activators and fibrin 
degradation products 
(FDP) increase due to 
activation of the 
fibrinolytic system. 
This activation can 
last up to 6-10 hours 
postpartum, causing 
more bleeding 5. It 
was because of this 
activation of the 
fibrinolytic system 
that we decided to 
use tranexamic acid in 
this trial. 
During placental 
delivery there is 
activation of the 
fibrinolytic system 
resulting in rapid 
degradation of 
fibrinogen and fibrin. 
Also there is increase 
in plasminogen 
activators and fibrin 
degradation products 
(FDP). This activation 
can last up to 6 to 10 
hours postpartum. 
This is one of the 
cause of bleeding in 
the postpartum 
period. 
During placental 
delivery, fibrinogen & 
fibrin are rapidly 
degraded, whereas 
plasminogen 
activators & fibrin 
degradation products 
(FDP) increase due to 
activation of 
fibrinolytic system. 
This activation can 
last up to 6-10 hrs 
postpartum, causing 
more bleeding. It was 
because of this 
activation of 
fibrinolytic system 
that we decided to 
use tranexamic acid in 
this trial. 
During placental 
delivery, fibrinogen 
and fibrin are rapidly 
degraded, whereas 
plasminogen 
activators and FDP 
increase due to 
activation of 
fibrinolytic system1. 
This activation can 
last up to 6-10 hours 
postpartum causing 
more bleeding 1. It 
was because of this 
activation of the 
fibrinolytic system 
that we decided to 
use tranexamic acid.1 
During placental 
delivery, fibrinogen 
and fibrin are rapidly 
degraded, whereas 
plasminogen 
activators and fibrin 
degradation products 
increase due to 
activation of the 
fibrinolytic system. 
This activation can 
last up to 6–10 h 
postpartum; causing 
more bleeding. 
According to this 
activation of the 
fibrinolytic system, 
we decided to use 
tranexamic acid in 
this trial.  
During placental 
delivery, fibrinogen 
and fibrin are rapidly 
degraded, whereas 
plasminogen 
activators and fibrin 
degradation products 
(FDP) increase due to 
activation of the 
fibrinolytic system. 
This activation can 
last up to 6 – 10 hours 
postpartum, causing 
more bleeding, which 
can be taken care of 
by anti-fibrinolytic 
agents. 
At the time of 
placental 
delivery there is 
activation of the 
fibrinolytic 
system which 
leads to rapid 
degradation of 
fibrinogen and 
fibrin. There is 
also an increase 
in plasminogen 
activators and 
fibrin 
degradation 
products (FDP). 
This activation 
can last up to 6-
10 hours 
postpartum, 
causing more 
bleeding. As we 
known that 
tranexamic acid 
acts as an 
Antifibrinolytic 
agent, so in this 
study we used 
tranexamic acid 
to reduce post 
LSCS bleeding. 
Our study showed 
that tranexamic 
acid significantly 
reduces bleeding 
from placental 
delivery to 2 h 
postpartum.  
 
 
 
 
Our study showed 
that tranexamic acid 
significantly reduces 
bleeding from the 
time of placental 
delivery to 2 hours 
postpartum in LSCS. 
Results show that 
study group patients 
had mean blood loss 
of 360.9ml ± 110.3 as 
This study showed 
that tranexamic acid 
significantly redues 
bleeding from time of 
placental delivery to 2 
hours postpartum in 
LSCS (P=0.001). This 
study shows 
significant decrease in 
the incidene of > 500 
mL blood loss in the 
 Our study showed 
that tranexamic acid 
significantly reduces 
bleeding from time of 
placental delivery to 2 
hrs postpartum in 
LSCS.  
 
Results show that 
study group patients 
had mean blood loss 
The study shows that 
tranexamic acid 
significantly reduced 
the bleeding from 
placental delivery to 
2hr postpartum in 
LSCS (p < 0.001).  
 
Our study showed 
that tranexamic acid 
significantly reduces 
bleeding after 
cesarean section. The 
study group's total 
blood loss was 
significantly less than 
control group.  
This study was a 
double blind placebo 
controlled trial which 
showed that TXA 
significantly reduced 
bleeding from the 
time of placental 
delivery to two hours 
postpartum in LSCS. 
This study shows 
significant decrease in 
During this study 
we found that 
the amount of 
blood loss is very 
much reduced 
from the time of 
placental 
delivery to 2 
hours 
postpartum in 
lower segment 
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standard deviation, 
while control group 
patients had mean 
blood loss of 443ml ± 
88.552 as standard 
deviation. Thus, there 
is reduction in blood 
loss by about 20% & 
was found to be 
statistically highly 
significant (p value= 
0.000).* 
study group as 
compare to control 
group (P-0.049).  
 
of 362.70ml ± 110.3 
as standard deviation, 
while control group 
patients had mean 
blood loss of 
476.70ml ±88.552 as 
standard deviation. 
Thus, there is 
reduction in blood 
loss by about 30% & 
was found to be 
statistically highly 
significant (p value= 
0.001). 
the bleeding volume 
in TXA group as 
compared with the 
placebo group.  
 
 
 
caesarean 
section (Table 
3). 
 Similar study carried 
out by Ming-Ying Gai, 
Lian-Fang Wu and co-
workers5 in China 
showed blood loss 
reduction by 30% as 
compared to control 
group and also 
reduced the 
incidence of 
postpartum 
hemorrhage by 
25.7%. These results 
co related well with 
our study.  
Zheng SR, Yang HX et 
al.6 showed similar 
results.  
 
 
 
 
Similar study carried 
out by Ming-ying Gai 
et al 5 in China 
showed that 
tranexamic acid 
significantly reduces 
bleeding from the 
time of placental 
delivery to 2 hours 
post partum. The 
study showed 
significant decrease in 
the incidence of > 500 
ml blood loss in the 
study group as 
compared to control 
group (P-0.029). 
Zheng et al 6, showed 
similar results after 
vaginal delivery. 
 
 Similar study carried 
out by Ming-ying Gai, 
Lian-fang Wu & 
coworkers (28) in 
China showed that 
tranexamic acid 
significantly reduces 
bleeding from the 
time of placental 
delivery to 2 hrs 
postpartum. The 
study group showed 
total blood loss 
reduction by 30% as 
compared to control 
group. Tranexamic 
acid also reduced the 
incidence of 
postpartum 
hemmorhage by 
25.7% in the study 
group (22 cases Vs 35 
cases in the study & 
controlled group 
respectively) 
(P value was 0.029). 
These results 
Similar study carried 
on by Gohel Mayur et 
al.1 and Ming Ying Gai 
et al. showed similar 
results. 
In the study by Ming 
Ying et al.3, Gohel 
Mayur et al. the drug 
was administered 
between 10 – 20 
minutes here in 
present study it was 
administered 30 
minutes before and 
hence the amount of 
bleeding from 
placental delivery to 
end of LSCS is 
significantly reduced. 
It also reduced the 
amount of PPH 
between the two 
groups but not 
statistically 
significant. 
 
 
 Similar study carried 
out in India by Mayur 
et al.8 showed 
comparable results 
reducing the blood 
loss in the study 
group. Another study 
carried out by Ming-
Ying et al., in China 
showed 
that TXA significantly 
reduces bleeding 
from the time of 
placental delivery to 
the end of caesarean 
section, which was 
351 mL in the study 
group while 440 mL in 
the control group.15 
Zheng et al. showed 
similar results after 
vaginal delivery; there 
was significantly less 
blood loss in the TXA 
group (243 mL) when 
compared to those 
who receive no 
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correlated well with 
our study. 
Zheng SR, Yang HX, et 
al81 showed similar 
results.  
 
treatment (309 
mL).16 
The incidence of 
thrombosis during 
pregnancy and 
peuperium is 5–6 
times higher than 
that in the general 
population [4].  
When the anti-
fibrinolytic drug 
tranexamic acid is 
administered, the 
increased risk of 
thrombosis should 
be considered, 
especially in the CS 
postpartum 
population. 
The incidence of 
thrombosis during 
pregnancy 
&puerperium is 5-6 
times higher than that 
in general population.  
When the 
antifibrinolytic drug 
tranexamic acid is 
administered, 
increased risk of 
thrombosis should be 
considered, especially 
in the LSCS 
postpartum 
population. In our 
study, not a single 
patient developed 
signs of thrombosis.  
The incidence of 
thrombosis during 
pregnancy and 
puerperium is 5-6 
times higher then that 
in the general 
population 7. When 
the antifibrinolytic 
drug tranexamic acid 
is administered, the 
increased risk of post 
partum thrombosis 
after LSCS should be 
considered. In the 
present study, not a 
single patient 
developed 
thrombosis… 
 The incidence of 
thrombosis during 
pregnancy & 
puerperium is 5-6 
times higher than that 
in the general 
population. When the 
anti fibrinolytic drug 
tranexamic acid is 
administered, the 
increased risk of 
thrombosis should be 
considered, especially 
in the LSCS 
postpartum 
population. In our 
study, not a single 
patient developed 
signs of thrombosis. 
The incidence of 
thrombosis during 
pregnancy and 
puerperium is 5-6 
times higher than that 
in the general 
population. When the 
antifibrinolytic drug 
tranexamic acid is 
administered the 
increased risk of 
postpartum 
thrombosis after LSCS 
should be considered. 
In the present study 
not a single patient 
developed 
thrombosis… 
The incidence of 
thrombosis during 
pregnancy and 
peuperium is 5–6 
times higher than that 
in the general 
population [11]; when 
the antifibrinolytic 
drug tranexamic acid 
is administered, the 
increased risk of 
thrombosis should be 
considered, especially 
in the CS postpartum 
population…. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All data 
demonstrated that 
tranexamic acid can 
be used safely 
without increasing 
the occurrence of 
thrombosis, but we 
still need more 
cases to be 
observed for the 
occurrence of 
thrombosis. 
Tranexamic acid 
significantly reduces 
the amount of blood 
loss during & after the 
LSCS. Its use is not 
associated with 
increased risk of 
adverse drug reaction 
like nausea, vomiting, 
diarrhoea or 
thrombosis. 
Tranexamic acid can 
be used safely during 
LSCS to reduce the 
blood loss. 
Tranexamic acid 
significantly reduced 
the amount of blood 
loss during and after 
the lower segment 
cesarean section and 
its use was not 
associated with any 
side effects and.or 
complication like 
thrombosis. Thus, 
tranexamic acid can 
be used safely and 
effectively in subjects 
undergoing LSCS. 
 1) Tranexamic acid 
significantly reduced 
the amount of blood 
loss during & after the 
lower segment 
cesarean section. 
2) Its use was not 
associated with any 
adverse drug reaction 
like nausea, vomiting, 
diarrhea or 
thrombosis. Fetal 
outcome as evaluated 
by apgar score was 
not adversely 
affected by use of 
tranexamic acid. 
Tranexamic acid 
significantly reduced 
the amount of blood 
loss during and after 
LSCS with no 
significant side 
effects. Thus 
tranexamic acid can 
be safely and 
effectively used in 
subjects undergoing 
LSCS. 
All data 
demonstrated that 
tranexamic acid can 
be used safely to 
reduce bleeding after 
CS and its use was not 
associated with any 
side effects or 
complications. Thus, 
tranexamic acid can 
be used safely and 
effectively to reduce 
bleeding resulting 
from CS, but we still 
need more cases to 
be observed for the 
Tranexamic acid 
significantly reduced 
the amount of blood 
loss during the lower 
segment caesarean 
section, but it did not 
significantly reduced 
the blood loss after 
the 
caesarean section. Its 
use was not 
associated with any 
side effects and or 
complication like 
thrombosis. Thus, 
TXA can be used 
safely and effectively 
Tranexamic acid 
significantly 
reduces the 
amount of blood 
loss during and 
after the lower 
segment 
caesarean 
section. The use 
of tranexamic 
acid was not 
associated with 
any side effects 
or complication 
like thrombosis, 
nausea, 
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3) Tranexamic acid 
can be used safely in 
subjects with lower 
caesarean section. 
occurrence of 
thrombosis. 
 
 
in subjects 
undergoing LSCS. 
vomiting and 
diarrhea. 
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Appendix JJ. Research Paper 6: Summary of response to review authors’ requests for additional trial information. 
 
Trial Date 1st 
randomised 
Date last 
randomised 
Copy of ethics 
approval received? 
Trial data sent? Notes 
Abdel-Aleem 2013 03/08/2011 01/12/2011 Y Y  
Gai 2004 
    
No response 
Gobbur 2014 
  
Y 
 
Response from ethics committee (no response from 
authors) 
Gohel 2007 03/08/2004 25/07/2005 N* Y *Author response: "This study was carried out as a thesis 
of the first author Dr Mayur Gohel who was a post-
graduate student in the department at that time. At the 
point in time when this study was carried out, according 
to the local guidelines, conducting a study for thesis 
purpose required just an information to the ethics 
committee and not a formal approval. Hence we are 
unable to provide you with an approval letter from the 
ethics committee." (This was confirmed in response from 
the ethics committee) 
Goswami 2013 * * Y Y *Author response: "we did not keep any record of the 
exact dates of the cases done, i can only say that the study 
was conducted between November, 2009 to 2011"[sic] 
Gungorduk 2010 01/06/2009 30/09/2009 Y N* *Author response: "Dear Sir; Thank you for your email. I 
sent the all information within 5 day. I am on holiday now. 
Unfortunately, last year ( 22-june-2013) my computers 
and hard disk was stolen therefore, I can not sent the 
patients data. A police burgary report was attached. I am 
very sorry about this topic." [sic] 
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Gungorduk 2012 01/03/2011 31/08/2011 Y see above see above 
Halder 2013 
    
No response 
Mirghafourvand 2015 12/08/2012 13/11/2012 Y N 
 
Movafegh 2011 
    
No response 
Poonia 2012 
    
No response 
Ramani 2014 07/03/2013 29/05/2013 Y N  
 
Ramesh 2015 
    
No response 
Rashmi 2012 
    
Author response: "Sir, The work has been actually 
undertaken after proper clearance. And details of the 
same are available with the competent authority. We 
don't want to be get disturbed as I discussed with our 
main author. Excuse us..Bye." [sic] 
Safdarian 2015 
    
No response 
Samimi 2013 21/11/2012 16/03/2013 Y Y No response 
Sekhavat 2009 
    
No response 
Senturk 2012 
  
Y Y 
 
Shahid 2013 20/03/2009 28/04/2011 N* Y *Response from ethics committee: "After detailed 
scrutiny of our records I regret to inform you that no such 
approval was given by the Institutional Review Board of 
Dow University of Health Sciences.” 
Sharma 2011 
    
No response 
Taj 2014 
    
No response 
Tarabrin 2012 
    
No response 
Xu 2012 
    
No response 
Yang 2011 
    
No response 
Yehia 2014 
  
Y* Y *Approval dated approximately 3 months after start of 
recruitment. 
Zizi 2013 
    
No response 
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Appendix KK. Research Paper 6: Forest plots showing the difference in age between women 
allocated to the TXA group and those allocated to the control group. 
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Appendix LL. Research Paper 6: Forest plots showing the difference in haemoglobin between 
women allocated to the TXA group and those allocated to the control group. 
 
 
 
 
 
 
